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Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder, caused by 
mutations in either of the PKD1 or PKD2 genes, which leads to the development and growth of 
multiple fluid-filled cysts in the kidney. The cysts are present at birth and grow throughout the 
lifetime of the afflicted individual, eliciting pain and eventually leading to end-stage renal disease 
(ESRD). The PKD1 and PKD2 genes and their corresponding encoded proteins, polycystin-1 
(PC1) and polycystin-2 (PC2), are necessary for proper tubulogenesis, and for the repair processes 
that maintain the architecture of the tubules after injury in the adult kidneys. Mutations in PC1 and 
PC2 results in phenotypic changes in renal epithelial cells, which consist, among others, in a more 
dedifferentiated state of the cells, increased proliferation, increased fluid secretion, increased 
apoptosis, epithelial-to-mesenchymal (EMT)-like features, abnormal activity of various cell 
signaling pathways, and alterations in intracellular calcium.  
An enzyme essential for the proper function of the kidney is the Na,K-ATPase (NKA). 
NKA uses the free energy from ATP to catalyze the movement of Na+ in exchange for K+ across 
the cell plasma membrane. Its function in the kidney is key for solute and water reabsorption and 
formation of urine. In addition, NKA is the receptor and signal transducer for the hormone ouabain, 
which regulates the sodium transport of normal renal epithelial cells. In ADPKD kidneys, the 
binding of ouabain to NKA has an important role in exasperating cystic progression. Specifically, 
ouabain stimulates both the proliferation and the fluid secretion of ADPKD cells, as well as 
cystogenesis in embryonic kidneys from a mouse model of ADPKD. This thesis was undertaken 
to determine how ouabain contributes to the overall phenotype of ADPKD cells. In particular, 
emphasis was placed on the effect of ouabain on the cystic phenotypes of apoptosis, EMT and 
intracellular calcium.  
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 Ouabain significantly increased the apoptotic rate in renal cystic epithelial cells obtained 
from the kidneys of patients with ADPKD (ADPKD cells). Ouabain-mediated apoptosis occurred 
via the intrinsic pathway, and was reliant on cytochrome c release from the mitochondria and on 
an altered ratio of Bcl-2 associated X protein (BAX) to B-cell lymphoma 2 (BCL-2) protein. These 
results agree with findings from other authors that show that apoptosis of epithelial cells is a 
characteristic of ADPKD cells. While ouabain can increase apoptosis in ADPKD cells, it also 
increases proliferation, and overall proliferation remained greater than overall apoptosis induced 
by ouabain. Therefore, ouabain creates a misbalance towards cell growth, which helps the 
development of ADPKD cysts. 
 Additionally, epithelial to mesenchymal (EMT)-like signaling was altered by ouabain. A 
hallmark of EMT is the decrease in expression of E-cadherin and the increase in N-cadherin. 
Ouabain was able to induce this affect in ADPKD cells, without altering cadherin levels in NHK 
cells. Additionally, ouabain increased tumor growth factor- (TGF) expression and SMAD3 
phosphorylation, as well as increased expression of downstream targets, such as collagen-I and 
Snail. However, ouabain was not able to induce a complete switch to a mesenchymal phenotype, 
as evidenced by unchanged levels in the mesenchymal protein vimentin, the presence of -catenin 
in the plasma membrane, and the unchanged invasive properties. Interestingly, despite the 
decreased cell-cell adhesion, ouabain increased transepithelial electrical resistance, but did not 
affect the permeability of monolayers to neutral dextran, suggesting that the tightness of junctions 
and the permeability of the paracellular transport pathway are preserved in the cells. In contrast, 
epithelial cells from normal human kidneys (NHK cells) did not display any of the mentioned 
effects of ouabain. Together, these results reveal that while ouabain contributes to the development 
v 
 
of the dedifferentiated phenotype of ADPKD cells, but does not lead to a complete EMT, which 
stimulates cyst formation and growth. 
 Finally, intracellular calcium concentration ([Ca2+]i) is constitutively lower in ADPKD 
cells relative to NHK cells. NHK cells were found to respond to ouabain with an increase in [Ca2+]i, 
while ADPKD cells did not. Further, ADPKD cells had lower concentrations of ER calcium than 
NHK, but neither ER nor mitochondrial calcium levels appear to be altered by ouabain. The 
ouabain-induced increase in [Ca2+]i in NHK cells occurred through L-type calcium channels 
(LTCC). ADPKD cells did not respond to ouabain in the same manner, and this was found to be 
due to lower expression of full-length LTCC at the plasma membrane. Indeed, increased calpain 
activity was observed in ADPKD cells relative to NHK, and this correlated inversely with 
expression of the endogenous calpain inhibitor, calpastatin. The expression of c-Myc is elevated 
in ADPKD cells, and this negatively regulates calpastatin expression. Indeed, inhibition of the 
transcriptional activity of c-Myc resulted in increased calpastatin protein, decreased calpain 
activity, and decreased cleavage of LTCC yielding increased levels of basal intracellular calcium 
in ADPKD cells. Although we did not find that ouabain was able to further exasperate the calcium 
phenotype, we expect longer treatment with ouabain may have a more pronounced effect. 
 In conclusion, both apoptosis and EMT are enhanced by ouabain in ADPKD cells and 
unaffected in NHK cells. Conversely, ADPKD cells do not appear to alter calcium in response to 
ouabain in the time points assayed. However, the knowledge that calpains are more active in 
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CHAPTER 1: INTRODUCTION 
ADPKD 
Overview of the disease 
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder 
characterized by the formation of multiple fluid-filled cysts in both kidneys, which continually 
expand throughout the lifetime of the affected individual.  Renal cyst enlargement occurs as a 
consequence of two major mechanisms, increased cell proliferation of the cystic epithelium, and 
aberrant transepithelial fluid secretion into the cysts. Expansion of the cysts ultimately leads to 
mechanical compression and destruction of the renal parenchyma [1-3], resulting in renal 
insufficiency and eventually end-stage renal disease (ESRD). ADPKD is responsible for roughly 
10% of all cases of ESRD [4, 5] and is the fourth leading cause of ESRD requiring dialysis and 
kidney transplantation therapy in the United States [6, 7]. Even before the patients exhibit 
significant loss of kidney function, they have symptoms that cause detrimental effects on patient 
quality of life. Abdominal or flank pain and hematuria are the most common presentations of 
ADPKD. Pain is attributed to the cyst-mediated compression of the internal organs, while 
hematuria is due to cyst rupture into the urinary tract [8, 9].  
ADPKD is caused by mutations in the PKD1 and PKD2 genes that encode for polycystin-
1 (PC1) and polycystin-2 (PC2) respectively. While mutations in PC1 account for 80-85% of 
ADPKD cases, alteration in PC2 accounts for the remaining 15-20% [10]. Recently, mutations in 
the glucosidase-II alpha subunit, GANAB, have been shown to inhibit the proper localization of 
PC1 and thus may also give rise to ADPKD [11]. Patients with mutations in PC1 or PC2 have 
identical renal manifestations [12], with the exception of varying rates of ESRD progression [13]. 
2 
 
Specifically, patients with defects in PKD1 on average progress to ESRD by age 57, while the 
kidney function of PKD2 patients persists longer, with 69 years as the average age for the onset of 
ESRD [13]. PC1 and PC2 interact with each other to form a macromolecular receptor/signaling 
complex, the function of which is still not fully elucidated. However, there is evidence that 
PC1/PC2 are involved in the regulation of different pathways in renal epithelial cells that control 
cell proliferation, polarity, and the normal structure of the renal tubules [14-17]. 
To date, genetic screens of patients with ADPKD have identified as many as 2323 PKD1 
and 278 PKD2 unique germline mutations (2016; pkdb.mayo.edu). In the PKD1 gene, mutations 
are found in all areas of the gene, from exons 1 to 46, with no clear hotspot identified [18]. 
However, mutations are twice as frequent in the C-terminal half of the protein [18]. In the PKD2 
gene, mutations have been detected in most of the 15 exons [19], with truncation mutations 
accounting for 65% of PKD1 and 83% of PKD2 mutations [20, 21]. ADPKD is the most common 
monogenetic disease of the kidney, affecting 1:400-1:1000 births worldwide [22, 23]. This high 
incidence, coupled with the many mutations identified, illustrates the sensitivity of PC1 and PC2 
to any hindrance in their function, and also foreshadows the polymodal nature of these proteins.  
ADPKD is diagnosed on the basis of ultrasound and prior family history; although 6-8% 
of ADPKD patients are de-novo mutations and their diagnosis is a random event during clinical 
examination [24]. Despite the genetic basis of the disease, genetic testing is not performed as part 
of the standard diagnosis due to the unique technical challenges presented in confirming PKD1 
mutations. [25] The search for mutations in PKD1 transcript is complicated by the surrounding 
genomic region. Specifically, 50 kb of genomic DNA encoding the first 31 exons of PKD1 are 
duplicated at least three times on chromosome 16 (16p13.1) and this area also encodes 3 genes 
that share substantial homology to the PKD1 exons [26, 27]. Currently, there is no specific 
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treatment for ADPKD approved in the United States, although several guidelines for disease 
management exist (reviewed in [28, 29]). At present, finding therapeutic approaches to treat 
ADPKD is necessary to relieve the physical burden of the patients that suffer from this disease, as 
well as to decrease the health care costs associated with the palliative measures used to prolong 
the life of the patients.   
 
The genetic basis of ADPKD and its correlation with disease development and progression 
ADPKD progression is slow, occurring over several decades. Despite thousands of 
microcysts already present in the kidneys of ADPKD patients at birth [30, 31], and their relentless 
growth during the lifetime of the affected individual, overall renal function remains normal due to 
compensatory hyperfiltration by the nephrons that continue to be functional [32]. However, during 
the later stages of the disease, the destruction of adjacent renal parenchyma, results in the initiation 
of fibrotic and inflammatory processes which contribute to the progressive and rapid deterioration 
in renal function [33]. The growth rate of individual cysts is extremely variable and can range 
between 2.2 and 71.1% per year [30]. One of the major factors which predicts accelerated ADPKD 
progression is the type of polycystin mutation [28]. In general, PKD2 patients have later onset, 
longer renal survival, and present fewer complications compared to PKD1 patients [12]. The next 
best prognosis goes to PKD1 non-truncating mutations, while PKD1 truncations present the worst 
phenotype [28]. Within the PKD1-truncation mutations, it appears that the severity of the PKD1 
mutation depends on the length of the truncated PKD1 protein, with truncations in the N-terminal 
portion leading to ESRD more quickly [34, 35]. Other subtleties in genetic expression may also 
impact disease progression, such as the expression levels of PC1 and PC2, penetrance of 
4 
 
pathogenic alleles, and the stage of kidney development affected by the particular PKD1 mutation 
[36-40]. 
Interestingly, microdissection studies on ADPKD kidneys have shown that, despite the 
presence of polycystin germline mutations in every kidney cell, just 1% of nephrons form cysts 
[41]. This phenomenon has been explained by a “second hit” theory [41]. This theory states that 
in addition to the germline mutation, a somatic mutation must occur in the second normal allele 
for cyst initiation. In support of this theory, cystic epithelial cells show a loss of heterozygosity in 
the PKD1 gene in a subset of cysts [41, 42]. Environmental factors could influence the rate of the 
second hit, which may account for the variability in cystogenesis and renal disease progression 
[43]. Indeed, the genetic defect alone cannot account for the observed high intrafamilial variability 
of the disease. The heritability of ADPKD severity has been estimated at just 42% within family 
members whose kidney function has not yet declined to ESRD [44]. Comparison between the age 
of ESRD onset in siblings to that of monozygotic twins [45] has shown that siblings underwent 
ESRD within 6.9±6 years of each other, while in monozygotic twins, the variability to kidney 
failure was shortened to 2.1±1.9 years difference [45]. Thus, while the progression of ADPKD to 
ESRD is clearly affected by the presence of modifier genes, a difference in ESRD onset of up to 4 
years is observed between genetically identical monozygotic twins, and this difference can be 
attributed to environmental factors [45].  
Other major factors which predict accelerated progression in ADPKD are the patient’s age 
at diagnosis, total kidney volume, kidney function, and gender [28]. The first three parameters are 
indicative of a worse disease phenotype. Younger age at diagnosis, early renal enlargement, and 
lower glomerular filtration rate (GFR) are bound to be correlative not causative factors, but are 
useful to clinicians in disease management and counseling. With respect to gender, males and 
5 
 
females have the same incidence of ESRD [10], but males more rapidly progress to ESRD [1, 3, 
46]. However some studies have found that the gender effect was not present in PKD1 families 
[34, 47, 48] and might be restricted to families where PKD2 is affected [49]. 
 
ADPKD as a ciliopathy and defective wound healing process 
Two conceptual ideas of APDKD pathophysiology co-exist, and are not mutually 
exclusive. The first is that ADPKD is a ciliopathy, or a disease caused by defects in the structure 
or function of cilia [50]. This view was derived by the discovery that the phenotype of the Oak 
Ridge Polycystic Kidney mouse, a model of polycystic kidney disease, was caused by a mutation 
in IFT88, a protein required for the assembly of primary cilia and intraflagellar transport [51]. 
Subsequently, both polycystins, as well as fibrocystin, the cause of autosomal recessive polycystic 
kidney disease (ARPKD), were found to localize to the primary cilium [52]. In addition, other 
diseases that cause renal cysts are induced by mutations in proteins which normally localize to 
cilia; these diseases include nephronophthisis, Bardet-Biedl syndrome, orofaciodigital syndrome 
and others [53, 54].  
Like most cells of the body, the majority of renal tubular epithelial cells have a primary 
apical cilium [55], which functions as a receptor that senses urine fluid flow. When mouse 
embryonic kidney cells are subjected to fluid flow, at a rate comparable to the physiological urine 
fluid flow rate, a calcium influx into the cells is observed [56]. In contrast, PKD1-null cells, or 
cells with truncated forms of PKD1, fail to respond to fluid flow with calcium influx [56, 57]. 
Also, renal cells lacking a primary cilium, but expressing both polycystins, also lack this response 
to fluid flow [58]. As will be discussed in more detail later, the polycystin proteins create a 
6 
 
functional, nonselective cation channel permeable to Ca2+, Na+, and K+ ions [14]. PC2 contains 
the pore-forming domains of this channel, while PC1 is thought to regulate PC2 channel activity 
[56].  On the primary cilium, the large extracellular N-terminal domain of PC1 is hypothesized to 
function as a sensing antenna for mechanical [59], chemical [60], or peptide stimuli [61]. 
Therefore, stimulation of the cilium may induce a conformational change in PC1, which activates 
its binding partner PC2 to mediate calcium entry into the cell [56]. However, this remains 
controversial due to recent studies by Delling, et al which suggest that the ciliary PC1/2 complex 
is not responsible for fluid-flow mediated calcium influx [62]. 
The second view of ADPKD is focused on the hypothesis that upon lack of fluid flow, 
normal renal cells may use the primary cilia to signal the presence of injury. Several renal injuries, 
such as ureteral obstruction and ischemic injury halt fluid flow [63, 64]. Therefore, it has been 
theorized that PC1/2 signals “all is well” in response to fluid flow [63]. However, in ADPKD cells, 
the mutant PC1 or PC2 fail to signal this response even under normal fluid flow, leading to the 
reactivation of developmental signaling pathways and cell proliferation [65, 66]. Indeed, several 
observations suggest that polycystins are instrumental in normal renal repair. PC1/2 levels have 
been observed to be elevated after ischemic injury [67-69]. Also, kidneys heterozygous for PKD1 
or -2 mutations cannot repair themselves as effectively as kidneys from wildtype mice, and instead 
tubule dilation and formation of microcysts occur [70, 71]. These observations have led to the idea 
of the “third hit” hypothesis [72]. This theory postulates that, as an individual ages, the kidneys 
are more likely to suffer transient obstructive or ischemic injuries that stimulate tissue repair 
signaling pathways, which reactivate development and epithelial cell proliferation of the renal 
tubular epithelial cells [65, 66]. Thus, in renal injury, the kidney may rely on the activities of 
polycystins for its repair. The third hit theory is supported by observations of increased cystic 
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expansion after injury induction in adult polycystic mouse models with slowly progressive cystic 
disease [40, 72-74]. Ischemic injury also triggers cyst formation in kidneys lacking cilia [75-77], 
emphasizing the importance of proper ciliary signaling in the wound healing processes.  
Additional support for the third hit theory is the observation of tissue repair processes 
occurring in the interstitium surrounding the cystic cells [78-81]. Thus, the distortion of tubules 
and vessels sets up an inflammatory response that becomes chronic and leads to fibrosis as well as 
dedifferentiation in kidneys from ADPKD patients [82, 83]. In particular, ADPKD kidneys are 
characterized by severely thickened basement membranes and excessive ECM deposition [78]. 
Similarly, accumulation of ECM is observed in ischemic acute renal failure and after ureteral 
obstruction [84-86]. Additionally, infiltrating immune cells are observed after renal ischemic-
reperfusion injury, ureteral obstruction, and also in human ADPKD and polycystic models [79, 
80]. There is some experimental evidence showing the presence of epithelial to mesenchymal 
transition (EMT) in ADPKD, which contributes to the appearance of fibroblasts [81]. For example, 
gene analysis of normal and ADPKD kidneys, has shown the upregulation of smooth muscle-
related genes, indicative of cell dedifferentiation and EMT [87]. 
As will be shown later, the experiments in this thesis support the third hit theory through 
the abilities of the hormone ouabain to act directly on renal epithelium to enhance the 
dedifferentiated phenotype of ADPKD cystic cells. However, the non-renal complications of 
ADPKD will be discussed in the following section in order to give a complete physiological picture 





Non-renal complications of ADPKD 
ADPKD is a systemic disease with a large morbidity burden on the patient. Along with 
renal manifestations, PKD1 and PKD2 patients have identical extrarenal manifestations [12]. In 
addition to the kidney, cysts can also arise in the liver, spleen, and pancreas. Liver cysts are the 
most common extrarenal cysts, occurring in about 80% of patients [88]. Women tend to have a 
higher prevalence of liver cysts, and the number and size of the liver cysts appears to be related to 
multiple pregnancies or prolonged exogenous estrogen exposure [89, 90]. Liver cysts cause 
chronic pain, but the function of the liver usually remains normal [91, 92]. Pancreatic cysts have 
been described in approximately 10% of ADPKD patients [22, 93] and splenic cysts in fewer than 
5% [94]. 
Despite the pro-proliferative phenotype of cystic cells with mutations in polycystins, the 
incidence of renal cell carcinoma is not increased in ADPKD [95]. However, multiple 
cardiovascular, musculoskeletal, and gastrointestinal abnormalities are associated with ADPKD 
(reviewed in [96]). For instance, ADPKD patients have increased incidence of cardiac valve 
abnormalities, aortic dissection, intracranial aneurysms, and abdominal wall hernias (reviewed in 
[97, 98]). Hypertension is found in 49-75% of patients, even before the patients show a noticeable 
loss in renal function [23, 99]. Over 90% of ADPKD patients develop high blood pressure by the 
time they reach ESRD [100]. One theory attributes this rise in blood pressure to cyst expansion. 
Compression of the intrarenal vasculature by cysts could cause renin release and activate the renin-
angiotensin aldosterone system (RAAS) pathway, leading to increased blood pressure [89, 101].  
Coincidentally, the RAAS system can also be activated by renal injury [102], and this mechanism 
has been found to be involved in the hypertension of ADPKD patients [103-107]. In PKD1-null 
mice, two molecules involved in RAAS activation, pro-renin and angiotensinogen, are increased 
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[108]. Additionally, elevated levels of angiotensin-II, the effector molecule of RAAS, is increased 
in cyst fluid, and cyst-derived cells in vitro express several components of RAAS [109].  
Hypertension in ADPKD is associated with development of left ventricular hypertrophy, 
increased cardiovascular mortality and morbidity, as well as progression of renal destruction [3, 
110]. Importantly, although ESRD is used to measure ADPKD progression, cardiovascular disease 
is responsible for nearly 80% of deaths in ADPKD [111, 112]. 
 
POLYCYSTINS 
Expression and Structure 
ADPKD was first linked to the PKD1 gene, on chromosome 16 (16p13.3), in 1985 [113]. 
A second locus, PKD2, on chromosome 4 (4q21-23) was identified in 1993 [114]. A year later, 
the PKD1 gene was first cloned and partially characterized [26, 115], while cloning of PKD2 was 
achieved by 1996 [116]. It was soon found that PC1 and PC2 interact with one another [14-17] via 
their C-terminal cytoplasmic tails [15, 16, 117]. It has been proposed that the polycystin complex 
contains one PC1 and three PC2 subunits [118, 119]. Reinforcing the fact that mutations in either 
polycystin can cause ADPKD, the interaction between polycystins reciprocally influences the 
functional properties of each. For instance, the interaction of PC1 with PC2 is important for 
modulating the ion channel abilities of PC2 [14, 120], while conversely, the interaction decreases 
the ability of PC1 to activate G proteins [121]. 
Polycystins are expressed in epithelial cells of the developing and mature renal tubules, as 
a well as in other somatic tissues including heart, liver, brain, bone, as well as the thyroid and 
adrenal glands [67, 122-124]. PC1 expression is temporally regulated, with high levels observed 
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in fetal renal tissue and low, but still detectable, levels present in adult tissue [125]. This early 
upregulation of PC1 is of significance when considering that cystogenesis occurs in utero, during 
tissue development [30, 31]. Studies of cystic growth rate have concluded that cysts grow at 
vigorous rates in utero and at slower rates thereafter [30, 126]. Indeed, in vivo experiments have 
shown the importance of the developmental expression of polycystin on the growth of cysts. 
Specifically, temporally controlled inactivation of PC1 or PC2 expression in murine kidneys has 
revealed that the loss of these proteins during renal development causes a far more severe cystic 
phenotype than when the loss of PC1 or PC2 occurs in the mature kidney [72, 127, 128].  
Further evidence for the importance of PKD1 expression during nephrogenesis to prevent 
cysts comes from a mouse PKD1-knockout model. Murine PC1 is not detectable in the early stages 
of nephrogenesis but peaks at E15.5 in the collecting ducts, papillary ducts and renal pelvis [37]. 
PKD1 knockout mice develop normally until the induction of cystic dilations at day E15.5 [37]. 
This suggests a role of polycystin in tubular elongation and maintenance of tubular architecture, 
rather than in nephron formation [37]. The PKD2 knockout mouse showed a similar pattern of 
normal kidney development until E15.5, at which point cysts began to form [129].  
In humans, PC1 and PC2 are highly expressed in proximal tubules from 10-24 weeks of 
gestation, then the expression drops precipitously between gestational week 28 and 38 [125, 130]. 
In contrast, expression of both polycystin proteins is found in the cortical and medullary collecting 
ducts by 14 weeks gestation, and this expression is increased and maintained high until term (40 
weeks) [130]. Adult human kidneys weakly express polycystins in proximal tubules, while 
expression of both PC1 and PC2 continues in medullary collecting ducts [130]. Interestingly, 
although ADPKD cysts derive from all segments of the nephron, a significant portion of the cystic 
cells are stained by markers that are specific for a collecting duct origin [131, 132]. Moreover, 
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inactivation of PKD1 leads to the formation of the largest cysts predominantly in collecting ducts 
[133].  Therefore, cysts primarily form in the segments in which the strongest expression of 
polycystins is observed. 
Paradoxically, both reducing the expression of PC1, as well as inducing its overexpression, 
leads to renal cyst growth in transgenic mice [40, 134]. Additionally, PC2 is expressed at higher 
levels in cyst-lining epithelium of ADPKD [135-137], and cysts of patients with ADPKD have 
continued expression of PC1 in many instances [122, 138-140]. Therefore, it has been suggested 
that polycystin proteins need to be expressed at a certain ratio to maintain their stoichiometry and 
prevent cystogenesis [141, 142].  
The polycystins play several roles in both development and in response to injury. Both of 
those conditions involve certain processes, like increased proliferation, which are important in 
ADPKD cystic growth. The sections that follow will discuss the structure of the polycystins, and 
then emphasize the roles of the polycystins in calcium regulation, EMT, and apoptosis - processes 
which are central to the experiments of this thesis. 
PC1 and PC2, also known as TRPP1 and TRPP2, respectively, are members of the transient 
receptor potential (TRP) superfamily of cation channels, which includes more than 20 members 
(reviewed in [143, 144]). The activation of TRP channel members is often polymodal, allowing 
them to respond to multiple forms of stimuli (reviewed in [145]). PC1 shows significant sequence 
homology with TRP channels [146], but it cannot by itself form an ion channel, as PC1 
overexpression alone does not yield any measurable channel activity [147]. Therefore, despite 
being a TRP channel family member, PC1 is considered to be an integral membrane receptor and 
not a channel. It bears 11 transmembrane domains, a large N-terminal extracellular region, and a 
short cytoplasmic C-terminus ([4] and Figure 1.1).  
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The extracellular N-terminus of PC1 is large, about 3000 amino acids long [148, 149], and 
is made up of domains thought to play a role in protein-protein or protein-matrix interactions [150-
153]. The extracellular domains of PC1 may also be involved in sensing fluid flow and pressure 
in the kidney (reviewed in [154]). As Figure 1.1 shows, the domains present in the PC1 N-terminus 
include: 2 complete leucine rich repeat (LRRs) motifs flanked by cysteine-rich sequences, a cell 
wall stress-responsive component (WSC) domain, a C-type lectin domain, a low density 
lipoprotein (LDL-A) region, a receptor of egg jelly (REJ) domain [155], and 15 PKD repeat motifs, 
which are Ig-like [149]. Atomic force microscopy showed that the PKD domains on PC1 exhibit 
remarkable mechanical strength further supporting the proposed mechanosensory function of PC1 
on cilia [147]. 
PC1 also contains 11 transmembrane domains (~1000 amino acids) [12, 156, 157]. The 
first cytoplasmic loop after TM1 contains a lipoxygenase domain (also called a PLAT or LH2 
domain), which adopts a -sandwich fold [158]. PLAT domains are usually involved in protein-
protein or protein-lipid interactions [159]. Additionally, between the domains TM5 and TM6 is a 
binding site for the adapter protein, Homer [160]. 
The cytoplasmic C-terminal tail (CTT) of PC1 is small, yet has garnered much attention as 
it appears to have many and varied roles in both signaling and transcription. In support of its 
importance are experiments showing that a naturally occurring truncation mutation which removes 
the PC1 C-terminal segment is sufficient to cause ADPKD [161]. The domains present in CTT 
include a G protein binding domain [162], a coiled-coil domain, which is necessary for its 
interaction with PC2 [67, 163], a PEST domain which may facilitate its ubiquitin mediated 
degradation [139], and a putative nuclear localization sequence, by which it affects transcription 
[164]. The functions of the cleaved CTT will be discussed in detail below. 
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PC1 undergoes cleavage in both its N- and C-terminal domains. The N-terminal cleavage 
occurs at the GPS cleavage site (T3049), located immediately before the first transmembrane 
domain [165], and shown in Figure 1.1. This cis-autoproteolysis is caused by a self-catalyzed 
protein rearrangement and requires the presence of the adjacent REJ domain to occur [165]. GPS 
cleavage occurs early in the secretory pathway, and results in the N-terminus remaining 
noncovalently bound to the C-terminal fragment [166]. Mutations that prevent GPS cleavage cause 
cystic disease in mice and humans [167]. Additionally, expression of a mutant form of PC1 which 
cannot undergo GPS cleavage does not rescue PC1-null cells in vitro or transgenic mice [165, 168, 
169], suggesting that GPS cleavage is necessary for PC1 function. However, not all PC1 in a cell 
are cleaved, yielding a heterogeneous population [166, 168]. The presence of PC2 enhances the 
GPS cleavage of PC1, which agrees with the proposed role of PC2 as an essential chaperone for 
PC1 maturation and plasma membrane [170] and ciliary localization [171]. However, the role of 
PC2-enhanced GPS cleavage in the trafficking of the polycystin complex is not fully agreed upon 
as some studies have suggested PC2 traffics to the cilia independently of PC1 [172, 173], others 
claim that PC2 ciliary localization requires PC1 [171] and some suggest that PC1 localization to 
the cilia does not rely on the GPS cleavage of PC1 or the RVxP sequence found on PC2 [174]. 
The C-terminal cleavage of PC1 appears to have several physiological roles. Three known 
cleavage sites, denoted by black arrows in Figure 1.1, have been found in the C-terminal portion 
of PC1 that release the CTT. Misregulation of PC1 cleavage appears to result in aberrant signaling 
which may in turn lead to the abnormal cellular growth behaviors that contribute to ADPKD 
pathogenesis (reviewed in [170]). One CTT fragment (100 kDa), contains the last 6 transmembrane 
domains and, when cleaved, prevents store-operated calcium entry [175]. This fragment has also 
been found to directly associate with inositol triphosphate receptors (IP3R) in the endoplasmic 
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reticulum (ER) and inhibit calcium release from the ER in response to IP3 stimulation [176]. 
Another 15 kDa CTT fragment has a clearly cystogenic action by its interaction with STAT6 and 
the STAT6-coactivator, P100. This interaction begins at the basal bodies of cilia. Upon flow 
cessation the 15 kDa CTT fragment of PC1 is cleaved off which promotes the nuclear translocation 
of itself and STAT6 [139]. Additionally, the presence of this 15 kDa fragment has been found to 
be increased in cells lining ADPKD cysts, exhibiting a high nuclear localization [139].  Indeed, 
overexpression of this 15 kDa CTT in zebrafish promoted renal cyst formation [139]. In contrast, 
cleavage of an anti-cystogenic 35 kDa fragment occurs under the opposite condition than that of 
the pro-cystogenic 15 kDa fragment. In response to mechanical stimulation by fluid flow, gamma-
secretase cleaves this 35 kDa CTT [177], and it is observed to accumulate in the nucleus [125].  
Indeed, gamma-secretase inhibition during 3D culture of wild-type renal epithelial cells induced 
cyst formation, similar to what occurs in PKD1-/- cells [177]. This 35 kDa CTT fragment is able 
to decrease aberrant proliferation as well as aberrant apoptosis in ADPKD cells, by binding to and 
inhibiting the transcription factors TCF and CHOP, respectively [177]. Production of this 35 kDa 
CTT fragment is also stimulated by the presence of functional PC2 [178], although increased 
cleavage of all known fragments occurs in response to PC2 expression [175].  
Finally, an engineered C-terminal tail (CTT) containing the last 193 amino acids (~21 kDa) 
has been used as a dominant negative against full-length PC1 [179]. Overexpression of this CTT 
was found to increase net fluid secretion and proliferation in response to cAMP, as is what is 
observed in ADPKD cells [180]. When this construct is co-expressed with -NKA in an insect 
expression system, the cells acquire a phenotype of increased proliferation in response to ouabain 







The structure of PC2 is simple in comparison to PC1, as shown in Figure 1.1. PC2 is an 
integral transmembrane protein with 6 transmembrane regions, beginning and ending with 
intracellular N- and C-termini [116]. Both the N- and C-terminals of PC2 contain dimerization 
domains, which according to one model, leads to the formation of PC2 homotetramers, although 
it is also predicted that PC2 forms heterotetramers with other TRP proteins as well [182].  In fact, 
PC2 has been observed to interact with several TRP family members, including TRPC1, TRPV4, 
and PC1 [146, 147]. The N-terminal segment of PC2 is also important for its location within the 
Figure 1.1. The domains of the polycystin proteins. CR, cysteine-rich region; LRR, leucine-rich repeat; 
WSC, wall-stress component domain; Ctype, C-type lectin domain; LDL, low-density lipoprotein domain; 
REJ, receptor egg jelly domain; GPS, G-proteolytic site; PLAT, polycystin-lipoxygenase-alpha-toxin domain; 
G-pr, G-protein binding domain; CC, coiled-coil domain; ER-R, ER-retention signal; EF-H, EF-hand domain; 




cell, as it contains a RVxP amino acid motif  which allows PC2 to traffic to the cilia independently 
of PC1 [173]. This N-terminal portion of PC2 also contains a phosphorylation site (Ser-76) which 
directs PC2 localization from the plasma membrane to the endoplasmic reticulum [183].  
The transmembrane region of PC2 creates a nonselective cation channel, permeable to 
Ca2+, Na+, and K+ ions [14]. The conducting pore of PC2 is likely formed by the loop between the 
fifth and sixth transmembrane domains with some involvement of the third transmembrane domain 
[184, 185]. A missense mutation that perturbs this putative conducting pore is causative of 
ADPKD [185]. 
Immediately distal to the last transmembrane domain of PC2 is a functionally complex 
region that includes an EF-hand domain containing one calcium binding site [186, 187], an ER 
retention domain required for maintaining PC2 in the ER and Golgi [188], and a coiled-coil 
domain, which is necessary for the interaction with PC1 [16]. The coiled-coil domain of PC2 is 
also important for interaction with other cellular calcium channels [16, 189-192] as well as other 
interacting protein partners [193-195]. The deletion of the coiled-coil domain renders the channel 
properties of PC2 inactive [196].  
 
The Polycystin Cation Channel 
Despite the permeability of PC2 to Ca2+, Na+, and K+ ions [14], most studies have solely 
focused on misregulation of calcium levels in response to polycystin alterations. Cystic epithelial 
cells have constitutively lower intracellular calcium than cells derived from normal tubular 
epithelia [197-199]. The decreased intracellular calcium ([Ca2+]i) of cystic epithelial cells, alters 
the way cells respond to stimuli. For instance, ADPKD cells activate B-RAF in response to cAMP, 
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while normal collecting duct cells do not, and this response can be inhibited by pharmacologically 
increasing [Ca2+]i in ADPKD cells [197, 198]. Other manipulations have underlined the 
importance of alterations in [Ca2+]i to cyst growth. For example, the size of cysts could be 
decreased by the pharmacological increase of [Ca2+]i in metanephric organ culture [200]. 
Conversely, the knockdown of PC2 in 3D microcyst cultures, presumably decreasing [Ca2+]i, 
supports cyst growth [199].  
 The subcellular localization of the PC1/2 complex is still contentious. PC2 is widely 
expressed in either the endoplasmic reticulum, where perhaps 99% of the protein resides [185, 
188] or in the primary cilia, a compartment which PC2 reaches through a highly regulated 
trafficking mechanism [172, 201]. In some studies a small percentage of PC2 can be isolated with 
the plasma membrane fraction of epithelial cells [17, 183]. The ability of the PC1/2 complex to 
bring calcium into the cell is maintained while localized on the plasma membrane [14], or on the 
cilia [56]. As mentioned previously, in the cilium, PC2 forms a complex with the mechanosensitive 
PC1, and is theorized to convert shear forces on the cilium membrane into ciliary calcium influxes. 
These influxes could further induce the release of calcium from intracellular stores through the 
calcium-induced calcium response [56, 59]. In support of this theory, loss of ciliary polycystins 
leads to defective calcium transients in response to several stimuli, such as fluid flow, angiotensin, 
and vasopressin [169]. However, recent studies have suggested that the ciliary PC1/2 complex is 
not responsible for fluid-flow mediated calcium influx [62, 202]. Despite these new observations, 
ciliary localization of PC1/2 must still play some role in cystic progression, however, as ablation 
of cilia in PC1- or PC2-deficient cells reduces cyst growth [203]. Perhaps in future studies, ciliary 
PC1/2 will be found to mediate cyst growth via influx of Na+ or K+, or via mechanically mediated 
PC1-CTT cleavage.  
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Whether the PC1/2 complex does or does not bring in calcium into the cell in response to 
fluid flow, the bulk of PC2 appears to be present in the endoplasmic reticulum to mediate release 
of calcium from intracellular stores [185] in response to local increases in intracellular calcium 
[204]. Additionally, PC2 has been suggested to act as an ER calcium leak channel [185]; such leak 
channels determine the steady-state levels of ER luminal calcium concentration (reviewed in 
[205]). PC2 can also indirectly regulate cellular calcium by interacting with two ER calcium 
channels. In cardiomyocytes, PC2 inhibits ryanodine receptors (RyR) by binding and decreasing 
RyR conductance [190]. PC2 is also able to bind inositol triphosphate receptors (IP3R) and modify 
IP3-induced calcium influx [189, 206]. Additionally, PC1 on the plasma membrane may still 
interact with PC2 on the ER [10] and indeed, PC1 may also help position the ER to facilitate an 
interaction between PC2 localized at the ER and molecules at the cell surface [185, 207, 208]. In 
general, overexpression of PC2 results in decreased ER calcium concentration, while the opposite 
occurs with PC1 overexpression [209-212].  
The open probability of the PC2 channel is regulated by [Ca2+]i in a bell-shaped curve, with 
highest PC2 activity at 0.1 uM [Ca2+]i and comparably less activity at both 0.001 uM and 10 uM 
[Ca2+]i [185]. The calcium-dependent activity of the PC2 channel can also be affected by direct 
interactions at the C-terminal tail of PC2 with a number of protein partners, including PC1 [16, 
17], actin binding proteins [213], IP3R [189, 192], and RyR [190]. The deletion of the coiled-coil 
renders PC2 inactive and not responsive to alterations in calcium levels [196]. Additionally, PC2 
activity can be altered by phosphorylation by casein kinase II [214] or by high levels of PI(4,5)P2 
in the membrane [215]. The importance of the ionic function of the PC1/2 complex is undeniable, 
however, the polycystin complex appears to have additional roles important during both 
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development and wound-healing processes which involve cell structure, polarity, migration, and 
EMT-related signaling.  
 
The Polycystin Structural Complex 
The PC1/2 complex interacts with many cytoskeletal structural components. In embryonic 
tubular epithelial cells, PC1 has a basolateral distribution [130, 135, 150, 216-220], where it has 
been localized to adherens junctions [217].  At these junctions, PC1 associates with E-cadherin as 
well as -, -, and -catenins [217, 221]. In renal epithelial cells from ADPKD patients, both PC1 
and E-cadherin are depleted from the plasma membrane, while N-cadherin is upregulated in an 
attempt to maintain the structure of adherens junctions [222]. PC1 also localizes to desmosomes 
[223, 224], and a severe mispolarization of desmosomal elements has been observed in cells from 
ADPKD cysts [225, 226].  The carboxy-terminus of PC1 binds vimentin, cytokeratins and desmin 
[224]. Additionally PC1 binds to extracellular-structural components. For instance, the LRR 
domain of PC1 binds to collagen, fibronectin, and laminin [227]. Indeed, the PKD domains of PC1 
itself are proposed to from homophilic interactions with other PC1 molecules on neighboring cells 
[151]. Therefore, not surprisingly, the intercellular adhesions between diseased cells are 
significantly more fragile and more sensitive to shear stress than normal renal cells [226]. 
The other polycystin, PC2, also co-localizes to cell-cell contacts [228], and interacts with 
tropomyosin-I, a protein involved in the stabilization of the actin cytoskeleton [229]. However, the 
interaction of PC2 with the cytoskeleton is likely to be important for its own stabilization and 
activity [230]. Thus PC2 needs to bind to actin [231], -actinin [213, 232] and microtubules [231, 
233] for activity, while binding to filamin-A inhibits PC2 activity [142, 195, 213].  
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 The interaction of PC1/2 with cytoskeletal and transcriptional pathways is important for 
the facilitation of tubulogenesis during development [234, 235]. While normal tubular epithelial 
cells assemble into a tubule-like structure when suspended in a collagen-matrigel mixture, cells 
lacking either PC1 or PC2 form cyst-like structures [236, 237]. The PC1 C-terminus is important 
for this role of the PC1/2 complex, as overexpression of it in murine inner medullary collecting 
duct (mIMCD3) cells can induce tubulogenesis, while expression of a truncation mutation lacking 
the coiled-coil domain of PC1 abrogated this affect [234]. 
Three overarching mechanisms may account for PC1/2-mediated tubulogenesis. First, the 
functional PC1/2 complex has a role in cell migration. Overexpression of full length PC1 in 
MDCK cells results in a strong migratory effect when the cells are challenged by wound healing 
[238]. This ability to induce migration was found to occur through G protein-mediated activation 
of the PI3K/AKT pathway [238]. The other polycystin, PC2, has been observed to localize to the 
lamellipodia of migrating cells where it interacts with Hax-1 [239], a protein which promotes 
migration by interacting with cortactin and Rac, two ARP2/3 complex regulators [240, 241]. 
Additionally, PC2 also associates with CD2AP, an adapter protein that regulates the assembly of 
focal adhesion complexes [242], however the functional consequences of these interactions with 
PC2 have not been fully investigated.  
Second, the PC1/2 complex may affect tubulogenesis through its role in the proper 
polarization of renal tubular cells. During tubulogenesis, cells undergo convergent extension, in 
which the tissue of an embryo is restructured along one axis and elongated along a perpendicular 
axis [243]. PC1 and its interaction with the polarity protein Par3 are necessary for convergent 
extension [243]. This interaction between PC1 and Par3 may also be important for the 
establishment of front-rear polarity during cell migration [243], which is defective in PC1-null 
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cells [244-246]. PC1 can affect cell polarity in yet another way, through the regulation of 
microtubule stability and dynamics. This effect is important for the regulation of the turnover rates 
of focal adhesion and ultimately impacts cell migratory rates and adhesive properties [247]. This 
dynamic regulation of microtubules is essential in PC1-mediated cell-orientation during migration 
[247]. In addition, polarized trafficking, which is necessary for proper apical-basal polarity, is also 
abnormal in ADPKD. Abnormalities in the exocyst complex, which is a docking factor for vesicles 
and is responsible for polarized trafficking, have been reported in ADPKD [248].  
Finally, the polycystins mediate transcriptional pathways important in both development 
and wound-induced epithelial-to-mesenchymal transition (EMT). Overexpression of full-length 
PC1 activates STAT1 and STAT3 via increased phosphorylation of JAK2 [249]. The effect 
requires the presence of the coiled-coil domain in PC1 [249]. Further studies corroborated that full 
length PC1 can bind JAK2, which leads to the phosphorylation and activation of STAT3 [138]. 
Indeed, tyrosine phosphorylation of STAT3 is abundant in cystic cells [138, 250]. Additionally, 
cleaved PC1 CTT can co-activate STAT3 in a JAK-independent manner, by direct interaction with 
STAT3 [138]. This 30 kDa fragment of PC1 CTT was further found to enhance STAT3 activation, 
and even allow STAT3 to be insensitive to its endogenous inhibitor, SOCS3, via a PC1-CTT 
interaction with SRC [251]. The WNT pathway is also important in ADPKD. Several WNTs have 
recently been found to be ligands for PC1 and to activate PC2-mediated calcium influx when 
bound [61]. Indeed, the persistent activation of -catenin-mediated transcription causes renal cyst 
formation in transgenic mouse models [252, 253].  Increased stabilization of -catenin results in 
cystogenesis in both PKD1 and PKD2 mutants. Thus, in PC2-null cells, -catenin levels are 
increased [254], and WNT/-catenin-mediated pathways are upregulated in PKD1 mutants, as 
determined by gene expression profiles [255]. Alternatively, MDCK cells engineered to 
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overexpress full-length PC1 have a more efficient turnover of -catenin at adherens junctions, and 
this results in reduced mechanical strength at cell-cell adhesion [238]. The increased turnover of 
-catenin was found to be due to increased activity of GSK3 induced by PC1 overexpression 
[238]. These structural roles of the polycystin complex are expected to play an important role in 
tubulogenesis as well as in response to renal injury. Another aspect of polycystin expression 
important in both renal injury and ADPKD is the induction of apoptosis. 
 
The Polycystins and Apoptosis 
ADPKD progression occurs relatively slowly throughout the lifetime of the affected 
individual, with GFR not decreasing below normal levels until around age 40 [33, 256], despite 
cysts having formed before birth [30, 31]. This slow disease progression is difficult to explain in 
an ailment characterized by increased cell proliferation. Interestingly, renal cyst formation is 
coupled to increased rates of apoptosis in models of several cystic diseases, including ADPKD 
[140, 257-259], ARPKD [258, 260, 261], and nephronophthisis [258].  Furthermore, cystogenesis 
has been found to be attenuated when apoptosis is inhibited pharmacologically [262]. It has been 
proposed that in the ADPKD cyst epithelium, the balance between cell proliferation and cell death 
is perturbed, and that loss of some tubular cystic cells by apoptosis may even stimulate 
proliferation in the surrounding cells [257]. Thus, the aberrant increase in programmed cell death 
of the cystic epithelium could be a mechanism that influences progression of ADPKD [67, 263].  
Direct manipulations of PC1/2 protein expression has found that sensitivity to apoptosis is 
altered by polycystins. PC1-null arterial myocytes that are subjected to mechanical stress undergo 
more cell death than cells expressing even just one allele of PKD1 [264]. Lack of mechanical 
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stimulation inhibits cleavage of the anti-cystogenic 35 kDa CTT of PC1, which increases CHOP-
mediated cell death [177]. Conversely, apoptosis is prevented in MDCK cells when full length 
PC1 is expressed, via activation of the PI3K/AKT pathway [235, 238]. PC2 also has been found 
to play a role in apoptosis. Functional PC2, via its purported role as an ER calcium release channel, 
can decrease cell sensitivity to apoptotic stimuli by lowering ER calcium [211]. Thus, several 
pathways exist by which dysfunctional PC1/2 proteins can lead to apoptosis, a cell death program 
which plays a definite, yet not clearly understood role in ADPKD progression. 
 
In summary, ADPKD cysts arise in utero during the particular developmental phase in 
which PC1/2 expression occurs for proper tubule formation. The pathophysiology of ADPKD 
renal cysts involves a complex cellular phenotype that includes increased proliferation, increased 
apoptosis, increased fluid secretion, altered apicobasal polarity, extracellular matrix abnormalities, 
changed calcium management and alterations to cilia or centrosomal fidelity [265, 266].  Cells 
lacking proper expression of PC1/2 protein products contain abnormal intracellular calcium 
concentrations, are mispolarized in several respects, and have altered sensitivity to apoptosis. 
These characteristics of PC1/2 mutants are instrumental in both cystogenesis and in the continued 
growth of the cysts. Intriguingly, cysts grow at varying rates. While genetic background does play 
a role in this variation, it cannot account for the discrepancy between ESRD onset entirely.  
 
THE NA,K-ATPASE 
Most animal cells maintain high intracellular concentrations of K+ and low cytoplasmic 
levels of Na+ compared with the extracellular milieu. This observation puzzled researchers, who 
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started looking for the mechanisms responsible for the transmembrane ion differences of cells 
(reviewed in [267]). In 1957, Skou discovered that the Na,K-ATPase (NKA) is the plasma 
membrane enzyme responsible for the countertransport of  Na+ for K+ across the cell plasma 
membrane [268]. NKA uses the energy of the hydrolysis of ATP to transport 3 Na+ out in exchange 
for 2 K+ that are brought into the cell [269]. The ionic gradients generated by the NKA contribute 
to creating the resting membrane potential of most cells and allows the generation of an action 
potential in excitable cells of the nervous system and muscles [270, 271]. In the kidney, NKA 
plays an important role in the reabsorption of sodium, water and various vital solutes (glucose, 
amino acids), which are linked to sodium transport [272]. NKA ensures basic cellular homeostasis 
in all cells, but it also contributes to the specialized roles of tissues. In heart and skeletal muscle 
cells, the activity of NKA, tightly coupled to the sodium-calcium exchanger, contributes to the 
control of intracellular calcium and contractility of the cells [273, 274]. In nerve and glial cells, 
NKA aids in the restoration of ion gradients after an action potential is triggered, to reestablish the 
basal transmembrane ion gradients of cells [270, 271]. Other roles of NKA derive from its 
functional association with other channels, including ATP-sensitive K+ channels [275, 276], 
glutamate transporters [277] and BKCa channels [278].  
 
Structure 
The NKA is a protein complex composed of an α, , and γ subunit ([279-281], and Figure 
1.2) in a 1:1:1 stoichiometric ratio [282]. While the α and  subunits are essential for ATPase 
activity [283, 284], the γ subunit is an accessory protein which regulates NKA activity, but is not 
essential for NKA function [285]. The α and  subunits are synthesized and assembled 
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independently in the ER, from which they are trafficked to the cell surface. Only assembled α- 







-NKA is considered the catalytic subunit of the complex. It has a molecular mass of 110 
kDa and contains the binding sites for Na+ and K+ and ATP. As shown in Figure 1.2, it is composed 
of ten transmembrane helices as well as three cytoplasmic domains: the nucleotide binding domain 
(N), the phosphorylation domain (P), and an actuator domain (A) [288], which is involved in the 
transmission of conformational changes required for the movement of the ions [289]. The N and 
P domains are formed by the loop between TM4 and TM5 while the A domain is formed by the 
Figure 1.2. The domains of the Na,K-ATPase. On the  subunit: A, actuator domain; N. nucleotide 
binding domain; P. phosphorylation domain.  Blue star denotes the Asp371 to which the terminal phosphate 
of ATP is attached during the catalytic cycle. On the  subunit: Yellow circles denote N-glycosylation sites 




N-terminal tail and the TM2-TM3 loop [289]. Another important structural feature of the -NKA 
include the extracellular loop between TM7 and TM8, which provides contact sites between the  
and  subunits [290]. Additionally, a caveolin binding domain, present in the -NKA N-terminus, 
allows the localization of NKA to caveolae via association with caveolin-1 [291]. Four isoforms 
of -NKA exist in mammalian cells (1, 2, 3 and 4), which share an overall identity of ~80% 
[292]. 1 is ubiquitously expressed and is the only subunit present in the kidney [293-295]. The 
2 isoform is expressed in skeletal muscle, smooth muscle, heart, brain, lung, and adipocytes [294, 
296, 297]. The 3 isoform is expressed in neurons, ovaries, and adult human heart [279, 281, 297]. 
Expression of 4 is limited to male germ cells of the testis and sperm [298-305].  
The -NKA subunit, is a 36 kDa type II membrane protein. It has a small N-terminal 
cytoplasmic domain, one transmembrane helix, and a large, highly glycosylated, extracellular 
domain [281]. -NKA enhances the rate of synthesis, half-life, trafficking, and membrane 
stabilization of -NKA [287, 306-308]. The presence of the -NKA is required for the maturation 
and insertion of the NKA complex into the plasma membrane [294, 309, 310]. Three disulfide 
bridges are also present in the -NKA extracellular domain, which are important for the targeting 
of the NKA complex to the plasma membrane [283, 311]. The disulfide bridges also have some 
role in -NKA catalytic activity, as their disruption decreases the binding and occlusion of K+ by 
the NKA [310]. Finally, the glycosylation of the extracellular domain of -NKA has little effect 
on NKA catalytic activity [312] or on its delivery to the plasma membrane [313], but glycosylation 
of -NKA does affect the structural role of NKA (see the section “Ouabain as an effector of 
EMT”).  Three isoforms of -NKA exist (1, 2 and 3), which share 39-48% sequence homology 
[314, 315]. All three  isoforms can associate with all four  isoforms [316-319]. Similar to -
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NKA, the  subunits are differentially expressed by tissues. 1 is expressed ubiquitously, 2 is 
observed in the heart, skeletal muscles, and glial tissue, and 3 is found in testes, retina, liver, and 
lung (reviewed in [320]). The cation affinity of each -NKA is affected by its association with 
different  subunits [316-318, 321]. This allows for the fine-tuned control of NKA in each specific 
tissue. In the normal kidney, as well as in ADPKD cysts, the only isoforms expressed at significant 
levels are 1 and 1 [322]. 
The γ subunit (or FXYD2) is an accessory protein that is not required for NKA catalytic 
activity [323]. This subunit was at first found in only renal tissue [324]. Since then, at least 6 other 
isoforms have been identified and grouped together into a family of proteins, characterized by a 
distinct amino acid motif, “FXYD” (reviewed in [325]). These are all small (7.5 - 19 kDa) single-
span membrane proteins [285, 326]. Members of the FXYD family are also expressed in a tissue 
specific manner [285, 327, 328], and they are more abundant in tissues that are either involved in 
fluid transport or are electrically excitable [326]. Specifically, FXYD1 is present in heart and 
skeletal muscle [329, 330], FXYD3 has been detected in uterus, stomach, colon and skin [331, 
332]. FXYD5 is not well characterized but is upregulated in several cancer tissues [333], while 
FXYD6 and FXYD7 have roles in the brain (reviewed in [334, 335]). In the kidney, FXYD2 and 
FXYD4 are present [336, 337]. FXYD4 induces a 2-3 fold increase in the affinity of the NKA to 
Na+ [338, 339]. It has therefore been suggested that in conditions of systemic Na+ depletion, the 
presence of a FXYD4-NKA complex will favor efficient Na+ reabsorption [338]. Indeed FXYD4 
expression is increased by a low salt diet [337]. The expression status of FXYD4 in ADPKD is 
unknown, however FXYD2 expression is known to be increased in ADPKD cells [322]. FXYD2 
increases the affinity of -NKA for ATP [340, 341] and expression of FXYD2 is upregulated in 
the kidney by increased hypertonicity, or high salt [342, 343]. Interestingly, collecting duct cells 
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subjected to high hypertonicity, a condition which induces FYXD2 expression, became more 
ouabain-sensitive [342], and elevated ouabain-sensitivity is also observed in ADPKD cells [322]. 
 
The NKA Catalytic Cycle 
The NKA is a member of the P-type ATPase family. This distinction refers to the 
intermediate formed during ATP hydrolysis in which the terminal phosphate of ATP is attached 
to -NKA via an aspartate residue 
(Asp371) [344, 345]. The active 
transport of Na+ and K+ ions by NKA 
occurs at a fixed stoichiometry (3:2, 
respectively) and this transport is 
accomplished through a continuous 
cycling of the enzyme through different 
conformations [346, 347]. Two main 
NKA conformations exist: the sodium-
bound E1 state and the potassium-
bound E2 state [281].  As illustrated in 
Figure 1.3, the entire catalytic cycle is 
described as follows: The E1 form has 
cation binding sites that face the cell 
cytoplasm and shows high affinity for 
Na+. Intracellular Na+ ions bind to -NKA and catalyze the phosphorylation of NKA by a 
Figure 1.3. 
Figure 1.3. The catalytic cycle of the Na,K-ATPase. 
Shaded areas denote each particular conformation of 
the -NKA. Ouabain binds when the enzyme is in E2P 
and SRC binds when in the E1 conformation. ATP and 
Na+ binds to the intracellular portion of NKA while K+ 
binds to the extracellular portion. 
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previously bound ATP molecule. The Na+-catalyzed phosphorylation produces a conformation 
called E1P. Then, ADP leaves the enzyme, and the 3 Na+ ions bound to the enzyme become 
occluded within α-NKA [348]. Another conformational transition occurs as the enzyme moves 
into the E2 conformation, losing affinity and releasing Na+ ions to the extracellular side. This 
conformation also has a high affinity for K+ ions, which become bound from the extracellular 
surface. The  subunit helps -NKA to trap K+ in a pocket [349]. The binding of 2 K+ ions results 
in the dephosphorylation of NKA, and Pi is released at the cytoplasmic surface. At this point, the 
2 K+ ions are occluded. Then ATP binds to the ATP regulatory site in -NKA, causing -NKA to 
return from the E2 to the E1 form, driven by the difference in binding energy for ATP. The E2 
conformation has a low affinity to K+ ions, and therefore the K+ ions are released into the 
cytoplasm. The NKA enzyme is then ready to initiate a new catalytic cycle [281].  
 
Subcellular localization of NKA  
In epithelial cells, the NKA has two different but integrated roles. The first, as previously 
discussed, is the translocation of ions across the plasma membrane [268]. The second role involves 
the movement of ions and solutes across the entire epithelium [350]. The NKA resides exclusively 
in the basolateral surface of most epithelial cells [270, 351, 352]. It is this polarized localization 
of NKA, and that of other co- and countertransporters, which drives the net transport of solutes 
across the whole epithelium [353, 354]. The targeting of NKA to the basolateral membrane may 
simply be attained due to the lack of a specific signal on NKA typically needed to join membrane 
rafts headed to the apical membrane during sorting in the Golgi [355]. Mislocalization of 25% of 
NKA has been described in some ADPKD models [356-358], but not consistently [359]. In the 
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ADPKD cells used in this lab, NKA is commonly found at its proper place in the basolateral 
membrane [322]. Thus, in the normal kidney, the exclusive localization of NKA in the basolateral 
membrane is the driving force for the Na+ reabsorption essential to maintain extracellular volume 
and blood pressure [272]. Meanwhile, in the ADPKD cystic epithelium, the basolateral localization 
of NKA helps drive fluid secretion into the cyst lumen [360, 361], promoting cyst growth. 
 
Mechanisms of NKA regulation 
The activity of the NKA is essential for the function of each cell. However, both the 
expression and activity of NKA can be regulated at multiple levels to fine tune responses to stimuli 
or to cater to a cell’s needs. Numerous mechanisms are involved in this regulation of NKA to adapt 
to changing physiological demands. These mechanisms can be broadly placed into 4 groups. 1) 
Any change in intracellular sodium or ATP affects the NKA activity, as both are limiting factors 
for the catalytic cycle of NKA (reviewed in [362]). 2) Peptide hormones or neurotransmitters cause 
the phosphorylation of NKA by protein kinases, such as PKA or PKC [363], which modulates 
NKA cell surface expression [324]. 3) NKA can also be regulated by glutathionylation and 
palmitoylation of cysteine residues [364, 365]. Thus, oxidant stress can cause the modification of 
NKA thiols, which leads to NKA inhibition [366, 367]. 4) Steroid hormones, like aldosterone, can 
affect-NKA and -NKA gene transcription, leading to an increased number of NKA pump units 
[295]. Indeed, several hormones are involved in the regulation of the NKA [295, 368, 369], the 






Ouabain is a steroid derivative [284] which has a high specificity for binding to the NKA 
[370]. Ouabain binds directly to the extracellular regions of the α-NKA subunit, between the 
transmembrane helices TM1 and TM2 [370], an interaction which does not involve -NKA [371]. 
In particular, ouabain selectively binds to E2P conformation of -NKA [372, 373], and inhibits 
the pumping abilities of NKA [374-376]. Depending on the species, the affinity of ouabain for -
NKA varies among the -NKA isoforms. In rodents, α1 has a very low affinity for ouabain (with 
an inhibition constant (Ki) of ~10-5 M), while the other isoforms are progressively more sensitive 
(Ki of ~10-7 and 10-8 M for α2 and α3, respectively), while the α4 isoform has the highest ouabain 
affinity ((Ki of ~10-9 M). In contrast, inhumans, α-NKA isoform affinities for ouabain are more 
similar, mainly due to α1 being much more sensitive to ouabain than its rodent homolog [377]. 
The structural basis for the isoform specific sensitivity to ouabain has been found to reside, at least 
in part, in the first extracellular domain of the α-NKA. Specifically, ouabain binding depends on 
two positively charged amino acids located at the boundary of TM1 and TM2 with the extracellular 
loop that connects them, whereas the other α-NKA remain highly sensitive [378, 379].  
 
Ouabain Synthesis and Regulation 
Ouabain is synthesized and released from the adrenal glands, similar to other steroid 
hormones [380]. This conclusion was reached by several observations. First, cultured bovine 
adrenal cells were found to secrete ouabain [380]. High concentrations of ouabain were reported 
in the adrenals of several species [380, 381]. Second, adrenalectomy can decrease levels of ouabain 
in blood [380, 382]. Interestingly, adrenal cortex tumors have been observed to overproduce and 
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secrete ouabain [383], and patients with these tumors have abnormally high ouabain plasma levels. 
Ouabain levels were normalized in those patients after removal of the adenomas [383-385].  Third, 
the administration of anti-ouabain antibodies to rats produces adrenal cortex enlargement, further 
implicating the adrenal gland as a source of ouabain [386]. In addition to production by the adrenal 
glands, ouabain can also be produced by other tissues, such as the hypothalamus [387, 388].  
The synthesis of ouabain is believed to follow a pathway similar to that of aldosterone. 
This is supported by the observed increase in secretion of ouabain by administration of the 
biosynthetic precursors of aldosterone: hydroxycholesterol, pregnenolone, and progesterone [389, 
390]. Inhibition of 11 -hydroxylase, the pen-ultimate enzyme in the aldosterone synthesis 
pathway, prevented the secretion of both aldosterone and ouabain [391], further implicating a 
similar synthesis mechanism. In addition, the molecular mechanisms which induce ouabain 
synthesis appear to be related to molecules involved in blood pressure regulation (illustrated in Fig 
1.4). Adrenocorticotropic hormone (ACTH), which stimulates production of steroid hormones in 
adrenal cortex cells, also increases ouabain production [392, 393]. ACTH administration also 
increases blood pressure, and this event is abrogated in mice expressing a ouabain-resistant form 
of the 2-NKA isoform [394], and exacerbated in mice expressing ouabain-sensitive 1-NKA 
isoform [395]. Ouabain synthesis is also increased by angiotensin II, an effector of the RAAS 
pathway which causes vasoconstriction and Na+ reabsorption [385, 388, 396, 397]. Other 
molecules which can increase ouabain expression include vasopressin, phenylephrine, and 
epinephrine [385, 392], which all cause vasoconstriction and increased blood pressure. In general, 








Elevated ouabain concentrations are particularly prominent in states of volume expansion. 
Four physiological conditions have so far been observed to result in increased levels of ouabain. 
1) Salt-loading increases plasma ouabain concentrations in both humans and rats [406-408]. 
Excessive salt intake is well known to cause volume expansion [287, 409]. 2) High circulating 
levels of ouabain also occur in pregnancy [410], and pregnancy is associated with plasma volume 
expansion as a result of renal Na+ and fluid retention [411]. 3) Exercise also induces blood volume 
Figure 1.4. Known stimuli of ouabain synthesis by the adrenal glands. Precursors of aldosterone 
synthesis increase ouabain concentrations; this effect can be inhibited by 11--hydroxylase inhibition. 
Epinephrine, produced by the adrenal glands, and its synthetic mimetic, phenylephrine, can increase 
plasma ouabain. ACTH and Vasopressin, secreted from the brain, increase ouabain concentrations. 




expansion, increasing volume 10-12% within 24 h of exercise [412]. Elevated plasma ouabain 
after exercise has been recorded in both humans and dogs [413]. Additionally, physical exercise is 
associated with increased epinephrine and norepinephrine [414], which augments the synthesis of 
ouabain, as mentioned previously. 4) Importantly, renal stress increases ouabain levels. Following 
nephrectomy, serum levels of ouabain are substantially elevated [415]. Nephrectomy can cause 
elevations in blood pressure, as well as diastolic dysfunction, ventricular hypertrophy, and cardiac 
fibrosis [405, 416, 417]. These symptoms can also be observed in ESRD, another condition in 
which patient serum levels of ouabain are substantially elevated [418, 419]. In fact, plasma ouabain 
levels have been suggested as a biomarker to predict acute kidney injury after cardiac surgery [420, 
421]. Additionally, as progressive congestive heart failure is often associated with a rapid fall in 
renal functions (reviewed in [422]), it is unsurprising that heart failure patients were observed to 
have nearly a 4-fold increase in mean plasma ouabain concentrations compared to healthy controls 
[423].  
  
Ouabain targets the heart and vasculature 
The ionic gradients generated by NKA are important to maintain membrane potential 
excitability in cells like myocytes [272]. Ouabain, as well as other structurally similar molecules 
capable of inhibiting NKA, are called cardiac glycosides due to their ability to increase heart 
contractility and cardiac output. For this reason ouabain is considered a cardiotonic steroid. 
Myogenic tone is controlled by NKA activity via the functional relationship that exists between 
NKA, and the sodium-calcium exchanger (NCX) [273, 274]. The NCX is the major extrusion 
mechanism for the calcium in cardiac cells. The removal of calcium is necessary for muscle 
relaxation between beats and for cellular calcium balance [424]. Ouabain, by inhibiting NKA, 
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causes intracellular Na+ levels to rise, which reduces the gradient necessary for NCX to pump 
calcium out of the cell. The NCX and NKA exist together in a complex with the cytoskeletal 
protein ankyrin-B [425], and thus local, subcellular increases in Na+ are enough to mediate this 
process. 
The increased intracellular calcium caused by ouabain and other cardiotonic steroids 
enhances the ability of myocytes to contract. Since the 18th century, cardiac glycosides have been 
prescribed for congestive heart failure, in the form of herbal remedies, such as foxglove [426]. 
Later, cardiac glycosides were isolated from these natural sources and used medically until they 
were set aside for safer alternatives, although in some countries they are still being used [426, 427]. 
The main isoforms of the NKA in cardiac and vascular smooth muscle cells are 1 and 2 [428-
430]. The 2 subunit has been suggested to play a specific subcellular role in the cardiotonic effect, 
while the 1 subunit may play more of a housekeeping role in regulating bulk cytoplasmic Na+ 
[394]. In support for the functional linkage of 2-NKA to NCX, mice heterozygous for the 2 
isoform have a hyper-contractile phenotype as a result of increased calcium transients, while 1 
heterozygotes were hypocontractile [431]. 
The cells of the vasculature are also a target of ouabain effects, via the same mechanisms 
described for the heart. Contraction of the vasculature by ouabain results in increased peripheral 
vascular resistance and higher blood pressure, and thus the infusion of ouabain is observed to 
increase blood pressure [432, 433]. Other situations have also revealed the importance of the 
activity of NKA in the vasculature in regulating blood pressure. For instance, NKA overexpression 
in mouse vascular smooth muscle, caused the opposite effect of ouabain administration, a decrease 
in blood pressure [434]. In cardiac hypertrophy, which is an adaptive response to high blood 
pressure, NKA active ty was observed to be reduced [435-438]. Finally, chronic treatment with 
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ouabain induces the upregulation of the arterial expression of the NCX1, SERCA2, and TRPC6 
and so may contribute to arterial remodeling and thus lead to established hypertension [439-441].  
 
Ouabain targets the kidney  
 One of the most essential functions of the kidney is the maintenance of fluid and salt 
balance. The mechanisms in place for this balance require the function of the NKA. For instance, 
under systemic excess of K+, basolateral NKA activity is required to provide the necessary gradient 
to move K+ across the renal epithelium in order for its secretion [442]. Under low Na+, the kidney 
maintains Na+ blood plasma levels by increasing Na+ reabsorption in the renal tubules. This 
depends on the activity of NKA, which moves Na+ across the basolateral side of the tubular cells 
into the interstitium, generating a Na+ gradient which allows the apical transport of Na+ via Na+-
dependent channels.  
Ouabain is especially important for body fluid homeostasis in response to volume 
expansion. Low volume and low sodium is mainly handled by RAAS activation, resulting in 
increased volume retention and increased Na+ reabsorption by the kidney [102]. While the 
activation of RAAS accounts for the physiological and pathophysiological responses to volume 
depletion, it cannot fully explain the responses to acute or chronic blood volume expansion [443, 
444]. Originally, two factors, aldosterone and glomerular filtration rate (GFR) were considered 
instrumental in natriuresis, the excretion of Na+ in urine, which is a mechanism to decrease blood 
pressure. However, saline infusion-induced natriuresis was found to be maintained even under 
conditions that held these factors static, and thus unable to cause the observed natriuresis [445]. 
This led to the postulation of the “Third Factor Theory,” which suggests that volume expansion is 
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associated with an increase in a circulating factor that is natriuretic [445]. Subsequently it was 
found that a factor in plasma from volume-expanded animals could inhibit the renal NKA [446-
449]. Studies from many researchers point to either ouabain, or other cardiac glycosides, as being 
this third factor.  For instance, the presence of a plasma factor that could inhibit NKA correlated 
positively with blood pressure in patients with essential hypertension [402]. Additionally, plasma 
volume expansion is associated with elevated levels of cardiac glycoside-like immunoreactive 
material in dogs [450], and anti-cardiac glycoside antibody lowers blood pressure in rats with 
DOCA-induced hypertension [451]. However, a bona fide natriuretic factor would be produced in 
response to elevated blood pressure in order to reduce blood pressure by increasing natriuresis. 
While ouabain is increased in response to blood pressure, its ability to decrease blood pressure by 
natriuresis has not been definitively proven. While studies in both normotensive [386] and 
hypertensive [452] animals showed reduced natriuresis in response to administration of anti-
ouabain antibodies, administration of ouabain itself does not consistently increase natriuresis 
[453]. Thus, the exact reason by which ouabain is increased during volume expansion still requires 
further investigation. In any case, it is clear that excessive ouabain can lead to high blood pressure 
conditions, such as pre-eclampsia [454] and essential hypertension [402, 451]. As cystic expansion 
in ADPKD is accelerated by high blood pressure [455], it is tempting to speculate that ouabain 
may also play a role in the generation of ADPKD related hypertension, and thus cystic progression. 
The experiments of this thesis have been focused exclusively on the direct actions of ouabain on 
renal collecting duct cells, not its actions on blood pressure. However, the systemic effects of 





The Na,K-ATPase as a signal transducer 
 Not only does ouabain inhibit the catalytic function of NKA to elicit many of its effects, 
but it also induces the activation of signaling pathways via conformational changes in the NKA. 
This role of ouabain was first discovered in 2002 by Xie and Askari and it depends on the ability 
of NKA to serve as a receptor and signal transducer for ouabain effects [456]. The ouabain-induced 
and NKA-mediated signaling pathway begins with the activation of the kinase SRC. In its E1 
conformation, NKA binds to SRC [457], which sequesters SRC from the cytosol and inhibits its 
activity [458]. Ouabain selectively binds to the E2P conformation of -NKA and blocks it from 
further progressing in the catalytic cycle [372, 373]. In the E2P conformation, NKA releases SRC, 
which becomes active [457, 458]. As proof of the validity of this model is the enhancement of 
SRC activity obtained by shifting the NKA equilibrium towards E2, with low extracellular K+ 
concentrations [457]. Not all NKA expressed in the cell is able to signal ouabain effects; only a 
NKA subpopulation residing in caveolae forms part of the ouabain activated cascade of cellular 
events [459]. Once SRC has been activated, several other downstream pathways are activated by 
ouabain, including the transactivation of the epidermal growth factor (EGFR), the RAS-RAF-ERK 
pathway, and the PI3K-AKT pathway [460-472]. NKA may exhibit different signaling pathways 
(shown in Fig. 1.5) depending on the nature of the existing neighboring proteins and those that are 
recruited upon stimulation in a cell-specific, locus-specific, and stimulus-specific manner [473].  
Therefore, ouabain has been observed to elicit diverse cellular functions such as proliferation, 
adhesion, motility, calcium alterations, and metabolic pathway modifications important in cardiac 
hypertrophy, ischemia, as well as the development and postnatal maturation of kidneys [322, 403, 
460, 471, 474-486]. 
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The signaling abilities of NKA also have a role in the previously described tissues targeted 
by ouabain. For instance, in the heart, ouabain can activate signaling pathways that lead to cardiac 
myocyte hypertrophy, specifically by induction of the PI3K/AKT pathway [472]. Ouabain aids the 
differentiation of cardiomyocytes via ERK activation [487]. Finally, ouabain treatment before 
ischemic injury is cardio-protective via a pathway that relies on SRC activation [483, 484], and/or 
PI3K and PKC [485, 486].  
Additionally, the signaling abilities of ouabain can also have a role in the salt handling in 
the renal proximal tubule. This was clearly shown in experiments using Dahl salt-sensitive and 
salt-resistant rats, animals which respond to salt-loading with hypertension and without 
hypertension, respectively. The salt-sensitive animals did not respond to ouabain with SRC 
pathway activation. However, in salt-resistant animals ouabain induced the SRC/MEK/ERK 
signaling cascade, which culminated in the decreased plasma membrane localization of the apical 
sodium transporter, NHE3, leading to an increase in sodium excretion [488, 489]. Thus, ouabain-
mediated signaling in proximal tubule cells promoted natriuresis, while conversely, the impairment 
of NKA signaling may contribute to the salt-induced hypertension of the salt-sensitive rats [490].  
Importantly, NKA signaling is activated by physiological levels of ouabain in ADPKD 
cells but not in NHK cells. Nguyen and colleagues showed that ouabain enhanced ADPKD cell 
proliferation, but not that of NHK cells [322]. They further showed that this increased proliferation 
was due to increased phosphorylation of ERK in response to ouabain, which did not occur in NHK. 
Interestingly the 1-NKA of ADPKD cells is more sensitive to ouabain. Thus, ADPKD cells have 
approximate 25% of their total NKA activity inhibited by ouabain with a IC50 value of ~1 nM, 
while the remaining 75% has the typical lower affinity of the 1-NKA of normal cells (IC50 of 0.1 
µM) [322]. This increase in ouabain affinity for a subpopulation of NKA in ADPKD cells is not 
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due to the expression of different α isoforms in the cells, but appears to rather depend on different 
protein/protein associations [322]. Subsequently, SRC and B-RAF activity were also found to be 
increased by ouabain in ADPKD cells, confirming the pathway induced by ouabain in ADPKD 
cells is the NKA-SRC-RAS-BRAF-MEK-ERK cascade [491]. This signaling pathway required 
the presence of caveolae, considered to be the prime location for NKA-mediated signaling [492], 
and ultimately caused increased proliferation by the downregulation of p21 and p27, two cell cycle 
inhibitors [491].  
Another characteristic of ADPKD cystic cells is their penchant to increase apical fluid 
secretion in response to cAMP [493-496], while NHK cells do not significantly increase secretion 
in response to the same stimulus [493, 497]. Ouabain was not able to increase fluid secretion on 
its own, but significantly enhanced cAMP-stimulated fluid secretion in ADPKD cells [360]. In 
contrast, ouabain did not have a significant effect in fluid secretion in normal kidney cells. 
Interestingly, the ability of ouabain to enhance cAMP-mediated cyst area expansion was subjective 
to the expression of PKD1, as the ability of ouabain to increase cyst size was greatest in a PKD1-
/- kidney, compared to PKD1+/- and PKD1+/+ kidneys, during metanephric organ culture [360]. 
These effects of ouabain on fluid secretion and on the total surface area of microcysts could be 
abrogated by the pharmacological inhibition of components of the ouabain-mediated signaling 
cascade [360]. Subsequent studies found that ouabain could not induce cyst formation in a 
metanephric organ culture without the presence of the chloride channel CFTR [361]. Fluid 
secretion in response to cAMP is mediated by chloride transport in ADPKD cells [493], and 
ouabain increased CFTR membrane expression, and also elevated the expression of the positive 








The compelling data outlined in the previous paragraphs, shows ouabain as a novel factor 
able to enhance the ADPKD phenotype and perhaps speed the progression of the disease. The data 
also suggests that ouabain might enhance other characteristic features of the cystic epithelium. In 
this thesis, focus has been placed on three cellular processes that are particularly related to the 
Figure  1.5. Ouabain‐mediated  signaling pathways. Ouabain‐bound NKA by  acting  through  a 





developmental and wound response phenotype of ADPKD cells, including apoptosis, EMT, and 
altered intracellular calcium of the cells. A brief overview of ouabain-mediated alterations 
regarding these three processes is given below, followed by a section outlining the multiple points 
at which the actions of polycystins and that of ouabain-bound NKA might intersect. 
 
Ouabain as an effector of apoptosis 
Ouabain has been shown to influence programmed cell death in a cell-type specific manner. 
For instance, ouabain has pro-apoptotic effects in normal neuronal cells, as well as in neuro- and 
glioblastoma cells, hepatic cells, blood peripheral lymphocytes, lymphoma cells, and prostate 
cancer cells [498-506]. In contrast, ouabain protects endothelial cells, cerebellar granule cells, 
renal proximal tubule cells, and COS-7 cells against apoptosis [476, 507-510]. Ouabain also has a 
dual pro- and anti-apoptotic effect in smooth muscle, umbilical vein endothelial cells, and 
fibroblast [511-513].   
One would hypothesize that the inhibition of enough NKA pumps by ouabain would lead 
to the dissipation of the Na+ and K+ ion gradients that are essential for the cell and thus cause cell 
death. However, even when a sharp elevation in the cell [Na+]/[K+] ratio is caused by ouabain, a 
decrease in cell survival does not occur in all cell types (reviewed in [514]). In some cases, 
ouabain-mediated cell death can be blunted or fully abrogated by inhibition of ouabain-induced 
signaling pathways, [515, 516], suggesting that ouabain-mediated cell death isn’t solely reliant on 
ionic alterations. The observed cell death mediated by ouabain can occur by conventional 
mechanisms, such as apoptosis [503, 517-522] anoikis [523], autophagy [524, 525], and necrosis 
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[508, 526]. In some cases, researchers have observed hybrid forms of cell death, including features 
of both necrosis and apoptosis, in response to ouabain [499, 515, 527, 528].  
Interestingly, the NKA has been suggested to act as a sensor protein capable of facilitating 
a rapid response to apoptotic stimuli [362, 529, 530], which may account for the cell type-specific 
induction towards, or protection from, cell death. The strongest evidence for NKA as an apoptotic-
sensor comes from Lauf and co-workers, who found canonical BCL-2 protein motifs in the N-
terminal domain of-NKA subunits and who subsequently co-immunoprecipitated the BCL-2 
proteins, BCL-XL and BAK, with the -NKA enzyme [530, 531]. Indeed, cells overexpressing 
BCL-2 are less susceptible to ouabain-mediated cell death [523, 532], and conversely, protection 
from radiation-induced cell death due to BCL-2 overexpression is abrogated by ouabain [533]. It 
has also been suggested that the pro-apoptotic effects of ouabain may have some function on tissue 
repair [519]. 
 
Ouabain as an effector of EMT 
 Along with its pumping and signaling functions, the NKA also has a structural role. Thus, 
the extracellular domain of -NKA subunits form bridges between adjacent cells [286, 308, 534-
537]. It is estimated that half of -NKA subunits interact with other  subunits in adjacent cells 
(MDCK) [537]. 1-NKA has 3 N-glycosylation sites, all occupied by N-glycans [538]. Prevention 
of N-glycosylation has little effect on - assembly [312], trafficking to the plasma membrane 
[311, 539, 540] or NKA activity [311, 312, 541]. However, N-glycans on -NKA are important 
for the initiation, maintenance and regulation of epithelial junctions, as shown by Vagin and 
colleagues [539, 542].  
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Additionally, NKA co-distributes with the adherens junctional proteins, E-cadherin, -
catenin, -catenin, and occludin [543]. As ouabain-bound NKA leads to the internalization of the 
NKA complex, ouabain promotes turnover of these -bridges, which alters cell adhesion and 
permeability. Ouabain was found to decrease the adhesion of MDCK cells to substrate, and this 
depended on activation of MAPK (ERK) [461, 462]. In addition, ouabain has been observed to 
cause the removal of occludin and -catenin from the plasma membrane of MDCK cells due to 
the endocytosis of -NKA [544]. Also, depending on the dose, ouabain modifies the transepithelial 
electrical resistance (TER), which is dependent on the “tightness” of the adhesions between cells 
[461, 536, 545, 546]. 
 Interestingly, in some cases, ouabain-dependent effects on cell adhesion are similar to those 
elicited by either low extracellular K+ concentration or the presence of the Na+ ionophore, 
gramicidin [461, 547, 548]. This demonstrates that the maintenance of low intracellular Na+ by the 
NKA is crucial for the integrity of intercellular junctions (reviewed in [542]). Additionally, the 
polarization of cells requires the formation of tight junctions, and thus proper NKA localization to 
the basolateral membrane relies on these tight junctions [549]. However, the -NKA bridges 
themselves are critical for maintaining the integrity of tight junctions and apical-basolateral 
polarity, and therefore -NKA is also important in preventing the translocation of proteins from 
apical to basolateral membranes [286, 308, 534, 536, 537, 547, 548, 550, 551].   
Finally, the binding of ouabain to NKA affects several EMT-related signaling pathways. 
The nuclear translocation of -catenin from the plasma membrane is induced by ouabain in MDCK 
cells [461]. Also ouabain stimulates the expression of TGF1 in cardiac myocytes [552]. Finally, 
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collagen production increases due to EMT [553] and, through SRC activation, ouabain induces 
collagen-I synthesis in cardiac fibroblasts [417] and in dermal fibroblasts [554]. 
 
Ouabain as a regulator of intracellular calcium 
Ouabain has a role in calcium signaling. In response to ouabain binding to -NKA, 
activation of a calcium channel is often observed; however, the specific channel involved appears 
to be cell type dependent, as illustrated in Figure 1.6. As mentioned previously, in myocytes of the 
vasculature and heart, ouabain inhibition of NKA leads to increase in calcium via the NCX [374-
376, 555, 556]. This mechanism is responsible for the cardiotonic effect of ouabain and other 
cardioglycoside steroids, as well as for the changes in blood pressure, secondary to contraction of 
the vascular smooth muscle cells (reviewed in [555, 557]). Alternatively, in renal proximal tubule 
(PT) cells, ouabain-bound NKA causes slow calcium oscillations that have a periodicity of 4-5 
minutes [403, 477, 558-560]. In these cells, the mechanism responsible does not depend on NCX, 
but rather, is due to a direct interaction between -NKA on the plasma membrane and IP3Rs on 
the ER membrane [558-560].  
The binding of ouabain induces a conformational change in NKA which leads to release of 
calcium from intracellular stores, without affecting the pumping activity of NKA [558-560]. 
Finally, in cardiomyocytes and in some neurons, ouabain-mediated calcium alterations rely at least 
partially on the activity of L-type calcium channels found on the plasma membrane, which bring 
in calcium in response to membrane depolarization [561]. This depolarization is a result of 









Summary and areas of investigation  
Due to their role in the renal filtration system, renal epithelial cells are constantly working 
to secrete and reabsorb as necessary. It is likely that renal cells will need to cope with wounding 
Figure 1.6. Ouabain targeted tissues and calcium alterations. Ouabain-bound NKA decreases the 
activity of NCX in cardiomyocytes and in smooth muscle cells of the vasculature, resulting in increased 
intracellular calcium. This effect relies partially on LTCC activity. In proximal tubule (PT) cells of the 
kidney, ouabain causes the activation of IP
3
R channels, yielding calcium oscillations. Before this thesis, 
the effect of ouabain on calcium in collecting duct (CD) cells was not elucidated. 
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stresses which could be caused by transport of toxic components, or by free radical generation 
[568]. ADPKD has many features in common with a kidney that is responding to ischemic damage 
or ureteral obstruction (reviewed in [63]). For instance, renal epithelial cells partially 
dedifferentiate and proliferate in response to ischemia, ureteral obstruction, and this also occurs in 
ADPKD [64, 78, 569]. Additionally, an increased rate of apoptosis is also observed in these cases 
[64, 78, 569]. Specific calcium signals are known to occur in development and in wound healing 
[570-573] and abnormal calcium handling also occurs in ADPKD [197-199, 209-212].  Therefore, 
the central hypothesis of this work is that ouabain enhances the phenotypes which yield the 
observed dedifferentiated cystic cells of ADPKD [226, 574, 575]. 
The actions of ouabain may intersect with those of the polycystins at several points. From 
a purely theoretical point of view, ouabain may act systemically to enhance cystic progression. 
Polycystins are highly expressed in utero during renal tubule development. Ouabain 
concentrations have also been shown to be increased during pregnancy [410]. In fact, ouabain may 
aid in the development of the renal system by promoting cell survival during stress [403, 482].  In 
adults, mutated polycystins eventually lead to increased blood pressure, a condition in which 
enhanced ouabain levels are detected in plasma. Additionally, 80% of ADPKD patients die from 
cardiovascular complications [111, 112]. Left ventricle (LV) mass is increased in ADPKD patients 
[107, 576-578], and abnormal LV are associated with impairment of LV function and impose 
significant risk for cardiovascular disease morbidity and mortality [579]. Ouabain plasma levels 
positively correlate with LV mass in hypertensive subjects [580, 581], and are elevated in patients 
with impaired LV performance [423]. Indeed, sustained infusion of ouabain is sufficient to induce 
LV hypertrophy in normotensive rats [432], together suggesting that ouabain may significantly 
decrease the survival of ADPKD patients. The average plasma concentration of ouabain between 
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ADPKD patients and healthy controls has not been determined. However, cysts undergo rapid 
growth in utero and after GFR decline, and under both conditions high concentrations of ouabain 
can be expected. However, it is also important to bear in mind that ADPKD cells are more sensitive 
to ouabain-mediated signaling [322], so increased levels of ouabain may not be necessary. 
Systemic conditions then, may or may not provide an intersection between the activities of 
polycystins and NKA. However, at a cellular level, PC1 and NKA do directly interact.  -NKA 
can co-immunoprecipitate with full-length PC1 in MDCK cells [582]. This interaction was shown 
to depend on PC1 CTT (specifically, the last 193 amino acids of PC1) and the intracellular domains 
of -NKA (A, P and N domains) [582]. Further, overexpression of PC1 significantly increased 
NKA activity, without affecting the apparent affinity of Na+ for NKA [582]. Work from this lab 
has further shown, using an insect cell expression system, that co-expression of membrane-
targeted PC1 CTT with -NKA increased the sensitivity of -NKA to ouabain [181] similar to 
what is seen in ADPKD cells [322]. Additionally, co-expression of the dominant negative PC1-
CTT with -NKA phenotypically altered the cells to increase proliferation in response to ouabain 
[181], which is once again similar to what is observed in ADPKD cells [322], and was in fact 
found to use the same SRC/MEK/ERK signaling pathway to accomplish the ouabain-mediated 
proliferation [322, 491]. 
In addition to this physical interaction, ouabain has the potential to affect multiple 
processes which are dysregulated by the mutated polycystin complex. First, dysregulation of 
polycystins sensitizes cells to apoptosis [211, 235, 264, 583]. Ouabain also affects apoptosis in a 
concentration and cell-type dependent manner, potentially by an integration of life-death signals 
[362, 529, 530]. Therefore, in Chapter 2, the ability of ouabain to induce apoptosis in ADPKD was 
determined.  Secondly, in addition to their roles in maintaining ionic concentrations, both NKA 
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and PC1 have structural roles, accomplished through homophilic interactions with themselves and 
through interactions with cytoskeletal proteins. Further, both may affect the dedifferentiation 
processes essential for proper wound-healing through activation of EMT-related signaling. For 
instance, TGF is upregulated by both ouabain treatment and in cystic epithelium [552, 584-586].  
Also, the basement membrane of ADPKD cells is abnormally thick [78], and ouabain increases 
collagen deposition [417, 554]. Therefore, in Chapter 3, the junctional properties of ADPKD cells 
in response to ouabain have been assayed and it was also determined if EMT-related pathways are 
altered. Thirdly, dysregulated calcium concentrations are a driving force of ADPKD progression. 
Mutations in the polycystin proteins are intimately tied to this dysregulated calcium [197-199, 209-
212]. As ouabain is known to induce alterations in intracellular calcium in several cell types [374-
376, 403, 477, 556, 558-560, 562-567], in Chapter 4, therefore, the ability of ouabain to alter 
calcium concentrations in NHK and ADPKD cells was determined. 
Cystic cells are characterized by a complex cellular phenotype that includes changes in 
proliferation, apoptosis, fluid secretion, apicobasal polarity, directional cell migration, matrix 
abnormalities, calcium management, and cilia or centrosomal fidelity [265, 266]. These processes 
are also involved in development and in response to injury. The effects of ouabain on proliferation 
and fluid secretion have previously been elucidated. In both cases, ouabain enhanced the cystic 
phenotype without altering the normal function of NHK cells, suggesting that any method of 
decreasing ouabain may be beneficial for slowing the progression of ADPKD. Thus, outlined in 
the following chapters is the effect of ouabain on three other processes dysregulated in ADPKD 
cystic epithelium, apoptosis, EMT, and calcium concentrations, with the hope of increasing the 





In this thesis, the hypothesis addressed was that ouabain enhances the ADPKD phenotype by 
inducing apoptosis, stimulating epithelial-to-mesenchymal transition (EMT) and affecting calcium 
signaling. Renal epithelial cells obtained from normal and diseased kidneys, affected with 
ADPKD, were used. To address this hypothesis, the following specific aims were utilized: 
 
1. Understand the effect and mechanism of action by which ouabain mediates apoptosis in 
ADPKD cells. In ADPKD, it has been proposed that there is a misbalance between cell 
proliferation and programmed cell death. Previous reports have shown that ouabain induces 
cell growth; however, the role of ouabain in ADPKD cell apoptosis is unknown. The 
working hypothesis was that ouabain stimulates ADPKD cell apoptosis through BCL-2, 
BAX and cytochrome c release.  
 
2. Determine the role and mechanism of action of ouabain in inducing EMT changes in 
ADPKD. ADPKD cells have been shown to have a dedifferentiated phenotype, losing 
properties typical of the mature renal epithelium, such as cell apical-to-basal polarity, as 
well as planar polarity, and the development of a mesenchymal-like phenotype. The 
working hypothesis was that ouabain, via the TGFpathway, induces EMT-related 
changes that cause upregulation of mesenchymal markers, relaxation of cell adhesion 




3. Investigate the effect of ouabain on calcium signaling in NHK and ADPKD cells. 
Intracellular calcium concentration is decreased in ADPKD cells relative to NHK cells. In 
addition, the low calcium of ADPKD cells has been shown to alter signaling pathways that 
lead to cell proliferation and fluid secretion by the cells, which maintains the ADPKD 
phenotype. The working hypothesis was that ouabain regulates the intracellular calcium 
concentration in NHK and ADPKD cells differently, to favor the cystic phenotype in 





CHAPTER 2: OUABAIN ENHANCES APOPTOSIS VIA THE INTRINSIC PATHWAY 
ABSTRACT 
Progression of autosomal dominant polycystic kidney disease (ADPKD) is highly 
influenced by factors circulating in blood. We have shown that the hormone ouabain enhances 
several characteristics of the ADPKD cystic phenotype, including increase in cell proliferation, 
fluid secretion and the capacity of renal epithelial cells obtained from kidney cysts of patients with 
ADPKD (ADPKD cells) to form cysts. In this work, we found that physiological levels of ouabain 
(3 nM) also promote programmed cell death in ADPKD cells. This was determined by Alexa Fluor 
488 labeled-Annexin-V staining and TUNEL assays, both biochemical markers of apoptosis. 
Ouabain-induced apoptosis also takes place when ADPKD cell growth is blocked; suggesting that 
the effect is not secondary to the stimulatory actions of ouabain on cell proliferation. Ouabain 
alters the expression of BCL family of proteins, reducing BCL-2 and increasing BAX expression 
levels, anti- and pro-apoptotic mediators respectively. In addition, ouabain caused the release of 
cytochrome c from mitochondria. Moreover, ouabain activates caspase-3, a key “executioner” 
caspase of the cell apoptotic pathway, but did not regulate caspase-8. This suggests that ouabain 
triggers ADPKD cell apoptosis by stimulating the intrinsic, but not the extrinsic pathway of 
programmed cell death. The apoptotic effects of ouabain are specific to ADPKD cells and do not 
occur in normal human kidney cells (NHK cells). Taken together with our previous observations, 
these results show that ouabain causes an imbalance in cell growth/death, to favor growth of the 
cystic cells. This event, characteristic of ADPKD, further suggests the importance of ouabain as a 





Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic 
disorder of the kidney, characterized by the formation and progressive enlargement of numerous 
fluid filled cysts, which severely distort renal morphology and function, reviewed in [587, 588]. 
ADPKD cysts are formed in utero and continue progressing after birth at a relatively slow, but 
relentless rate throughout the life of the affected individual [30]. Patients with ADPKD eventually 
develop renal insufficiency and end-stage renal disease (ESRD), requiring dialysis or kidney 
replacement therapy [589-591].  
ADPKD is caused by mutations in the genes that encode for polycystin-1 and polycystin-
2 (PKD1 and PKD2 respectively); however, progression of the disease is highly influenced by 
factors circulating in the bloodstream [25, 592, 593]. We have shown that the hormone ouabain, 
in concentrations similar to those present in plasma, stimulate the proliferation of renal epithelial 
cells obtained from kidney cysts of patients with ADPKD (ADPKD cells), the growth of 
microcysts generated by ADPKD cells, and cyst-like tubule dilations in embryonic kidneys from 
a mouse model of ADPKD [322, 360]. In contrast, ouabain does not significantly influence cell 
proliferation and cyst formation in normal kidney cells (NHK cells) and metanephric organs from 
wild type mice [475].  
The slow progression of ADPKD is difficult to explain in a condition that is primarily 
characterized by continuous cell proliferation. Cell growth is maintained by a balance between cell 
proliferation and apoptosis, a process of programmed cell death [594, 595]. Interestingly, an 
imbalance between increased rates of cell apoptosis have been reported in kidneys from animal 
models of ADPKD and in humans carrying the disease, a phenomenon that may contribute to the 
uncontrolled, but slow progression of the disease [67, 140, 257, 263, 596-599]. 
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Apoptosis is an essential process during normal tissue development and aging and is also 
found in several pathological situations [600-603]. Apoptosis involves an intricate cascade of 
molecular events, with the B-cell lymphoma 2 (BCL-2) protein family and a series of cysteine 
proteases, the caspases, being essential mediators of the process. The BCL-2 family include several 
members that are pro-survival and pro-apoptotic factors, such as BCL-2 and BAX respectively. 
The proteolytic caspases include the “initiator” caspases-8, -9 and -10, and the “executioner” 
caspases-3 and -7 [594, 600, 604]. Two main caspase-mediated pathways control programmed cell 
death. The extrinsic pathway, a ligand triggered and transmembrane receptor mediated cascade 
[605], and the intrinsic pathway, which comprises mitochondrial changes and the release of 
cytochrome c from the mitochondrial intermembrane space to the cell cytosol [606]. Both intrinsic 
and extrinsic pathways converge to stimulate the activity of caspases-3 and -7, which are 
responsible for the events that are characteristic of apoptosis, including DNA fragmentation, 
protein cross-linking and degradation, and cell disintegration into apoptotic bodies [607].  
While apoptosis has been described as a feature of ADPKD, the factors and mechanisms 
that influence programmed cell death in ADPKD cells are poorly understood. Ouabain has been 
shown to influence programmed cell death in a cell type specific manner. For instance, ouabain 
has pro-apoptotic effects in normal neuronal cells, neuro- and glioblastoma cells, hepatic cells, 
blood peripheral lymphocytes, lymphoma cells, and prostate cancer cells [498-506]. In contrast, 
ouabain protects endothelial cells, cerebellar granule cells, renal proximal tubule, and COS-7 cells 
against apoptosis [403, 476, 507-510]; and has a dual pro- and anti-apoptotic effect in smooth 
muscle, umbilical vein endothelial cells, and fibroblast [511-513]. At present, the role of ouabain 
in ADPKD apoptosis is unknown. In this work, we show that ouabain enhances apoptosis in 
ADPKD, but not in NHK cells, by activating the intrinsic pathways of programmed cell death.  
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MATERIALS AND METHODS  
Cell culture:  
 Primary cell cultures of ADPKD cells, derived from surface cysts of ADPKD kidneys and 
NHK cells were generated by the PKD Biomaterial Core at University of Kansas Medical Center 
(KUMC). A protocol for the use of discarded human kidney tissues was approved by the 
Institutional Review Board at KUMC. Primary cultures were prepared as described [608]. Cells 
were seeded and grown in DME/F12 supplemented with 1% heat-inactivated fetal bovine serum 
(FBS), 100 IU/ml penicillin G and 0.1 mg/ml streptomycin, 5 µg/mL insulin, 5 µg/mL transferrin, 
and 5 ng/mL sodium selenite (ITS). Twenty-four hours before cells were subjected to various 
experimental manipulations, serum was reduced to 0.002% and ITS removed. As previously 
shown, these cells are epithelial in nature and they stain positive for specific lectin markers for the 
collecting duct and distal nephron, indicating that they are derived from the distal nephron [198]. 
  
Annexin-V and propidium iodide staining: 
Alexa Fluor 488 labeled-Annexin-V and propidium iodide (PI) staining were utilized as 
biomarkers for the detection of apoptosis and necrosis in ADPKD and NHK cells by flow 
cytometric analysis, following the manufacturer’s protocols (Invitrogen, Carlsbad, CA, USA). 
Briefly, cells were trypsinized, washed in PBS, and resuspended in binding buffer (50mM HEPES, 
700 mM NaCl, 12.5 mM CaCl2, pH 7.4). After addition of 5µL Annexin-V and 1µL PI, cells were 
incubated at 37 °C and protected from light for 15 minutes. Samples were diluted with binding 
buffer and were analyzed using a LSRII flow cytometer (Beckton Dickinson, Franklin Lakes, NJ). 
Alexa Fluor 488 labeled-Annexin-V, which detects changes in distribution of phosphatidylserine 
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and phosphatidylethanolamine at the cell plasma membrane; and propidium iodide (PI) staining, 
which reveals loss of cell plasma membrane integrity, allowed distinguishing cells undergoing 
early and late stages of apoptosis, and necrosis [609]. 
 
Measurement of fragmented DNA by TUNEL assay: 
 Cells cultured on glass coverslips were treated with 3nM ouabain for 24h and analyzed for 
apoptosis using the DeadEnd fluorometric TUNEL system (Promega, Madison, WI). This method 
determines nuclear fragmentation, an important biochemical marker for cell apoptosis, by using 
terminal deoxynucleotidyl transferase to transfer fluorescein (FITC)-12-dUTP to the free 3’-OH 
of cleaved DNA. Cells were counter-stained with DAPI to label the nuclei. The percentage of cells 
undergoing apoptosis was determined using fluorescence microscopy. Carbobenzoxy-valyl-
alanyl-aspartyl-[O-methyl]-fluoro-methylketone (z-VAD-fmk), at a concentration of 20 µM and 
camptothecin, at 5 uM (Promega Corporation, Madison, WI), were applied as an inhibitor and 
inducer of apoptosis, respectively. 
 
Immunoblot analysis: 
 Cells treated with and without 3nM ouabain for 24 h were washed once with ice-cold 
phosphate buffered saline (PBS) and lysed in a solution containing 10 mM Tris-Cl (pH 7.4), 10 
mM NaCl, 3 mM MgCl2, and 0.1% NP-40. Samples were centrifuged at 10,000 x g for 10 min. 
Protein concentrations were determined by Bio-Rad Protein Assay (Bio-Rad, Hercules, CA). Fifty 
μg of the cleared lysates were subjected to SDS-PAGE (15% gel) and blotted on to nitrocellulose 
membranes. Immunoblots were probed with different primary antibodies that recognize PARP-1, 
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BCL-2, BAX, caspase-3 or caspase-8 (Cell Signaling Technology, Boston, MA). Species-specific 
secondary antibodies conjugated to horse-radish peroxidase and enhanced chemiluminescence was 
used for protein detection (Santa Cruz Biotechnology, Dallas, TX). Protein expression levels were 
determined by densitometry and were expressed as a ratio of the corresponding untreated controls. 
 
Cytochrome c analysis:  
 Cytochrome c release from mitochondria was studied in NHK and ADPKD cells after 
treatment with or without 3nM ouabain for 24 h by immunoblot and immunocytochemistry. For 
the immunoblot analysis, cells were harvested and cytosolic or mitochondrial fractions were 
prepared using the Cell Fractionation Kit ab109719, according to the manufacturer’s instructions 
(AbCam, Cambridge, UK). Samples were subjected to SDS/PAGE and proteins transferred to 
nitrocellulose membranes. Cytochrome c was determined using a monoclonal antibody from BD 
Biosciences (San Diego, CA) and horse-radish peroxidase conjugated secondary antibodies; and 
its levels were estimated by densitometric analysis of the obtained bands. For the 
immunocytochemical analysis, cells were plated on coverslips and treated with or without ouabain 
for 23.5 h. Then, 100nM MitoTracker Red CMXRos (Thermo Fisher Scientific, Waltham, MA) 
was added to the cells and they were incubated for an additional 30 minutes at 37 °C, protected 
from light. Cells were fixed with 3.7% paraformaldehyde in serum-free media for 15 min at 37 °C. 
Samples were washed in PBS and permeabilized with acetone for 5 minutes. Anti-cytochrome c 
antibody (BD Biosciences, San Diego, CA) (1:75) was applied to the cells overnight at 4 °C. 
Coverslips were washed once with PBS, and then slides were incubated with secondary Alexa 
488-conjugated antibodies for 1 hour at room temperature. Samples were washed in PBS and 
mounted onto microscope slides with DAPI Slowfade Gold solution (Thermo Fisher Scientific, 
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Grand Island, NY). Slides were viewed using an Eclipse 80i Upright microscope (Nikon 
Instruments, Inc., Melville, NY). Analysis of cytochrome c release from the mitochondria was 
determined from the obtained images, by quantifying the number of pixels in the cell cytosol 
divided by the number of pixels in mitochondria. Values were expressed as the ratio of 
cytosolic/mitochondrial cytochrome c levels, as previously described [610]. This allowed 
characterizing the mitochondrial to cytosolic distribution of cytochrome c.  
 
Caspase-3/7 activity determination: 
 Caspase-3/7 activity was determined using the Caspase-Glo-3/7 Assay according to 
manufacturer's instructions (Promega, Madison, WI). Briefly, NHK and ADPKD cells were plated 
into black-walled, clear-bottomed 96-well plates (Corning Inc., Corning, NY) at a density of 4,000 
cells per well and treated with or without ouabain for 24 h. The luminescent caspase-3/7 substrate 
was added following the manufacturers specifications. The luminescent signal resulting from 
cleavage of the substrate specific to caspase-3 or -7 is proportional to the amount of caspase 
activity present. Data were expressed as a percentage of untreated controls. 
 
Data analysis: 
 Statistical significance of the differences between ouabain treated and untreated controls 
was determined by one way analysis of variance (ANOVA), followed by Student’s T-test. 




Ouabain stimulates apoptosis in ADPKD but not in NHK cells 
 Ouabain has been reported to stimulate apoptosis in a cell type specific manner [611]. We 
explored whether ouabain affected programmed cell death in NHK and ADPKD cells. For this, we 
treated NHK and ADPKD cells with 3 nM ouabain, a concentration of this hormone that is within 
the levels commonly found to be circulating in blood. Twenty-four hours later, we determined cell 
apoptosis and necrosis using Alexa Fluor 488 labeled-Annexin-V and PI labeling and flow 
cytometry. Sorting of the cells based on these markers showed that ouabain treatment significantly 
increased the number of ADPKD cells undergoing apoptosis compared to untreated controls (Fig. 
2.1A, top panel). This increase corresponded to cells showing signs of late apoptosis, while the 
number of ADPKD cells showing early manifestations of apoptosis, or undergoing necrosis did 
not significantly change with ouabain administration (Fig. 2.1A bottom panel). Different from 
ADPKD cells, ouabain did not induce programmed cell death (either early or late apoptosis), or 
necrosis in NHK cells (Fig. 2.1A, top and bottom panels).  
To further estimate apoptosis, we determined DNA nuclear fragmentation by TUNEL 
assay in NHK and ADPKD cells. In agreement with the Alexa Fluor 488 labeled-Annexin-V and 
PI studies, ouabain increased TUNEL staining in ADPKD cells (Fig. 2.1B). This ouabain-induced 
increase in DNA fragmentation could be rescued by the pan-caspase inhibitor, carbobenzoxy-
valyl-alanyl-aspartyl-[O-methyl]-fluoro-methylketone (z-VAD-fmk), further suggesting that 
ouabain is inducing apoptosis in ADPKD cells. The topoisomerase I inhibitor, camptothecin, was 
used as a positive control for apoptosis (Fig. 2.1B). Altogether, these experiments show that 






Figure 2.1. Ouabain induces apoptosis in ADPKD, but not in NHK cells. A) Alexa Fluor 488 
labeled-Annexin V and PI staining. After treatment with ouabain for 24h, cells were labeled and sorted 
using flow cytometry. The top panel shows representative plots for the sorted NHK and ADPKD cells, 
without and with addition of ouabain. Different cell populations undergoing necrosis, early and late 
apoptosis, identified by differential annexin-V/PI labeling, were quantified and expressed as percent of 
total cells (bottom panel).  B) DNA fragmentation assays. Cells seeded onto glass coverslips were 
incubated with 3nM ouabain and the indicated experimental conditions for 24 h, fixed and analyzed for 
apoptosis using the Dead-End d Fluor Metric TUNEL System. At least 10 random fields were analyzed 
from each of three different ADPKD kidneys. In all graphs, bars represent the mean ± SEM of three 
different experiments. The asterisks indicate values that are statistically different compared to the 
corresponding untreated control, with P < 0.05.  
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Ouabain modulates expression of BCL-2 protein family members in ADPKD cells 
Whether a cell undergoes apoptosis is in part determined by the ratio of pro- to anti-
apoptotic members of the BCL-2 protein family [594].  Within the BCL-2 members, BAX and 
BAK function as pro-apoptotic agents, while BCL-2 behaves as an anti-apoptotic mediator [604].  
To further characterize the mechanisms by which ouabain induces cell death in normal and cystic 
renal cells, we examined the role of these apoptotic regulators in NHK and ADPKD cells. Ouabain 
treatment for 24 h did not alter the expression levels of either BAX or BCL-2 proteins in NHK 
cells (Fig. 2.2A). However, in ADPKD cells, ouabain caused a significant decrease in the anti-
apoptotic BCL-2 protein, with a concomitant increase in the pro-apoptotic BAX protein levels 
(Fig. 2.2B). This change towards a pro-apoptotic protein ratio supports the role of ouabain as an 
Figure 2.2 
 
Figure 2.2. Ouabain modifies the expression of BCL-2 and BAX protein levels in ADPKD, but 
not NHK cells. NHK and ADPKD cells were treated in the absence and presence of 3 nM ouabain and 
24 h later, expression levels of BCL-2 and BAX were determined by immunoblot. Tubulin was used as 
a loading control.  Top panels show the densitometric analysis of the protein bands, while bottom panels 
show representative blots. Bars are the mean + SEM of three experiments. Asterisks indicate statistically 
different values, with P < 0.05.  
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inducer of apoptosis in ADPKD cells, and suggests that its effects are mediated via the intrinsic 
pathway of programmed cell death. 
 
Ouabain enhances cytochrome-c release from ADPKD cell mitochondria 
A pro-apoptotic change in BCL-2/BAX protein ratio is commonly followed by the release 
of cytochrome c from mitochondria, another event in the activation cascade of programmed cell 
death [612]. Therefore, we determined the release of cytochrome c from mitochondria to the 
cytosol in cell fractions from NHK and ADPKD cells by immunoblotting. As shown in Fig. 2.3A, 
cytochrome c levels were much higher in mitochondrial than cytosolic fractions of both NHK and 
ADPKD cells. Importantly, cytochrome c was significantly augmented by ouabain in cytosolic 
fractions from ADPKD, but it was slightly decreased in NHK cells (Fig. 2.3A). This suggest that 
the change in BCL-2/BAX ratio in ADPKD cells did result in release of cytochrome c from the 
cell mitochondria.  
In addition, changes in cytochrome c localization were studied by immunocytochemistry. 
For this, cells were labeled with MitoTracker Red, a dye which allows the visualization of 
mitochondria, and an anti-cytochrome c. Then, the ratio of cytoplasmic to mitochondrial 
localization of cytochrome c was determined by quantification of pixel density as described [610]. 
As shown in Fig. 2.3B, the ratio of cytoplasmic/mitochondrial cytochrome c did not change with 
ouabain treatment in NHK cells. In contrast, this ratio was significantly increased by ouabain in 
ADPKD cells (Fig. 2.3B). Altogether, these results show that ouabain promotes the release of 
cytochrome c from the mitochondria of ADPKD cells and are in agreement with the notion that 
ouabain induces apoptosis in these cells.  
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Ouabain activates caspase-3/7 in 
ADPKD cells 
Proteases of the caspase 
family play an essential role in the 
cleavage of specific substrates that 
mediate cell apoptosis [613, 614]. 
To assess the involvement of 
caspases in ouabain-induced 
apoptosis of ADPKD cells, we 
treated NHK and ADPKD cells in 
the presence and absence of 3nM 
ouabain for 24h and determined 
activation of the “executioner” 
caspase-3 via its cleavage status. 
Caspase-3 cleavage was 
determined by immunoblot. As 
shown in Figure 2.4A, caspase-3 
cleavage was not modified by 
ouabain in NHK cells (left panel). 
In contrast, in ADPKD cells, 
ouabain significantly increased the 
cleavage of pro-caspase-3 into its 
Figure 2.3 
 
Figure 2.3. Ouabain stimulates cytochrome c release from 
mitochondria in ADPKD, but not NHK cells. A) 
Immunoblot analysis. After treatment with or without 3 nM 
ouabain for 24 h, cells were processed to obtain cell 
cytoplasmic and mitochondrial fractions, and samples were 
subjected to immunoblot analysis to determine cytochrome c 
levels. Tubulin was used as a loading control, while VDAC 
was used as a mitochondrial marker. Relative densitometric 
levels for cytochrome c are shown in the upper panels and they 
represent data compiled from three different experiments. The 
bottom panels show representative immunoblots. B) 
Immunocytochemical analysis. After treatment with 3 nM 
ouabain for 24 h, NHK and ADPKD cells were labeled for 
cytochrome c and MitoTracker, to visualize mitochondria. 
Cytochrome c release was quantified and expressed as the 
cytosol to mitochondrial ratio. Bars represent the compiled 
data from 3 different experiments. In A and B, bars represent 
the mean + SEM. Asterisks indicate statistically different 
values, with P < 0.05 versus untreated control.  
64 
 
active large (p17) and small (p12) fragments (right panel).  
In addition, we directly measured the levels of caspase-3 activity, in ADPKD cells treated 
with and without 3nM ouabain. Once activated, caspase-3 cleaves the same peptide sequences as 
caspase-7 and so their activities cannot be distinguished with the assay that we used. In any case, 
both caspase-3 and -7 are “executioner” caspases, involved in downstream cleavage of substrates 
that mediate many of the typical biochemical and morphological events of apoptosis [613, 614]. 
As shown in Figure 2.4B, ouabain significantly stimulated caspase-3/7 activity of ADPKD cells.  
Ouabain dependent caspase-3 activation by ouabain was also estimated by immunoblot 
analysis of poly(ADP-ribose) polymerase-1 (PARP-1), a known target of caspase-3 action [615]. 
Consistent with activation of caspase-3, ouabain increased the cleavage of PARP-1 in ADPKD 
cells, but not in NHK cells (Fig. 2.4C). 
 
Ouabain does not activate the extrinsic pathway of ADPKD cell apoptosis  
The factors involved in triggering cell apoptosis can act through two main mechanisms, 
the intrinsic and extrinsic pathways [594]. Our findings that ouabain stimulates the release of 
cytochrome c from mitochondria suggest a role for the intrinsic pathway in the mechanisms 
leading to ouabain-mediated apoptosis in ADPKD cells. To determine the involvement of the 
extrinsic pathway in ouabain-induced ADPKD apoptosis, we measured the activation of caspase-
8. This protease is involved in the extrinsic pathway of programmed cell death and its cleavage is 
a marker for its activation [616]. We treated NHK and ADPKD cells in the presence and absence 
of 3 nM ouabain for 24 h and determined the total and cleaved forms of caspase-8 by immunoblot. 




Figure 2.4  
 
Figure 2.4. Ouabain stimulates caspase-3 cleavage and activity in ADPKD, but not NHK cells. A) 
Caspase-3 cleavage. After treatment with 3 nM ouabain for 24 h, the total (35 kDa) and cleaved products 
(17 kDa and 12 kDa) of caspase-3 were determined in NHK and ADPKD cells by immunoblot and 
densitometric analysis. Upper panels show representative blots and bottom panels the densitometric 
analysis from three different experiments. Bars are the mean ± SEM of three experiments. B) Relative 
caspase-3 and -7 activity levels. ADPKD cells were treated in the absence and presence of 3 nM ouabain 
and caspase activity was measured using the Caspase-3/7 Glo Assay. Data are the mean ± SEM of 
sextuplicate experiments. C) PARP-1 cleavage. After ouabain treatment for 24h, NHK and ADPKD cell 
lisates were subjected to immunoblot to determine fragmentation of the caspase-3 substrate, PARP-1. 
The top panels show the densitometric analysis of the total and cleaved (89 kDa) PARP-1 bands. 
Cleaved PARP-1 is expressed relative to the corresponding untreated controls. The bottom panels show 
representative immunoblots. Bars represent the mean ± SEM of 5 different experiments. Asterisks show 
statistically different values, compared to untreated controls and with P < 0.05. 
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cells (Fig. 2.5A), but it did not affect caspase-8 cleavage in ADPKD cells (Fig. 2.5B). These results 
suggest that the apoptotic effects of ouabain in ADPKD cells are not mediated by caspase-8 and 
the extrinsic pathway of programmed cell death. In addition, the reduction in caspase-8 in NHK 
cells suggests a protective effect of ouabain toward apoptosis in normal cells.  
 
The effect of ouabain on ADPKD apoptosis is independent from cell proliferation 
We have previously shown that ouabain enhances the growth of ADPKD cells [322]. The 
ouabain-induced activation of apoptosis that we observe in ADPKD cells could just be secondary 
to the hyperproliferative effects of the hormone in these cells. To investigate this possibility, we 
inhibited cell proliferation in NHK 
and ADPKD cells with thymidine, 
and treated the cells with 3nM 
ouabain for 24 h. Finally, we 
determined apoptosis levels by cell 
sorting, after labeling the cells Alexa 
Fluor 488 labeled-Annexin-V. As 
shown in Fig. 2.6A, ouabain had no 
effect on NHK cell apoptosis, either 
in the presence or absence of 
thymidine. In ADPKD cells, 
ouabain-induced programmed cell 
death was not abrogated by the 
inhibition of cell proliferation with 
Figure 2.5 
 
Figure 2.5. Ouabain does not affect the extrinsic pathway 
for apoptosis in ADPKD cells. NHK (A) and ADPKD (B) 
cells were treated with 3 nM ouabain for 24 h and the total 
(57 kDa) and cleaved (43 kDa) forms of caspase-8 were 
determined by immunoblot analysis and quantified by 
densitometry. The top panels show the densitometric 
analysis of the bands from 4 different experiments. The 
bottom panels show representative blots. Values are the 
mean + SEM. Asterisks indicate statistically different values, 
with P < 0.05 versus untreated control.   
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thymidine (Fig. 2.6B). This shows that the effects of ouabain on ADPKD cell apoptosis directly 
target programmed cell death and they are not an indirect consequence of the exacerbated growth 
that the hormone causes in the cells.  
Figure 2.6 
 
Figure 2.6. Ouabain induces ADPKD cell apoptosis independent from its proliferative effects. 
NHK (A) and ADPKD (B) cells were treated with or without 3 nM ouabain, in the presence and absence 
of 2.5 M thymidine to arrest cell growth. Alexa fluor-labeled-annexin-V and PI staining and cell sorting 
were utilized to detect apoptosis/necrosis.  Bars represent the mean + SEM of 3 different experiments. 




In this work we have shown that ouabain stimulates apoptosis in human ADPKD cells. 
Thus, ouabain causes changes in plasma membrane phospholipids, induces DNA fragmentation, 
alters the balance of BCL-2 protein expression, favors release of cytochrome c from mitochondria, 
and activates caspase-3/7; all of which are typical events of programmed cell death. Ouabain-
induced ADPKD apoptosis occurs even when cell proliferation in the cells is blocked. This 
suggests that the enhancement of ADPKD cell apoptosis by ouabain is due to a direct action of 
ouabain on programmed cell death, and not a secondary consequence of  increased cell growth, 
which is another effect induced by ouabain in these cells [475]. The role of ouabain on apoptosis 
has been shown to be cell type dependent [611]. Similar to ADPKD cells, various cancer cell types 
either undergo apoptosis when treated with ouabain, or are sensitized for apoptosis triggered by 
other compounds [500, 504, 515, 519, 527, 617-620]. Therefore, ADPKD are not the only diseased 
cells that react to ouabain with an apoptotic response.  
We show that, different from ADPKD cells, ouabain does not induce apoptosis in NHK 
cells. In agreement with these observations, ouabain does not trigger programmed cell death in 
renal proximal tubule cells and explanted embryonic kidneys from normal rats. Moreover, in those 
studies, ouabain was shown to have a protective effect against apoptosis induced by serum-
starvation [403] and Shiga toxin-2 infection [476]. While the goal of our experiments was not to 
explore the effects of ouabain under stimuli that challenge the cells to undergo apoptosis, we find 
a decrease in cytochrome c release from mitochondria, a reduction of ouabain-induced caspase-8 
cleavage, and a trend for lower caspase-3 cleavage in NHK cells after ouabain treatment. This 
suggests that ouabain may be shifting NHK cells towards a pro-survival phenotype. In any case, it 
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appears that, despite the differences in species and renal origin, ouabain acts as a pro-survival 
agent in normal kidney cells.  
Interestingly, increased apoptosis is a feature of early and late stages of human ADPKD 
[140, 258], and it is linked to cystogenesis in various animal models of polycystic kidney disease 
[259, 621-623]. ADPKD apoptosis has been shown to take place in the epithelial cells lining the 
kidney cysts, and in cysts formed by Madin-Darby canine kidney cells (MDCK) grown in collagen 
matrix, a model of kidney cystic disease [258, 598, 623, 624]. Moreover, polycystin-1, the primary 
gene altered in ADPKD, has been shown to be a regulator of programmed cell death in renal cells, 
and its over-expression confers the host cells resistance to apoptosis [235]. Apoptosis has also been 
detected in non-cystic tissue in ADPKD kidneys, which suggests that programmed cell death of 
the normal remaining kidney contributes to the progressive deterioration of ADPKD renal function 
[258, 598, 599]. Therefore, it appears that apoptosis is an essential concomitant event that helps 
kidney cyst development, and along with cell proliferation contributes to the pathophysiology of 
ADPKD. Our results show that in human cells, the target for ouabain-induced apoptosis is the 
cystic ADPKD cells, and not the NHK cells. The apoptotic effect of ouabain in ADPKD cells, 
along with the aberrant increase that ouabain promotes in ADPKD cell growth [322], places 
ouabain as a modulator of two essential mechanisms involved in the pathophysiology of ADPKD. 
It is clear that that the increase in apoptosis caused by ouabain is not sufficient to overcome the 
ouabain-induced ADPKD cell growth. Therefore, ouabain functions as a factor that creates a 
dysregulation of ADPKD cell growth/death, in favor of cell proliferation. 
Our studies used amounts of ouabain that are within those observed circulating in plasma 
[625]. This highlights the relevance of ouabain as a factor that contributes to the pathophysiology 
of ADPKD.  At present, the molecular basis for the different responses of ADPKD and NHK cells 
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to ouabain is unclear; however, we have previously found that, different from NHK cells, ADPKD 
cells contain a fraction of the total NKA with an abnormal higher affinity for ouabain [322]. Due 
to their increased ouabain affinity, ADPKD cells may be more susceptible to the endogenous 
circulating levels of ouabain, to which NHK cells do not respond to the same extent. In addition 
to their differential sensitivity to ouabain, ADPKD cells also differ from NHK cells in the activity 
of several intracellular signaling pathways. For example, it is known that the kinase B-RAF and 
the ERK pathway have an abnormal reactivity to different circulating factors in ADPKD cells 
[198, 626]. It is therefore possible that, in ADPKD cells, ouabain impinges on pathways which 
respond in an exacerbated manner on apoptotic effectors to cause programmed cell death. 
Undoubtedly, more studies are necessary before we can fully understand the molecular 
mechanisms by which ADPKD cells respond differently to the variety of stimuli that circulate in 
blood, including ouabain.   
As shown from our labeling experiments with PI, ouabain does not cause cell necrosis, 
which suggests that ouabain effects are non-toxic for the ADPKD cells. This agrees with the notion 
that, in ADPKD cells, ouabain is not completely inhibiting NKA ion transport, but that at relatively 
low, physiologic amounts, it activates downstream effectors, as we have shown before [491]. In 
further support of this, we here found that ouabain activates several mediators in the signaling 
pathway that leads to apoptosis. Thus, in ADPKD, but not NHK cells, ouabain causes an imbalance 
in the expression of the BCL-2 and BAX proteins, involved in anti- and pro-apoptotic effects 
respectively. Ouabain slightly inhibited BCL-2 expression and augmented BAX levels, agreeing 
with induction of apoptosis in the cells. Interestingly, BCL-2 deficient mice show increased kidney 
apoptosis and the development of renal cyst disease [627]. The downregulation of BCL-2 and the 
pro-apoptotic effects of ouabain may represent mechanisms, which together with those on cell 
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growth and fluid secretion, contribute to the enhancement of the cystic phenotype of ADPKD cells. 
The decrease in BCL-2 protein concentration in response to ouabain is not unique to ADPKD cells 
and it has been found in other cell types [502, 517, 524]. Moreover, overexpression of either BCL-
2 or BCL-XL has been reported to abrogate the pro-apoptotic effects of ouabain in a lymphoma 
cell line [533]. Interestingly, the involvement of the BCL-2 family of proteins in ouabain-mediated 
effects in cells is also supported by the finding that the α–NKA subunit contains BH1- and BH3-
like motifs, similar to those involved in the pairing of BCL-2 family proteins among each other 
[531, 628], and that the BCL-2 family member proteins, BCL-XL and BAK co-immunoprecipitate 
with NKA in A549 lung cancer cells and in fetal human epithelial lens cells [531]. While it is 
unknown whether NKA acts as a scaffolding protein to mediate pro-apoptotic effects via its BH1- 
and BH3-motifs in ADPKD cells, it is clear that BCL family proteins are involved in ouabain-
induced apoptotic effects in the renal epithelial cystic cells.   
Besides stimulating the expression of BCL-2 protein, ouabain also impacts other important 
mediators of apoptosis in ADPKD cells, such as the mitochondria, through the release of 
cytochrome c. Moreover, ouabain activates the executioner caspases 3 and 7. In contrast, ouabain 
does not activate the cleavage of caspase-8, an essential effector of the extrinsic apoptotic pathway. 
Therefore, ouabain induces ADPKD cell apoptosis via specific activation of the intrinsic pathway 
of programmed cell death. Ouabain has been shown to activate the intrinsic apoptotic pathway in 
other cell types [499, 502, 519]. Importantly, our results concur with studies in the Han:SPRD rat, 
a rodent model of ADPKD, in which the increase in apoptosis is dependent on activation of the 
intrinsic pathway of programmed cell death [262, 263]. In this manner, ouabain enhances an 
apoptotic route, which commonly participates in ADPKD programmed cell death.   
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In summary, we have further advanced our understanding of the effects of ouabain in 
ADPKD cells and found that physiological amounts of ouabain stimulate apoptosis in these cells 
through activation of the intrinsic pathway of programmed cell death. Activation of this 
characteristic event of ADPKD, together with other enhancing actions of ouabain on the ADPKD 
phenotype [475], further supports the role of ouabain as a non-genetic factor that can modulate 
renal cystogenesis and the progression of ADPKD. 
 
 Note: This chapter of the thesis was previously published: Venugopal, J. and G. Blanco, 





CHAPTER 3: OUABAIN & THE EPITHELIAL-TO-MESENCHYMAL TRANSITION 
ABSTRACT 
 ADPKD renal epithelial cells are characterized by an undifferentiated phenotype, with 
changes in cell polarity and misexpression of proteins including markers of epithelial to 
mesenchymal transition (EMT). We have previously shown that the hormone ouabain has pro-
cystogenic effects on human renal epithelial cells from patients with ADPKD (ADPKD cells) and 
on embryonic kidneys of an ADPKD mouse model. Here, we studied whether ouabain at 
physiological circulating concentrations (3 nM) could trigger EMT in the cells. Our results show 
that ouabain decreases the expression of the epithelial marker E-cadherin and increases the 
expression of the mesenchymal markers N-cadherin, αSMA, and collagen-I. Ouabain also 
differentially affected the expression of the tight junction protein occludin, which was elevated in 
response to ouabain. Other adhesion molecules, such as claudin-1, ZO-1, β-catenin and vinculin 
were not significantly modified. At the cellular level, ouabain stimulated cell migration, but did 
not influence invasiveness of ADPKD cells. In addition, ouabain reduced cell-cell interaction and 
the ability of ADPKD cells to form cell aggregates. Moreover, ouabain increased the 
transepithelial electrical resistance of ADPKD cell monolayers, but did not affect the permeability 
to neutral dextran, suggesting that the tightness of the tight junctions and permeability of the 
paracellular transport pathway were preserved in the cells. All of these effects of ouabain were not 
observed on normal renal epithelial cells (NHK cells). Altogether these results suggest that ouabain 
promotes changes in ADPKD cells that do not correspond to the full EMT phenotype; however, 
this partial EMT contributes to the abnormal cystic characteristics of ADPKD cells. These effects 





Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic 
disorder of the kidney, which occurs in approximately 1:400-1:1,000 individuals [22]. ADPKD is 
caused by mutations in the PKD1 or PKD2 genes, which encode for polycystin-1 and -2 
respectively (PC1, PC2), which together form a functional nonspecific cation channel [14, 629, 
630]. The main pathological manifestation of ADPKD is the development and relentless growth 
of multiple epithelial-lined cysts in the kidney, which progressively impairs renal function and 
eventually leads to end stage renal disease, requiring dialysis or transplant therapy [47, 631]. 
ADPKD cells have been shown to be dedifferentiated and to undergo changes similar to epithelial-
to-mesenchymal transition (EMT) as part of their phenotype. Thus, in ADPKD kidneys there is an 
upregulation of EMT-related genes and increased fibrosis [87, 584, 585, 632-635]. In addition, it 
has been suggested that in ADPKD, the renal epithelial cells show an abnormal response to injury, 
signaling a “wounded status,” which initiates a futile wound-healing program that exacerbates the 
progression of the disease [63]. The response to injury in the kidney has been shown to be 
associated with the conversion into an EMT phenotype [636, 637].    
Polycystin-1 has been shown to directly interact with a number of proteins that are involved 
in the development of the EMT phenotype. For instance, PC1 localizes in vitro at cell junctions in 
epithelial cells [151, 638], and polycystins interact with components of focal adhesions and the 
extracellular matrix (reviewed by [639]). Importantly, the altered expression of polycystin-1 in 
MDCK cells has been shown to promote an EMT-like phenotype, which involves cytoskeletal 
changes, rearrangement of adhesion proteins, and altered migration of the cells, implying that the 
aberrant expression of polycystin influences downstream pathways that activate EMT changes in 
the cells [238].  
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 Although ADPKD is a genetic disorder, environmental factors and hormones have been 
shown to significantly affect the severity of the disease [41, 640]. We have previously shown that 
the hormone ouabain, a steroid produced in the adrenal glands [388, 641, 642], is one of those 
effectors. Ouabain has been shown to activate signaling events that lead to changes in metabolism, 
adhesion, and proliferation in a cell type specific manner [322, 360, 544, 643]. These effects are 
mediated via the binding of ouabain to its receptor, the plasma membrane Na,K-ATPase (NKA). 
Ouabain not only causes changes in intracellular ion concentrations by modifying NKA ion 
transport activity, but ouabain binding to NKA can also stimulate a cascade of intracellular 
signaling events in target cells. We have previously shown that the NKA of epithelial cells derived 
from the cysts of ADPKD patients (ADPKD cells) exhibit an altered affinity for ouabain, which 
is significantly higher than that of normal human kidney epithelial cells (NHK cells) [322]. 
Ouabain, in physiologically relevant concentrations (3 nM), initiates extracellular regulated kinase 
(ERK) signaling and increases proliferation of ADPKD cells, while the proliferation of NHK cells 
is not affected [322, 491]. Moreover, ouabain stimulates the cAMP induced transepithelial 
secretion of fluid by ADPKD cell monolayers, and enhances microcyst growth in embryonic 
kidneys from ADPKD mice grown in culture [360, 361]. In contrast, ouabain does not elicit those 
effects on NHK cells, or in wild type mouse kidney embryos [360, 361]. Increased cell 
proliferation and fluid secretions are hallmarks in the pathogenesis of ADPKD cyst formation and 
development. Therefore, ouabain is a factor that circulates in blood, which affects cystogenesis 
and can potentially influence the progression of ADPKD [322, 360, 491]. 
Interestingly, signal transduction pathways that are known to promote cell EMT, such as 
EGFR, SRC, PI3K, ERK1/2, and PKC [360, 644-648], have been shown to be activated by the 
binding of ouabain to NKA. Additionally, ouabain can alter the protein content of the cell 
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junctional complexes in MDCK cells, affecting the adhesion of cells to the tissue culture substrate 
[536, 544, 546, 649]. Interestingly, in mouse kidneys a compound called marinobufagenin, another 
member of cardiac glycoside steroid family to which ouabain belongs, has been shown to induce 
fibrosis and other alterations which resemble EMT [398]. It is therefore plausible that ouabain 
could enhance the ADPKD phenotype, not only by activating cell proliferation and cAMP 
dependent fluid secretion, but perhaps also by promoting EMT in the ADPKD cells, which would 
help the progression of cyst growth. In the present study, we examined whether physiological 
concentrations of ouabain (3 nM) could influence events associated with the EMT process in NHK 
and ADPKD cells. We show that in ADPKD cells, but not in NHK cells, ouabain alters the 
expression of some EMT markers and proteins that are specific to the cell junctional complexes, 
but not all markers are affected.  In addition, ouabain increases the motility and adhesion of the 
cells, but not the paracellular permeability, or the invasive growth of the cells. This suggests that 
ouabain induces changes in ADPKD cells that do not correspond to a complete EMT phenotype. 
However, these partial EMT effects of ouabain promote the cystic phenotype of these cells. 





MATERIALS AND METHODS 
Cell culture:  
A protocol for the use of human kidney tissues was approved by the institutional review 
board at KUMC. The ADPKD and NHK cells derived from discarded human kidney tissues were 
cultured as described previously [322, 608]. Briefly, cells were seeded and grown in DMEM/F12 
supplemented with 1% heat-inactivated FBS, 100 IU/ml penicillin G and 0.1 mg/ml streptomycin, 
5 µg/ml insulin, 5 µg/ml transferrin, and 5 ng/ml sodium selenite (ITS). The cells were incubated 
in media with 0.002% serum 24 h prior to ouabain treatment. Cells were cultured on both filter 
supports (Transwell Costar, Corning, NY) or plastic culture dishes. All the studies were done in 
triplicate with ADPKD and NHK cells obtained from at least three different patients. 
 
Protein extraction and immunoblots: 
ADPKD cells and NHK cells were treated with 3 nM ouabain at 70% confluency for 24 h in 
low serum (0.002%) media. Untreated cells served as controls. Cells were then  washed with ice-
cold PBS and lysed with RIPA buffer (1% NP-40, 0.25% sodium deoxycholate, 1 mM NaVO3, 1 
mM NaF, 150 mM NaCl, 1 mM EDTA, 50 mM Tris, and protease inhibitor cocktail (Sigma, St. 
Louis, MO)). The cleared lysates were stored at -80oC. For the membrane extracts, CNM kit 
(Biochain Institute, Inc, Hayward, CA) was used as per manufacturer’s instructions. Protein 
concentration was measured using dye binding assay from Bio-Rad (Hercules, CA). Total protein 
extracts (20 µg) and membrane extracts (10 µg) were electrophoresed on a 10% acrylamide gel 
and transferred to nitrocellulose membrane. The immunoblots were probed for the levels of 
occludin, claudin-1, ZO-1, E-cadherin (ThermoFisher Scientific, Waltham, MA), vinculin 
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(Millipore, Temecula, CA), SMA (Sigma, St. Louis, MO), N-cadherin, vimentin, pSMAD3 (Cell 
Signaling, Danvers, MA), TGF, fibronectin, and snail (Santa Cruz Biotechnology Inc., Dallas 
TX) using western blot protocol described previously [322]. After detection by 
chemiluminescence, the images were scanned and quantified for band intensity using the Gel-Pro 
software.  The protein levels were normalized against tubulin levels and expressed as density units 
relative to the untreated controls.  
 
Cell aggregation assays: 
ADPKD and NHK cells were suspended in 0.002% serum media with or without ouabain 
(3 nM) at a concentration of 25,000 cells/mL in a 50 mL conical tube (Corning Inc., Corning, NY) 
with loosened cap at 37˚C, 5% CO2 for 1 hour. At this point an aliquot of 500 μL was removed 
from each tube and placed on ice; time point was denoted as “0 Hr.” The remaining cells were then 
incubated in the shaker at 100 rpm at 37˚C to form aggregates. Cells were then collected at 30 and 
60 min intervals and placed on ice. Samples were maintained on ice until all the samples were 
collected and then processed. To each tube containing cells, 500 μL PBS + 0.4% Tween-20 was 
added to yield a final concentration of 0.2% Tween-20, then DAPI was added to each tube at a 
concentration of 1x. Cell clusters were counted using flow cytometry (LSRII flow cytometer, 
Beckton Dickinson, Franklin Laks, NJ). 
 
Cell invasion assays: 
 Invasion assays were performed using Cultrex 96-well BME cell invasion assay kit, 
following manufacturer’s instructions (R&D Systems, Minneapolis, MN). Briefly, 50,000 serum-
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starved cells were plated on to basement membrane extract (BME)-coated transwell membranes 
followed by an addition of 150 L cell media either with or without ouabain to the bottom 
chamber. The cells were allowed to invade for 24 h. and the cells that migrated to the underside of 
the membrane were dissociated and labeled using Dissociation/Calcein-AM fluorescent solution 
(BD Biosciences, San Jose, CA) and read at an excitation/emission of 485nm/520nm using a 
BioTek Synergy HT plate reader (Biotek, Winooski, VT. The number of cells which invaded 
through the BME was quantified using a standard curve obtained from cells that migrated on 
uncoated membranes. 
 
Cell migration assays: 
 ADPKD or NHK cells were plated on 6 well plates and grown until confluency. Cells were 
then deprived of serum for 24 hours. Using a pipette tip, a scratch was made in the monolayer; 
ouabain was applied at the time of scratch. Pictures of the well were taken using a Celigo imaging 
cytometer (Nexcelom, Biosciences LOC, Lawrence MA), at 0, 4, and 8 after the scratch. Images 
were analyzed using ImageJ. In some experiments, cells were treated with or without ouabain 24 
h before the scratch, at which time ouabain was re-applied. 
 
Immunofluorescence analysis: 
ADPKD and NHK cells were used. Cells were grown until they achieved confluency on 
transwell insert plates. Then, they were deprived of serum for 24 h and ouabain at a concentration 
of 3 nM was applied to the basolateral side of the cells. Cultures were further maintained in culture 
for 24 h. At these time points, monolayers were washed three times with ice-cold PBS before 20 
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minutes of methanol at −20 °C to fix and permeabilize the samples. After three more washes with 
PBS, samples were blocked for 1 h with 0.5% BSA, and incubated for 1 h at 37 °C with a specific 
primary antibody. Samples were washed 3 times as above. Cells were then incubated with FITC 
conjugated goat anti-mouse or anti-rabbit antibodies (1:1000) depending on the source of the 
primary antibody. This was followed by 3 washes with PBS and cells were mounted on glass slides 
with Slow Fade Gold Antifade reagent with DAPI (ThermoFisher Scientific, Waltham, MA), and 
viewed on a Nikon Eclipse 80i equipped with digital camera. 
 
Dextran assays: 
Cells were grown at a density of 1 x 106 cells per well in six-well transwell inserts to form 
confluent monolayer on transwell filter supports (0.4 uM pore size, from BD Bioschiences, San 
Jose, CA). Ouabain was added basolaterally at given time points. Control cells had no ouabain in 
either chamber. Paracellular permeability was assessed by FITC-dextran (4 kDa, Sigma, St. Louis, 
MO) flux through monolayers treated for 24, 48, and 72 hours, as described [546]. Cells were 
washed with “P Buffer” [10 mM hepes (pH 7.4), 1 mM sodium pyruvate, 10 mM glucose, 3 mM 
CaCl2, and 145 mM NaCl]. A freshly prepared solution of 10 μg/mL of FITC-dextran was 
dissolved in the P buffer. The diluted mixture was added to the upper chamber of the transwell 
insert to measure the permeability from apical to basolateral (A-BL) direction and to lower 
chamber to measure the permeability from basolateral to apical direction (BL-A). After 1 h 
incubation at 37 °C, the basal medium was collected and the fluorescence of the transported FITC-
dextran was measured with a synergy HT fluorescence spectrometer (BioTek, Winooski, VT) at 
492 nm (excitation) and 520 nm (emission). The FITC was quantified by extrapolating from a 
standard curve. The unidirectional flux of dextran in the apical to basolateral direction (JDEX in 
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ng·cm−2·h−1) was calculated by dividing the fluorescence intensity of a given sample of the 
bottom solution (arbitrary units) by the corresponding value of the upper solution or vice versa. 
For convenience the JDEX values were normalized with control samples at the 24 h time point 
and expressed as a relative JDEX value.  
 
Transepithelial Electrical Resistance (TER) measurements: 
Transepithelial Electrical Resistance (TER) was performed using transwell permeable 
supports (0.4µm, 12 well, Corning Inc., Corning, NY). The cells were seeded on the filters in a 
density of 120,000 cells/cm2. Cells were grown until they achieved confluency on transwell inserts. 
Then, they were deprived of serum for 24 h and ouabain was applied at a concentration of 3 nM 
to the basolateral side of the cells. Cultures were further maintained in culture for 24, 48 and 72 h, 
then TER was measured by using automated cellZscope (NanoAnalytics, Munster, Germany).  
 
Statistical Analysis: 
All the experiments were performed in triplicates with cystic epithelial cells obtained from 
at least three different ADPKD patients. Statistical significance of the differences between ouabain 
treated and untreated controls was determined by Student’s T-test and Anova. Statistical 





Ouabain alters the expression of EMT markers in ADPKD cells.  
In ADPKD, cells have been shown to undergo changes resembling EMT, which may help 
their cystic phenotype [574]. Based on our findings that ouabain enhances other aspects of ADPKD 
cystogenesis, we were interested in studying whether ouabain could induce EMT changes in 
ADPKD cells. Our first approach to this end consisted in assaying commonly used markers of 
EMT after 24 h treatment of the cells with or without 3 nM ouabain. Immunoblot analysis of EMT 
related proteins in NHK cells showed that ouabain had no significant effect on expression levels 
of E-cadherin, N-cadherin, αSMA, collagen-I, vinculin, or fibronectin. In contrast, ouabain 
treatment decreased the epithelial marker E-cadherin and increased the mesenchymal markers N-
cadherin, SMA, and collagen-I in ADPKD cells (Fig. 3.1). The expression of other mesenchymal 
markers, such as vimentin and fibronectin where not changed in ADPKD cells with ouabain 
treatment (Fig. 3.1). This suggests that ouabain is able to induce protein expression changes that 
are commonly found in EMT; however, not all mesenchymal markers are upregulated by ouabain 
in ADPKD cells.  
 
Ouabain modifies cell-cell adhesion properties in ADPKD cells 
In order to investigate if ouabain influences cellular events that are associated with EMT 
in ADPKD cells, we studied the effect of ouabain on the adhesion properties of the cells. ADPKD 
and NHK cells in suspension were treated with and without 3 nM ouabain and then were allowed 
to form aggregates under incubation in a shaker. The number of 2n and 4n nuclei, indicative of 
aggregated cells, was evaluated by flow cytometry.  Ouabain reduced the ability of ADPKD cells 




60 minute time point as well (Fig. 3.2B). In contrast, ouabain did not significantly change cell 
aggregation in NHK cells (Fig. 3.2A). This suggests that ouabain affects the cell to cell attachment 
properties of ADPKD cells, but not NHK cells.  
Figure 3.1 
 
Figure 3.1. Ouabain effects on expression of EMT markers in NHK and ADPKD cells. ADPKD 
and NHK cells in culture were treated without and with 3 nM ouabain for 24 hours. Cells were harvested, 
lysed and the proteins of interest identified by immunoblot. A) E-cadherin, B) N-cadherin, c) αSMA, 
d) collagen-I, E) vimentin, and F) fibronectin. The lower panels show representative blots, while the top 
panels show the average values ± SEM of the densitometric analysis of 3 different experiments. 
Statistical significant differences are shown relative to control values, with asterisks indicating P<0.05. 
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Ouabain enhances migration, but not invasion of ADPKD cells 
Another functional consequence of EMT is the enhanced ability of the cells to migrate 
[553, 650]. Therefore, we tested if ouabain was able to alter the migration rate of ADPKD and 
NHK cells, using wound healing assays. For this, confluent cell monolayers were scratched with 
a micropipette tip to inflict a wound 
in the culture and were treated 
without and with 3 nM ouabain. 
Repair of the wound was analyzed 
over time, by taking serial pictures of 
the culture at 0, 4, and 8 h after the 
scratch was performed. Ouabain did 
not affect cell migration in either 
NHK or ADPKD cells at these short-
term treatments (data not shown). 
However, when cells were pretreated 
with ouabain for 24 h before 
wounding, then a significant 
enhancement of migration occurred 8 h after scratch induction in ADPKD, but not in NHK cells 
(Fig. 3.3A-C). This suggests that ouabain is able to enhance cell migration, a characteristic of 
EMT, in ADPKD, but the effect requires relatively prolonged exposure times to ouabain. 
To determine whether ouabain promotes not only cell migration, but also invasion, we 
tested the ability of the cells to cross through an extracellular matrix support after the addition of 
ouabain. Cells were grown on basement membrane extract (BME)-coated filter inserts and were 
Figure 3.2 
Figure 3.2. Ouabain effect on NHK and ADPKD cell-
cell attachment. NHK and ADPKD cells were incubated 
in suspension on a shaker and were treated with and 
without 3 nM ouabain. After the indicated times, the 
number of cell aggregates formed was determined, based 
on the number of 2n and 4n nuclei, measured by flow 
cytometry. A) NHK cells, B) ADPKD cells. Bars represent 
mean densitometry values ± SEM of 3 determinations 
using cells from different ADPKD kidneys. Asterisks 
indicate statistical significance, with P<0.05. 
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Figure 3.3                                                                                               
 
Figure 3.3. Ouabain effects on NHK and ADPKD cell migration and invasive growth. A-D) Cells 
were pretreated with ouabain for 24 h. Then a scratch was made in the confluent monolayer with a 
pipette tip and healing of the wound was followed by taking pictures at the indicated times after 
inflicting the scratch. Representative pictures are shown; black lines delineate edge of the wound. Cells 
from 4 separate kidneys were assayed, in duplicate. Bars indicate mean ± SEM, expressed relative to 
control values at time of scratch. Asterisks indicate statistical significance with respect to 0 time, with 
P<0.05. E) 24 h ± ouabain. The number of cells translocated through basement membrane extract 
(BME). Bars denote mean ± SEM. *P<0.05.
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treated in the absence and presence of 3 nM 
ouabain. After 24 h, the number of cells that 
invaded through to the support was quantified. As 
shown in Fig. 3.3E, ouabain did not increase 
invasiveness in either NHK or ADPKD cells. This 
shows that while ouabain enhances cell migration, 
it does not change the aggressiveness of cells to 
grow across their basement membrane support.   
 
Ouabain selectively modulates tight junctions in 
ADPKD cells.  
Tight junctions between epithelial cells 
maintain the structure of the cell monolayer and 
form a semipermeable diffusion barrier that restricts 
the passive diffusion of molecules, according to 
their charge and size (reviewed in [651]). These are 
dynamic structures, which consist of multi-protein 
transmembrane complexes that include claudins and 
occludins, as well as scaffold proteins, such as the 
ZO proteins [549]. Since we found ouabain to 
induce relaxation of cell-cell adhesion and increase 
cell migration, we hypothesized that ouabain 
treatment may alter the expression of tight junction 
Figure 3.4 
 
Figure 3.4. Ouabain effect on cell tight 
junctions in NHK and ADPKD cells. NHK 
and ADPKD cells were treated without and 
with ouabain (3 nM) for 24 hours and tight 
junction protein expression was analyzed by 
immunoblot and immunofluorescence.  
Representative pictures of the cultures are 
shown in the upper panels, while 
immunoblots of each sample are displayed 
below. A) Claudin-1, B) Occludin, and C) 
ZO-1. Bars denote mean densitometry levels 
± SEM of 3 determinations using cells from 
different ADPKD kidneys; relative to 
control values. Asterisks indicate statistical 
significance with respect to untreated 
controls, with P<0.05.  
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proteins in the cells, which will facilitate the capacity 
of the cells to migrate. In addition, changes in tight 
junction proteins are observed as part of EMT [553, 
650]. To test this, we cultured NHK and ADPKD 
cells for 24 h with and without 3 nM ouabain, after 
which protein lysates were prepared and a series of 
tight junction proteins were analyzed by immunoblot 
and immunocytochemistry. NHK cells did not 
respond to ouabain with changes in the tight junction 
proteins tested (Fig. 3.4A – 4C). In contrast, ouabain 
differentially affected tight junction protein 
expression in ADPKD cells. While claudin-1 and 
ZO-1 were not significantly modified (Fig. 3.4A, and 
3.4C), occludin amounts were elevated (Fig. 3.4B). 
Immunolocalization analysis of these proteins 
showed that ouabain did not change the plasma 
membrane localization of tight junction proteins 
either in NHK and ADPKD cells (Fig. 3.6A). These 
results show that ouabain is a selective regulator of tight junction protein expression in ADPKD 
cells, upregulating occludin. While ouabain did not induce subcellular localization changes of the 
tight junction proteins tested, localization of claudin-1, occludin, and ZO-1 is not altered in 
ADPKD mouse models, and thus the action of ouabain does not go against the described phenotype 
of ADPKD epithelium [652]. 
Figure 3.5 
 
Figure 3.5. Ouabain effect on adherens 
junction proteins in NHK and ADPKD 
cells. NHK and ADPKD cells were treated 
without and with ouabain (3 nM) for 24 
hours And the expression of adherens 
junction proteins was analyzed by 
immunoblots of each sample are shown A) 
β-catenin and B) Vinculin. Bars denote 
mean densitometry ± SEM of 3 
determinations using cells from different 
ADPKD kidneys; relative to control values. 
Asterisks indicate statistical significance 





Ouabain modulates adherens junctions in ADPKD cells in a selective manner. 
Adherens junctions lie more basal to tight junctions and serve to connect the actin 
cytoskeletons of neighboring epithelial cells. Interestingly, PC1 associates with a multiprotein 
complex containing E-cadherin, -, - and -catenins [217, 221]. In ADPKD cells, the polycystin-
1/E-cadherin/β-catenin complex is disrupted and both polycystin-1 and E-cadherin have been 
shown to be depleted from the plasma membrane as a result of the increased phosphorylation of 
polycystin-1 [153, 222]. Changes in adherens proteins are also typically observed during EMT. 
 We assayed the effect of ouabain on the expression levels and cellular localization of 
several adherens junction proteins, including E-cadherin, β-catenin, and vinculin in NHK and 
ADPKD cells.  In NHK cells, ouabain did not have a significant effect on either the expression 
levels or localization of E-cadherin, β-catenin or vinculin (Fig. 3.1, 3.5A-C, 3.6B). In ADPKD 
cells, ouabain decreased the expression levels of E-cadherin (Fig. 3.1A). In contrast, the expression 
and localization of β-catenin and vinculin remained unchanged after ouabain treatment (Fig. 3.1, 
3.5A-C, 3.6B). Therefore, similar to what occurred with tight junctions, ouabain also selectively 
regulated the expression of zonula-adherens proteins, specifically decreasing the levels of E-
cadherin.   
 
TER but not paracellular permeability is altered in response to ouabain in ADPKD. 
Junctional complexes control the diffusion of ions and hydrophilic solutes across the 





Figure 3.6. Ouabain effect on localization of junction proteins. NHK and ADPKD cells were 
treated without and with ouabain (3 nM) for 24 hours and the expression of adherens junction proteins 
was analyzed by immunocytochemistry. Representative pictures of the cultures are shown for A) 
Tight junction proteins and B) Adherens junction proteins. 
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complexes continue functioning as a selective barrier to maintain the tightness of the epithelium 
lining the cysts. However, some reports have shown that ADPKD is accompanied by alterations 
in the apical junctional complexes and dysregulation of the polarity and growth of the cells [238, 
248, 652]. This agrees with the dedifferentiated phenotype described of cystic cells and the 
EMT-like alterations that ADPKD cells exhibit [226, 574, 575]. We tested the ability of ouabain 
to influence transepithelial electrical resistance (TER) after treatment without and with 3 nM 
ouabain for different times. We found that ouabain significantly enhanced TER in ADPKD cells, 
an effect which was observed at 48 and 72 h treatment with ouabain (Fig. 3.7A). In contrast, no 
significant change in TER was found in NHK cells (Fig. 3.7A). 
The unidirectional flux of dextran (JDEX) from the apical to the basolateral side of the 
epithelium, or vice versa, is a measure of the restriction offered by tight junctions to the movement 
of neutral molecules across an epithelium [653]. To further assess the effects of ouabain on 
paracellular transport of NHK and ADPKD cells, we determined whether ouabain regulated the 
paracellular transport of solute in the cells. For this, the permeability of neutral dextran molecules 
(4 kDa in size) was measured in monolayers of NHK and ADPKD cells grown in transwell filters 
and treated in the absence and presence of 3 nM ouabain for different times.  We did not find any 
significant differences in the transport of 4 kDa dextran between the treatments in either cell type. 
This occurred for both the apical to basolateral, as well as for the basolateral to apical movement 
of dextran (Fig. 3.7B and 3.7C). Thus, it appears that ouabain does not cause functional changes 
in the paracellular pathway involved in moving solutes across the epithelial monolayer of NHK 







Figure 3.7. Ouabain effect on TER and paracellular movement of dextran in NHK and ADPKD 
cells. (A) Cells were grown to confluency on transwell inserts and treated with ouabain (3 nM) for the 
indicated times. TER was measured using an automated cellZscope. Bars denote mean ± SEM of cells 
obtained from 3 separate kidneys. *P<0.05. (B) Paracellular permeability was assessed by FITC-dextran 
flux through confluent monolayers treated without and with ouabain (3 nM) for the indicated times. 
Bars denote mean ± SEM of cells obtained from 4 separate kidneys. Asterisks indicate statistical 
significance with respect to untreated controls, with P<0.05. 
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The TGFβ-Smad3 signaling is activated by ouabain in ADPKD cells 
 TGFβ is a key factor in the development of fibrosis and in EMT promotion in several 
kidney diseases [585, 650, 654, 655], including ADPKD [584-586]. TGFβ activates TGFβR which 
then recruits transcription factors Smad2 and Smad3. Together with Smad4, the Smad2/3 complex 
translocates to the nucleus and binds to regulatory elements on DNA, leading to increased 
transcription of key genes which promote EMT [654]. We investigated the involvement of the 
TGFβ signaling cascade in relation to EMT-like alterations that ouabain produces in ADPKD cells. 
We observed that ouabain increased TGFβ protein levels in ADPKD cells treated with 3 nM 
ouabain for 24 h, compared to untreated cells (Fig. 3.8A). In addition, we also observed that the 
expression of Snail, a TGFβ target gene which governs EMT and fibrosis [656, 657], is increased 
in ADPKD cells in response to ouabain (Fig. 3.8B). These effects on TGFβ and Snail were not 
found in NHK cells (Fig. 3.8A and 3.8B). When Smad3 signaling was analyzed, we found that 
ouabain activated the phosphorylation of Smad3 in ADPKD cells within 15 minutes of ouabain 
application. In contrast, ouabain did not promote Smad3 phosphorylation in NHK cells (Fig. 3.8C). 
Taken together, these data show that ouabain can activate the TGFβ-Smad pathway, which agrees 







Figure 3.8. Ouabain effect on the TGF signaling pathway in NHK and ADPKD cells. (A, B) NHK 
and ADPKD cells were treated without and with ouabain (3 nM) for 24 hours and the relative levels of 
TGF were determined by immunoblot. (C, D) NHK and ADPKD cells were treated with or without 
ouabain and total and phosphorylated Smad3 levels were determined at the indicated time points. Bars 
represent phosphor-Smad3 levels as a fraction of the untreated comtrols and relative to the untreated 
controls. Bars represent the mean ± SEM of 3 determinations using cells from different ADPKD 




Phenotypic changes characteristic of EMT have been described in ADPKD [658] and a 
number of EMT-related genes have been found to be upregulated in kidney samples from patients 
with ADPKD [87]. Ouabain and other cardiotonic steroids have been shown to modify cell 
junctional complexes and induce EMT in various epithelial cells in culture [398, 544, 546]. 
Previous results from our laboratory have shown that ouabain is a factor that enhances several 
characteristics of ADPKD cells that are relevant to the progression of the disease. Among those 
are the exacerbation of ADPKD cell proliferation and the increase in cAMP-mediated fluid 
secretion [322, 360, 361, 491]. These effects contribute to the dedifferentiated phenotype that renal 
ADPKD cells are known to present [226, 574, 575]. In this work, we found that, in contrast to 
NHK cells, ouabain exerts complex effects on ADPKD cells that accentuate the dedifferentiated 
state of cystic cells, compatible with an EMT phenotype. For instance, ouabain decreased E-
cadherin and increased N-cadherin protein levels in ADPKD cells, two major markers of EMT. In 
addition, other typical markers of a mesenchymal phenotype also increased, including SMA, and 
collagen-I. While this supports the idea that ouabain is pushing ADPKD cells towards an EMT 
phenotype, a complete transition to a mesenchymal phenotype was not observed. Thus, some of 
the tight and adherens junctional proteins of the cells, such as vimentin and fibronectin appeared 
not to be affected. The complete transition from an epithelial state to a mesenchymal state is the 
classic definition of EMT [650]. However, recent studies have recognized the existence of 
intermediate, "metastable" stages of EMT in epithelial and cancer cells [659-661]. This implies 
that a range of heterogeneous patterns of mesenchymal change can be observed in cells [659-661]. 
Our observations on the effects of ouabain on EMT agree with the notion that this compound is 
causing a partial EMT or a metastable state in the ADPKD cells. Such a state is increasingly 
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recognized to occur in renal cells under conditions of wounding or stress [634, 662-664].  It is 
important to note that our experiments were performed on primary cell cultures. It is possible that 
when placed under in vitro conditions, the cells exhibit a degree of dedifferentiation that may not 
reach that achieved in the native in vivo environment. This could result in relatively higher 
background levels of expression of makers of cell EMT, which may make it more difficult to detect 
changes in EMT-related gene expression. In any case, our results clearly show a specific response 
in ADPKD cells in favor of a higher undifferentiated phenotype. Moreover, the increase that we 
observe in collagen-I suggests that ouabain treated ADPKD cells may be undergoing fibrotic 
changes. This effect coincides with the deleterious functional consequence that ADPKD has on 
renal function, which is in great part dependent on the fibrosis that affects and compromises renal 
function [665]. We also found that ADPKD, but not NHK cells respond to ouabain with selected 
changes in expression of proteins involved in cell tight junction and adherens junction proteins. 
Accordingly, we show that ADPKD cells respond to ouabain with a lower ability to form cell 
aggregates when in suspension cultures.  We observed a reduction in E-cadherin, which will reduce 
adhesion between ADPKD cells. The cellular localization of E-cadherin was not changed by 
ouabain treatment of the cells. Therefore, it appears that the effect is due to rapid degradation of 
the protein, rather than its mobilization to intracellular stores. Previous results in our laboratory 
have shown that ouabain causes an internalization of the NKA to the cytoplasm of ADPKD cells 
[322]. The β-NKA subunit is known to function as a cell-cell adhesion molecule, which interacts 
with other β-NKA polypeptides expressed at the plasma membrane of neighboring cells (reviewed 
in [536] and [542]). Therefore ouabain-induced endocytosis of NKA may be an additional 
mechanism to explain the decreased cell-cell adhesion observed with ouabain in ADPKD cells. 
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Interestingly, the expression level of NKA has been proposed to be included as a marker of EMT 
[666].  
Another adhesion protein found to be modulated by ouabain in ADPKD cells is occludin, 
the protein expression of which increased. This result was unexpected, since occludin commonly 
decreases in EMT [553]. While this finding does not agree with alterations typical of EMT, it may 
be related to a compensatory response by the cells to maintain the integral structure of tight and 
adherens junctions. This may help retain the overall structural integrity of the ADPKD cysts, in 
spite of the lower E-cadherin amounts. It may also permit the epithelium to continue accumulating 
fluid within the cyst lumen, despite other ouabain-modified tight junctional complex alterations 
which might otherwise cause fluid leakage. In support of this, our experiments that show an 
increase in the TER of the ADPKD cell monolayers. Therefore, ouabain is causing a remodeling 
of cell junctions that may help the functional needs of the cystic ADPKD epithelium.  
Similar to our studies, it has been shown that ouabain at relatively high concentrations (1 
uM) induces cell detachment in MDCK cells and this was associated with loss of tight junction 
complexes [462]. This effect however, was not seen when lower concentrations of ouabain (10 - 
50 nM) were used [546]. Lower concentrations of ouabain may be sufficient to elicit an effect on 
tight junctions in ADPKD cells compared to MDCK cells, as ADPKD cells have an abnormally 
high affinity to ouabain [322]. In addition, MDCK cells responded to high ouabain doses with 
changes in a different subset of adhesion proteins than the ones we find modulated by ouabain in 
ADPKD cells. While this could perhaps be attributed to differences in the cell type used in each 
of the studies, it appears clear that ouabain plays a role in the regulation of cell adhesion, and that 
this effect is different in normal and ADPKD diseased cells.  
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Ouabain decreased the adhesive properties and augmented the mobility of ADPKD cells, 
further supporting the undifferentiated phenotype of these cells. In contrast, ouabain does not 
influence the invasive properties of ADPKD cells. As ADPKD cells are not invasive (reviewed in 
[667]), the phenotype elicited by ouabain does not contradict the non-invasive phenotype of 
ADPKD, but does promote some migration. In contrast to ADPKD cells, ouabain has no effect on 
NHK cells.  
Our studies assessing dextran permeability also show that ouabain does not change the 
paracellular transport of neutral solutes in NHK or ADPKD cells. This effect agrees with a 
maintenance of the function of junctional complexes by ouabain, which is needed to maintain cyst 
functional and structural integrity [360, 361]. We observed that ouabain induced a time-dependent 
increase in TER in ADPKD cells. TER is an indicator of the paracellular resistance to ions of the 
epithelium. Its increase indicates that ouabain favors the ion differences between the cyst lumen 
and the interstitium, while still allowing the passage of solutes as shown from the constant 
permeability that the cells exhibit to the passage of dextran. At present, how the changes in TER 
that ouabain induces in ADPKD cells correlate with the composition of tight junction proteins is 
unclear. Further studies will be needed to ascertain the structure function relationship of tight 
junctional complexes in ADPKD cells. However, it is of interest that increases in occludin 
expression have been correlated with increased TER [545], two conditions which occur upon 
ouabain treatment in ADPKD. Changes in tight junction proteins in response to ouabain treatment, 
with an increase in TER values, but not dextran permeability have also been reported by Larre et 
al [546]. However, similar to our studies, these authors were not able to define how this correlated 
with the profile of different junctional proteins (reviewed in [651]).  
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Not only does ouabain induce EMT in ADPKD cells, we also observed activation of the 
TGFSmad pathway. Thus, we found a ouabain-dependent increase in the expression of TGF, 
the phosphorylation of SMAD3, and the levels of Snail protein.  In ADPKD patients, target genes 
of the TGFpathway are upregulated compared to normal controls [574, 584, 585], with 
SMAD2/3 rather than SMAD 1/5/8 found to be activated [584, 585]. Therefore, our data correlates 
well with ouabain-mediated enhancement of the EMT phenotype observed in ADPKD. TGF is a 
known driver of EMT, yet the targets of TGF signaling depend greatly on the cell type (reviewed 
in [668]). This may explain why in ADPKD cells we find that not all EMT markers are affected 
by ouabain. 
In conclusion, ADPKD cells, have been shown to exhibit altered apical to basal, as well as 
planar polarity, increased cell migration, and an undifferentiated cell state [238, 248, 652]. The 
dedifferentiated phenotype of ADPKD cells was found to be partially enhanced by ouabain. These 
results further support the role that we previously reported for ouabain as a factor that promotes 
ADPKD progression.  
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CHAPTER 4: OUABAIN-MEDIATED ALTERATIONS IN CELLULAR CALCIUM          
ABSTRACT 
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the 
progressive growth of renal cysts that alter the structure and function of the kidney.  Previously, 
we have shown that the hormone ouabain enhances cell proliferation, fluid secretion, and promotes 
cell dedifferentiation in cystic kidney epithelial cells from patients with ADPKD (ADPKD cells); 
but does not have these effects in normal human kidney epithelial cells (NHK cells). Intracellular 
calcium concentration ([Ca2+]i) plays an important role in the pathophysiology of ADPKD. In this 
work, we explored the effect of ouabain on [Ca2+]i levels in NHK and ADPKD cells and the 
mechanism of action by which ouabain elicits its effects. We found that ouabain increased [Ca2+]i 
in NHK cells, but not in ADPKD cells. While ouabain raised Ca2+ in the cell cytoplasm, it did not 
change endoplasmic or mitochondrial Ca2+. Ouabain-induced [Ca2+]i elevation in NHK cells was 
blocked by Ca2+ removal from the medium, suggesting that plasma membrane ion channels are 
involved in the response. The Ca2+ increase elicited by ouabain in NHK cells was abrogated by the 
L-type calcium channel (LTCC) inhibitor verapamil. Moreover, the LTCC agonists Bay K8644 
and FPL-64176 restored the ouabain-dependent [Ca2+]i increase in ADPKD cells. LTCC agonists 
also blocked ouabain-induced proliferation of ADPKD cells. Protein expression levels of full-
length LTCC were lower in ADPKD cells than NHK cells. Concomitantly, ADPKD cells 
contained higher amounts of LTCC cleavage products. We observed that ADPKD cells had higher 
expression of c-Myc, and that this correlated with decreased expression of the calpain inhibitor 
calpastatin, as well as increased levels of calpain activity, a protease involved in LTCC cleavage. 
Our data shows that ouabain stimulates [Ca2+]i increase in NHK cells by facilitating Ca2+ uptake 
from the extracellular space via LTCC. In contrast, ouabain fails to elevate [Ca2+]i in ADPKD 
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cells, due to low LTCC levels, which may be secondary to enhanced LTCC cleavage by the c-Myc 
dependent increase in calpain. We additionally found that ADPKD cells could be made to respond 
to ouabain with increased [Ca2+]i by inhibited Mitogen-activated protein kinase kinase (MEK 1/2), 
an action which was found to move LTCC channels into the plasma membrane. Therefore due to 
alterations in LTCC localization and cleavage, ADPKD cells are unable to fully respond to stimuli, 





Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary 
alteration of the kidney, afflicting 1 in 400-1000 births worldwide [22, 23, 669]. The disease is 
primarily characterized by the formation and progressive growth of multiple fluid-filled cysts in 
the kidney. Additionally, ADPKD can also present with extrarenal manifestations, including cysts 
in pancreas and liver, aortic and intracranial aneurisms, and cardiac valve prolapse [670]. The renal 
cysts are believed to form early in utero and they slowly expand during the life of the affected 
individual [30]. ADPKD compromises kidney function, leading to renal insufficiency by the fifth 
decade of life [13]. ADPKD is responsible for approximately 8-10% of all cases of end stage renal 
disease (ESRD), irreversibly requiring dialysis or transplant therapy [4, 5]. 
ADPKD has a multifactorial pathophysiology with the renal cystic cells exhibiting a 
complex phenotype. Among their characteristics, renal epithelial cells from ADPKD patients show 
an increased ability to proliferate, a greater capacity for net fluid secretion, altered apical to basal 
polarity, abnormal directional migration, and changes in the cell matrix (reviewed in [265, 266]). 
Another distinctive feature of renal epithelial cystic cells from ADPKD patients, as well as various 
ADPKD animal models is the dysregulation of several intracellular signaling pathways. 
Interestingly, the intracellular calcium concentration ([Ca2+]i) of ADPKD cells is constitutively 
lower relative to cells derived from the normal human tubular epithelium [197, 199]. The abnormal 
low [Ca2+]i of ADPKD cells alters the manner in which the cells respond to stimuli. Thus, ADPKD 
cells show excessive activation of B-RAF in response to cAMP, a response that can be reversed 
by pharmacologically increasing [Ca2+]i in the cells [197]. Further support for the crucial role of 
[Ca2+]i in ADPKD progression is illustrated by the decrease in cyst size upon application of a Ca2+ 
ionophore in metanephric organ culture [200]. 
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ADPKD is caused by mutations in the PKD1 and PKD2 genes that encode for polycystin-
1 (PC1) and polycystin-2 (PC2) respectively [113, 114]. While mutations in PC1 are responsible 
of 80-85% of ADPKD cases, the remaining 15-20% are associated with alterations in PC2 [10]. 
The average onset of ESRD due to ADPKD occurs at approximately the age of 57 for patients with 
PC1 mutations and age 69 for patients with PC2 mutations [13]. PC1 and PC2 interact with each 
other to form a macromolecular receptor/signaling complex that appears to have a role in the 
control of cytoplasmic Ca2+ levels.  PC2 has homology with the transient receptor potential (TRP) 
type of ion channels and it functions as a Ca2+ non-specific cation channel [14]. PC2 regulates 
cytoplasmic Ca2+ in renal epithelial cells [204, 671] and knockdown of PC2 increases cyst growth 
in microcyst cultures [199]. PC1 is thought to act as a sensor that regulates the activity of PC2 
[15]. The PC1/PC2 complex has been described to have roles both in inducing extracellular Ca2+ 
flux [14, 672], as well as modulating Ca2+ release from endoplasmic stores [185]. Thus, 
overexpression of PC2 results in decreased ER [Ca2+], while expression of PC1 generally increases 
ER [Ca2+] [176, 209-212]. Although ADPKD is a genetic disorder, the progression of the disease 
is highly dependent on factors circulating in blood and on different exogenous pharmacological 
agents (reviewed in [673]). Previous results in our laboratory have shown that ouabain, in 
concentrations similar to those circulating in blood, increases the proliferation of renal epithelial 
cystic cells obtained from kidneys of patients with ADPKD (ADPKD cells) [322, 491]. In these 
cells, ouabain also activates the intrinsic pathway that leads to apoptosis [674] and the cAMP-
dependent fluid secretion of ADPKD cell monolayers [360, 361]. Moreover, ouabain stimulates 
cyst-like tubular dilations in embryonic kidneys from PKD1 mutant mice [360, 361]. In contrast, 
ouabain does not cause any of these effects in normal human kidney epithelial cells (NHK cells) 
or wild type mouse kidneys [322, 360, 361, 491, 674]. Ouabain is a hormone synthesized by the 
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adrenal glands, which circulates in nanomolar amounts in the bloodstream of mammals [384, 388-
390]. The effects of ouabain are mediated by the Na,K-ATPase (NKA) [380, 675, 676]. NKA is a 
protein complex at the plasma membrane of most animal cells, which had been classically known 
for its ion transport function, consisting in the ATP driven exchange of cytoplasmic Na+ for 
extracellular K+ across the cell plasma membrane [268, 269]. However, more recently a new role 
of NKA as a signal molecule of ouabain effects has been established [456]. By binding to NKA, 
ouabain regulates metabolism, motility and proliferation in a tissue specific manner [322, 403, 
460, 471]. The mechanisms by which ouabain exerts its actions are complex, involving several 
intracellular mediators, including the modulation of intracellular Ca2+ concentration. For example, 
by partially inhibiting the ion transport function of NKA [374-376], ouabain causes a secondary 
increase in [Ca2+]i via Na+ dependent downregulation of function of the sodium/calcium exchanger 
(NCX) [555, 556]. This mechanism is responsible for the enhanced contraction of myocardial cells 
and vascular smooth muscle cells, which leads to the well-known regulatory effects of ouabain on 
cardiac and vascular smooth muscle cells (reviewed in [555, 557]). Alternatively, ouabain controls 
[Ca2+]i via activation of downstream effectors, such as the inositol triphosphate receptors (IP3Rs), 
which trigger the release of Ca2+ from the endoplasmic reticulum [558-560]. This mechanism has 
been shown to cause slow Ca2+ oscillations in renal proximal tubules epithelial cells in response 
to ouabain [403, 477, 558-560]. In addition, a rise in [Ca2+]i induced by ouabain has been reported 
to also take place via changes in activity of L-type calcium channels (LTCC). This mechanism, 
described in cardiomyocytes and in some neuronal cells, presumably depends on the alterations in 




We have previously determined that some of the effects that ouabain exerts on ADPKD 
cells involves the scaffolding of Na,K-ATPase with epidermal growth factor receptor (EGFR), the 
activation of the kinase SRC and the downstream stimulation of the extracellular signal-regulated 
kinase (ERK) pathway [322, 491]. However, the role of Ca2+ as a secondary mediator of the effects 
of ouabain in ADPKD cells has not yet been determined. In this work, we report that, similar to 
other cell types, NHK cells respond to ouabain with an influx of [Ca2+]i and this effect is mediated 
by activation of LTCCs. In contrast, ouabain is ineffective in increasing [Ca2+]i in ADPKD cells. 
Upon investigation, we found ADPKD cells have constitutively lower expression of full-length 




MATERIALS AND METHODS  
Cell culture: 
Primary cell cultures derived from surface cysts of ADPKD kidneys (ADPKD cells) were 
generated by the PKD Biomaterial Core at the University of Kansas Medical Center (KUMC). A 
protocol for the use of discarded human kidney tissues was approved by the Institutional Review 
Board at KUMC. Primary cultures were prepared as previously described [608]. Cells were seeded 
and grown in DMEM/F12 supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 
1U.ml penicillin G and 0.1mg/ml streptomycin, 5 ug/ml insulin, 5 ug/ml transferrin, and 5 ng/ml 
sodium selenite (ITS). 24 hours before the cells were subject to experimental manipulation, the 
serum was reduced to 0.002% and ITS was removed. As previously shown, these cells are 
epithelial in nature and derived from distal nephrons and collecting tubules, as shown by their 
labeling with lectin markers specific for collecting duct and distal nephron cells, such as Arachis 
hypogaea (PNA) and Dolichos biflourus agglutinin (DBA) [677].  
 
Chemical reagents: 
The Ca2+ indicator dyes used in this study were purchased from Molecular Probes 
(Thermo-Fisher Scientific, Waltham MA). They include Fura-2 AM, Fluoro-5N AM, and Rhod-
2, AM. The following compounds were used to elucidate the mechanism of action. From Santa 
Cruz (Santa Cruz, Carlsbad CA): FPL-64176 (20 nM), Xestospongin-c (5 uM), NAADP (50 nM), 
10058-F4 (25 uM). From Sigma (St. Louis, MO): A23187 (1-2 uM), (±)-Bay K8644 (5 uM), 2-
APB (5 uM), ORM-10103 (1 uM), Verapamil (2 uM) and Calpain-inhibitor I (N-acetyl-leu-leu-
norleucinal) (10 uM). Compounds from other companies include: Thapsigargin (10 uM; Cayman 
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Chemicals, Ann Arbor, MI), SEA0400 (5 uM; APExBIO, Houston TX), PP2 (10 uM; Calbiochem, 
Nottinghamshire UK), U0126 (1 uM, Promega, Madison WI), Boc-Leu-Met-CMAC (50 uM; 
Thermo-Fisher Scientific, Waltham, MA).  
 
Calcium trace:  
Cells were seeded at a concentration of 8,000 cells per well in a 96-well black with clear 
bottom plate (Corning, Kennebunk ME). Media was replaced with serum-free media as described 
under the cell culture section. To determine cytoplasmic Ca2+ levels, 2 uM Fura-2, AM in serum-
free media was added to each well and incubated at 37 ºC for 1 h. Then, cells were washed with 
PBS and the medium was replaced with HBSS and read in a FlexStation3 plate reader, at an 
excitation (Ex) of 340, 380 nm and an emission (Em) of 510 nm. The same protocol was used for 
Fluo-5N, except that this compound was used at 4 uM, and at an excitation/emission ratio (Ex/Em) 
of 488/521 nm; and for Rhod-2 (4 uM, Ex/Em of 552/581 nm). Before the addition of Rhod-2, the 
dye was reduced to dihydroRhod-2 to facilitate its uptake into the cell mitochondria, using 1 
mg/mL of NaBH4 in methanol.  For this, freshly prepared NaBH4 solution was added to 
resuspended Rhod-2 immediately before the addition of the dye to the cells. All Ca2+ indicators 
were resuspended in DMSO before they were added to medium. 
 
Immunoblot analysis: 
Cells treated with and without 3 nM ouabain for 24 hours were washed once with ice-cold 
PBS and lysed with buffer containing 10mM Tris-Cl (pH 7.4), 10mM NaCl, 3mM MgCl2, and 
0.1% NP-40. Fifty micrograms of the cleared lysates were analyzed by 8% SDS-PAGE and blotted 
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onto nitrocellulose membranes. Immunoblots were probed with antibodies at a concentration of 
1:1000 or 1:500, depending on the antibody, in TBS-T with 5% w/v BSA (Sigma, St. Louis, MO). 
The following antibodies were used: p65 NFB (sc-109), Histone H3 (sc-10809), NCX (sc-
32881), pan-LTCC (sc-98753), c-Myc (sc-764), calpastatin (sc-20779), all from Santa Cruz, 
(Carlsbad, CA), as well as -tubulin (#2144) GAPDH (#2118) from Cell Signaling (Danvers, 
MA). Secondary antibodies, obtained from Santa Cruz (sc-2004, sc-2005), were used at a 
concentration of 1:2000. 
 
Calpain activity assay: 
Cells were plated at a density of 8,000 cells per well on 96-well plates in complete medium. 
The next day, the medium was replaced with serum-free media. On the third day, cells were 
pretreated with calpain inhibitor 1 (10 uM), the MEK inhibitor U0125 (1 uM) or ouabain (3 nM) 
for 30 minutes at 37 oC before the addition of 50 µM of the calpain substrate, Boc-LM-CMAC 
(Thermo-Fisher Scientific, Waltham, MA). Cells were incubated for an additional 20 minutes at 
37oC, washed 3x with PBS and placed in a plate reader to quantify activity (Ex/Em of 351/430 
nm). Myc inhibitor experiments were nearly the same, with 24h treatment of the c-Myc inhibitor 
10058-F4 (25 uM) before Boc-LM-CMAC addition. 
 
Data analysis: 
The statistical analysis of samples was determined by one way analysis of variance 
(ANOVA), followed by Student’s T-test and Bonferroni’s test. Statistical differences were defined 




Ouabain changes cytoplasmic Ca2+ in NHK, but not in ADPKD cells 
We used the Ca2+ indicator Fura-2 to measure [Ca2+]i in NHK and ADPKD cells. In 
agreement with previous studies, [197], we observed that ADPKD cells exhibit overall lower 
[Ca2+]i than NHK cells (Fig. 4.1A - 4.1C). We treated the cells without and with 3 nM ouabain to 
determine its effect on [Ca2+]i in the cells. Ouabain increased [Ca2+]i in NHK cells (Fig. 4.1A and 
Figure 4.1 
 
Figure 4.1. Ouabain elicits an intracellular calcium increase in NHK cells. NHK (A) and ADPKD 
(B) cells in 96-well plates were loaded with Fura-2, and treated with ouabain (3 nM) [arrow]. The trace 
shown is a composite of the response of cells from 4 separate kidneys, in quadruplicate.  (C) Average 
fura-2 fluorescence of trace between untreated NHK and ADPKD. Bars indicate mean ± SEM of 
untreated cells. C. Average fura-2 fluorescence in response to 24 h treatment ouabain. Bars indicate 
mean ± SEM of 4 separate kidneys. *P<0.05.
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4.1C), but did not significantly affect [Ca2+]i in ADPKD cells (Fig. 4.1B and 4.1C). To explore the 
long term effects of ouabain on [Ca2+]i, we measured [Ca2+]i after treatment of the cells with 
ouabain for 24 h. NHK cells, but not ADPKD cells showed a ouabain induced increase in [Ca2+]i 
(Fig. 4.1D). Therefore, while ouabain elicits a Ca2+ response in NHK cells, it does not affect [Ca2+]i 
in ADPKD cells. 
 
Ouabain has no effect on endoplasmic reticulum and mitochondrial Ca2+ in both NHK and 
ADPKD cells  
In order to determine if ouabain was able to influence Ca2+ levels in the endoplasmic 
reticulum we used the Ca2+ indicator dye Fluo5N which has low affinity for Ca2+, making it suitable 
for detecting Ca2+ levels in the 1 uM-1mM range [678, 679].  Due to typical cytosolic Ca2+ 
concentrations of approximately 100 nM, Fluo5N is not able to detect Ca2+ in this cell 
compartment. In contrast, Fluo5N can detect the higher Ca2+ amounts of the endoplasmic reticulum 
(ER) [680], which has a Ca2+ concentration that ranges between 100-800 µM and is generally 
considered to be the largest Ca2+ store of cells [680]. Therefore, we used Fluo5N as an indicator of 
ER Ca2+ in NHK and ADPKD cells. We were also interested in the effect of ouabain on the 
mitochondria (which is an organelle with a typical Ca2+ concentration of ~100 nM Ca2+ [681]). 
Since the free mitochondrial [Ca2+] is similar to that of the cytosol [682], it is not detected by 
Fluo5N. Therefore, we used a second Ca2+ dye, Rhod-2, which preferentially enters mitochondria, 
to determine Ca2+ in this organelle. 
We initially validated the ability of Fluo5N to detect ER Ca2+ by treating the cells with the 





Figure 4.2. Ouabain does not significantly change ER or Mito calcium concentration. NHK (A) 
and ADPKD (B) cells loaded with Fluo5N show decreased fluorescence when ER stores are depleted 
using thapsigargin; composite of cells from 3 separate kidneys, in quadruplicate. (C) Average 
fluorescence of traces. Bars indicate mean ± SEM of trace values. Average ER calcium between 
untreated NHK and ADPKD cells is also shown.  Fluo5N trace showing average ER calcium response 
with and without ouabain in NHK (D) and ADPKD (E) cells. (F). Average ER calcium response. Values 
indicate mean ± SEM of trace values.   (G) Average mitochondrial calcium response. Bars indicate 
mean ± SEM of 3 separate kidneys. *P<0.05. 
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uptake. We observed decreased Fluo5N fluorescence with thapsigargin treatment consistent with 
our expectation (Fig. 4.2A and 4.2B). Using this model, we tested if ER Ca2+ concentrations were 
different between NHK and ADPKD cells. Indeed, ADPKD cells had significantly lower ER Ca2+ 
relative to that of NHK cells (Fig. 4.2C). This is in agreement with Xu, et al, whose work showed 
through the use of thapsigargin that the ER Ca2+ stores of ADPKD cells are lower than that of 
NHK cells [169]. Following the addition of ouabain no significant change in the ER Ca2+ 
concentration was observed in either NHK or ADPKD cells, (Fig. 4.2D-F). When mitochondrial 
Ca2+ was determined using Rhod-2, no significant difference in fluorescence was observed 
between NHK and ADPKD cells. Moreover, ouabain did not modify mitochondrial Ca2+ in either 
cell type (Fig. 4.2G). These results show that ouabain does not affect Ca2+ levels in ER or 
mitochondria in either NHK or ADPKD cells.  
 
The increase in [Ca2+]i caused by LTCC agonists, but not IP3R inhibitors rescues the normal 
Ca2+-response induced by ouabain in ADPKD cells 
In a study by Yamaguchi, et al., the proliferative response that ADPKD cells have towards 
forskolin was inhibited by pharmacologically increasing the [Ca2+]i in ADPKD cells [197]. This 
maneuver of Ca2+ rescue reverted the response of ADPKD cells to forskolin to mimic that of NHK 
cells, in which growth is not stimulated by forskolin. Conversely, in the reciprocal experiment, 
decreasing [Ca2+]i  of NHK cells caused the cells to respond to forskolin in a similar manner as 
ADPKD cells [683]. Following this strategy, we hypothesized that the response of ADPKD cells 
to ouabain could be made to resemble that of NHK cells by increasing their [Ca2+]i. We increased 
the [Ca2+]i by pretreating ADPKD cells for 1 h with the dihydropyridine L-type calcium channel 
(LTCC) agonist Bay-K8644, or the benzoyl pyrrole LTCC agonist FPL-64176 [684]. Both 
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agonists increased [Ca2+]i in ADPKD cells (Fig. 4.3A and 4.3B) When ouabain was applied to 
ADPKD cells which had previously received LTCC-agonist pre-treatment, the cells responded to 
ouabain with increased [Ca2+]i, in a manner similar to that of NHK cells (Fig. 4.3A). To determine 
whether this rescue of a normal [Ca2+]i response in ADPKD cells has functional consequences, we 
co-treated the cells with Bay-K8644 and 3 nM ouabain and measured cell proliferation 24 h later. 
In contrast to the typical stimulatory effect that ouabain elicits in ADPKD cells [322, 491], ouabain 
did not increase proliferation of ADPKD cells when co-treated with the [Ca2+]i enhancer Bay-
K8644 (Fig. 4.3C). 
As described above, ADPKD cells have lower Ca2+ levels in the ER than NHK cells (Fig. 
4.2C). Reduced ER Ca2+ levels can decrease the sensitivity of Ca2+ channels on the ER membrane 
to stimuli, which could in turn explain the lack of ouabain-induced Ca2+ increase in ADPKD cells 
[685, 686]. Additionally, reduced ER Ca2+ could increase Ca2+ uptake by SERCA [687, 688], 
which could mask any ouabain-induced [Ca2+]i increase in ADPKD cells. To ascertain whether 
this mechanism is involved in the insensitivity of ADPKD cells to the ouabain induced  Ca2+ raise, 
we increased ER Ca2+ levels and assessed the effect of ouabain on [Ca2+]i thereafter. To achieve 
this, two different IP3R inhibitors, xestospongin-c or 2-APB, were used. As shown in Figure 4.3D, 
pretreatment with the IP3R inhibitors did increase the Ca2+ concentration in the ER of ADPKD 
cells. However, despite the effect of xestospongin-c or 2-APB, ouabain was ineffective in raising 
the [Ca2+]i of ADPKD cells (Fig. 4.3E and 4.3F). Overall, our findings show that the failure of 
ADPKD cells to increase [Ca2+]i in response to ouabain can be reverted with agents that restore 







Figure 4.3. Pretreatment of ADPKD cells with LTCC agonists rescues the calcium response. A. 
ADPKD cells were pretreated with Bay K8644 or FPL-64176 for 1 h before being read. Cytoplasmic 
calcium is increased in response to the LTCC agonists. Cells pretreated with LTCC agonists respond 
to ouabain by increasing intracellular calcium. B. Ouabain-mediated proliferation is abrogated by Bay 
K8644 co-treatment. MTT assay. C. Low ER calcium in ADPKD can be rescued by 1 h pretreatment 
with IP3R antagonists. D. 1 h pretreatment with IP3R antagonists does not lead to an increase in 
intracellular calcium in response to ouabain. *P<0.05. 
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IP3R channels are not involved in the differential ouabain-mediated Ca2+ response of NHK and 
ADPKD cells 
Our next goal was to characterize the mechanisms by which ouabain modulates Ca2+ in 
NHK cells and to understand why they are unresponsive to ouabain in ADPKD cells. To achieve 
this, we first determined if the rise in Ca2+ in NHK cells was secondary to Ca2+ coming from the 
extracellular space, or if it originated by its release from the ER. Therefore, we stimulated NHK 
cells with or without 3 nM ouabain in standard medium, or in medium devoid of Ca2+. As shown 
in Fig. 4.4A, the absence of Ca2+ in the medium prevented ouabain from increasing [Ca2+]i in NHK 
cells. This suggests that the rise in [Ca2+]i in response to ouabain treatment in NHK cells involves 
the transmembrane transport of Ca2+ from the medium into the cells. 
However, we wanted to further confirm the [Ca2+]i response to ouabain did not require ER 
Ca2+ an so we directed our focus to the inositol triphosphate receptors (IP3Rs). The IP3Rs are 
[Ca2+]i release channels that are predominately localized in the ER membrane and release Ca2+ 
into the cytosol in response to IP3 (reviewed in [689-692]). Activation of IP3Rs often leads to 
formation of complex spatio-temporal Ca2+ signals which regulate various cell processes, 
including proliferation, differentiation, metabolism, secretion and cell death [693]. We found that 
depletion of ER Ca2+ using the SERCA antagonist, thapsigargin, did not inhibit the ouabain-
induced Ca2+ response in NHK cells (Fig. 4.4B).  Additionally, inhibition of IP3Rs with either 2-
APB or xestospongin-c pretreatment did not completely inhibit the Ca2+ response in NHK cells 
(Fig. 4.4C and 4.4D). 
Ouabain has been shown to increase [Ca2+]i in rat renal epithelial proximal tubule cells, via 
activation of the IP3Rs [403, 477, 558-560], resulting in the translocation of the p65 subunit of 
NFB into the nucleus [403]. We tested the possibility that the p65 subunit of NFB is involved 
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in the Ca2+ changes observed in NHK cells. For this, NHK and ADPKD cells were treated with or 
without 3 nM ouabain for 24 h and NFB levels were subsequently determined in cytosolic and 
nuclear fractions. We did not observe NFB translocation in response to ouabain in either NHK 
or ADPKD cells (Fig. 4.4E). These results show that the ouabain induced [Ca2+]i response of NHK 
relies very little on ER Ca2+ stores and that the changes in ER Ca2+ between NHK and ADPKD 
cells are not the basis for the different Ca2+ response to ouabain displayed by these cell types.  In 
addition, our data show that NHK cells, which are from collecting duct origin, respond to ouabain 
Figure 4.4 
Figure 4.4. The ouabain-mediated response does not rely on ER stores. A. Fura-2 loaded NHK cells 
treated in Ca2+-free media. B. Depletion of ER Ca2+ with 1 h pretreatment with thapsigargin. C. NHK 
cells pretreated with IP3R antagonists (1 h). D. 24 h ouabain treatment did not increase p65 NFB 
nuclear translocation. All cells from 3 separate kidneys used, in quadruplicate *P<0.05. 
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with Ca2+ increase by using mechanisms that are different from those of renal cells from proximal 
tubular origin.  
 
NCX function is not involved in the different ouabain-mediated Ca2+ response of NHK and 
ADPKD cells 
We next studied whether the sodium-calcium exchanger (NCX) plays a role in the response 
of NHK cells to ouabain induced [Ca2+]i increase, and if NCX is involved in the differences 
between NHK and ADPKD cells. NCX catalyzes the 3:1 counter-transport of Na+ and Ca2+ across 
the cell plasma membrane, using the energy of the inward Na+ gradient maintained by the NKA 
(reviewed in [694]). In fact, this mechanism is responsible for the “cardiotonic effect” that ouabain 
produces in the heart [425]. NCX expression has been shown in human collecting duct cells [695]. 
We found that NHK cells respond to the NCX inhibitor ORM10103 with an increase in [Ca2+]i 
(Fig. 4.5A). The NCX inhibitor did not increase [Ca2+]i above the levels already induced by 
ouabain. Comparison of the effect of ORM10103 in the absence and presence of ouabain shows 
no differences in [Ca2+]i. In contrast, ADPKD cells did not change their [Ca2+]i in response to 
ORM10103 (Fig. 4.5B), either in the absence or presence of ouabain (Fig. 4.5B).   We confirmed 
that NHK and ADPKD cells express similar levels of NCX (Fig. 4.5C). These results show that, 
different from NHK cells which have a functional NCX transporter, ADPKD cells cannot increase 
[Ca2+]i by inhibition of NCX. The NCX is known to be allosterically regulated by cytoplasmic 
Ca2+. Specificallty, the binding of calcium to intracellular regulatory domains increases NCX 
activity [696, 697]. Therefore, we hypothesized that increasing [Ca2+]i with Bay K8644, as 
performed before (see Fig. 3), could produce a Ca2+ response to ORM10103 in ADPKD cells. 
However, pretreatment with Bay K8644 did not result in increase of [Ca2+]i by ORM10103 in the 
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ADPKD cells (Fig. 4.5D). In summary, although pretreatment with Bay K8644 was able to rescue 
the ouabain-induced Ca2+ response in ADPKD cells, it was not able to rescue the lack of 
ORM10103-mediated calcium increase in these cells. Therefore, altered NCX activity between the 




Figure 4.5. ADPKD cells do not respond to NCX inhibition with calcium influx. A. Cells were 
loaded with Fura-2, and treated ± ouabain (3 nM) or the NCX inhibitor, ORM-10103, where indicated 
(arrows). B. Western blot analysis of NCX protein expression, 24h ± ouabain (3 nM). C. Pretreatment 
of ADPKD cells for 1 h with Bay-K8644 did not rescue the response to ORM-10103. All: cells from 
3 separate kidneys used, in quadruplicate *P<0.05. 
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LTCC mediates the [Ca2+]i response to ouabain in NHK cells 
L-type calcium channels (LTCCs) have been shown to become activated after ouabain 
addition [562-567]. The mechanism appears to depend on inhibition of NKA, which causes 
membrane depolarization and in turn, activation of LTCC, with the subsequent entry of Ca2+. 
Ouabain has been found to increase [Ca2+]i via this mechanism in cardiomyocytes and in some 
neurons [562-567]. LTCCs are hetero-tetrameric 
complexes which are composed of the pore-forming 
1 subunit and the auxiliary 2/ and  subunits 
(reviewed in [561, 698]). At least one subtype of 1-
LTCC, CaV1.2, is present in renal collecting duct 
cells [699]. In Figure 4.3A we show that LTCC 
agonists can rescue the ouabain dependent Ca2+ 
response in ADPKD cells. Therefore, we performed 
the reciprocal experiment and assayed whether the 
Ca2+ increase induced by ouabain could be inhibited 
in NHK cells by the LTCC antagonist verapamil. As 
shown in Figure 4.6, pretreatment with verapamil blocked the ouabain induced Ca2+ rise in NHK 
cells. This suggests that in NHK cells, Ca2+ flux in response to ouabain relies on the function of 
LTCCs. 
Figure 4.6 
Figure 4.6. L-type calcium channels are 
what mediate the influx of ouabain in 
collecting duct cells. The ouabain-
mediated Ca2+ increase is abrogated in 
NHK cells co-treated with verapamil. All: 




Different levels of LTCC are responsible for the dissimilar ouabain induced [Ca2+]i response in 
NHK and ADPKD cells  
We next assayed the expression levels of 
1-LTCC by western blot analysis and found 
significantly lower expression of the band 
corresponding to the full-length 1-LTCC (of 
240 kDa) in ADPKD than in NHK cells (Fig. 
4.7A). Decreased expression could be due to 
altered stability of the 1-LTCC protein. Indeed, 
Pedrozo, et al. showed in cardiomyocytes that 
polycystin-1 expression is required to stabilize 
1-LTCC, especially under conditions of stress 
[700]. Therefore, we assessed the stability of the 
1-LTCC protein in NHK and ADPKD cells by 
inhibition of protein translation with 
cycloheximide and followed the expression of 
the mature protein for different times. This 
provides an estimation of the half-life of 1-
LTCC protein. As shown in Fig. 4.7B, the half-
life of the 1-LTCC protein was not significantly 
different between NHK and ADPKD cells. In 
addition, to determine if both cell types present 
differences in 1-LTCC degradation, we assessed 1-LTCC protein levels over time in the 
Figure 4.7 
 
Figure 4.7 A. ADPKD cells have less full-
length (240 kDa) LTCC protein than NHK cells. 
B. Cycloheximide time course reveals that 
ADPKD cells do not have less stable LTCC 
protein. C. MG132 time course confirms that 




presence of the proteasome inhibitor, MG132. This showed no differences in degradation of 1-
LTCC between ADPKD and NHK cells (Fig. 4.7C). Therefore, while ADPKD cells have an 
abnormally low level of expression of 1-LTCC, this is not due to altered stability of this channel. 
 
LTCC undergoes increased cleavage in ADPKD than NHK cells  
When performing the immunoblots to detect 1-LTCC, we observed that in addition to the 
full length protein, there were lower molecular weight bands identified by the anti-LTCC antibody 
(Fig. 4.8A). Cleavage is an important mechanism that regulates 1-LTCCs, and has been well 
studied in neurons and cardiomyocytes [701-703]. The full length LTCC protein (240 kDa) is fully 
functional, while the cleaved products (150 kDa and 90 kDa) are known to bind to the full-length 
form and decrease the open probability of the channel [701-703]. Therefore, we analyzed and 
compared the expression levels of the lower molecular weight bands of 1-LTCC in NHK and 
ADPKD cells. We calculated the cleavage index of 1-LTCC, which has been previously defined 
as the 1-LTCC 150 kDa band / 240 kDa band ratio [701]. We found that a greater cleavage of 1-
LTCC occurs in ADPKD cells compared to NHK cells (Fig. 4.8B)  
The 1-LTCCs are known to be cleaved by the calpain family of proteases [704]. 
Therefore, we assessed the activity of calpains in NHK and ADPKD cells. Using a fluorescent 
calpain substrate, Boc-LM-CMAC, we found that, calpains are more active in ADPKD cells than 
in NHK cells (Fig. 4.8C). Altogether, these results suggests increased cleavage of 1-LTCCs may 






Figure 4.8. L-type calcium channels undergo increased cleavage in ADPKD cells due to increased 
calpain activity. (A) Lower bands observed in western blot analysis of LTCC protein. (B) Proteolytic 
index of LTCC (150 kDa band / 250 kDa band) is significantly greater in ADPKD cells. (C) Cleavage 
of the calpain-specific substrate, Boc-LM-CMAC; calpain inhibitor-1 (CI1) was used as a negative 
control, value shown in dotted line. (D) Western blot of c-Myc protein. (E) Western blot of calpastatin 
(CLPN). (F) Inhibition of c-Myc transcriptional activity with 10058-F4, decreased cleavage of Boc-
LM-CMAC. (G). Pretreatment with CI1 or 10058-F4 increases increases expression of full length 
LTCC. (H) CI1 or 10058-F4 pretreatment both increase intracellular calcium in ADPKD cells (average 
Fura-2 fluorescence).  *P<0.05. 
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Calpain activity is increased by c-Myc overexpression in ADPKD cells 
To gain insight into the mechanisms by which calpain activity is increased in ADPKD 
cells, we explored the expression levels of c-Myc. The c-Myc transcription factor is a regulator of 
cell growth, proliferation, dedifferentiation and apoptosis [705, 706]. c-Myc is known to be 
upregulated in human APDKD cells [140, 574, 707], as well as in several ADPKD models, 
including PKD1 transgenic animals, SBM mice, CPK mice, and Han:SPRD rats [356, 622, 708-
711]. We confirmed that c-Myc is increased in ADPKD cells compared to NHK cells (Fig. 8D).  
c-Myc transcriptionally represses an endogenous inhibitor of calpains, the protein 
calpastatin [712]. Therefore, we determined the expression of calpastatin in NHK and ADPKD 
cells and indeed found that ADPKD cells showed significantly lower calpastatin levels than NHK 
cells (Fig. 8E). Calpastatin appeared as a double band in our immunoblots. This may reflect the 
presence of different isoforms of calpastatin, derived from alternative splicing or proteolysis, as 
previously reported [713]. We combined both bands into “total calpastatin” when performing the 
densitometric analysis. To further confirm a relationship between c-Myc and calpain activity, we 
pretreated ADPKD cells for 24 h with the compound 10058-F4, which inhibits the transcriptional 
effects of c-Myc, and then measured calpain activity of the cells. We observed that the Myc 
inhibitor 10058-F4 significantly decreased calpain activity of ADPKD cells (Fig. 4.8F). 
Concomitant with this effect, inhibition of calpain or c-Myc increased [Ca2+]i of ADPKD cells 
(Fig 4.8G). Moreover, inhibition of either calpain or c-Myc decreased the cleavage of 1-LTCC 
in ADPKD cells (Fig. 4.8H). Altogether, these experiments show that in ADPKD cells, the 
abnormally high levels of c-Myc are associated with a reduction in calpastatin expression, which 
further leads to increased calpain activity and higher cleavage of 1-LTCC. 
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 Ouabain has been shown to enhance the expression of c-Myc [498, 714], therefore we 
were interested in testing whether ouabain could enhance 1-LTCC cleavage. Treatment with 
ouabain for 24 h had no effect on the amounts of full length 1-LTCC or the 1-LTCC cleavage 
index (Fig. 4.9A and 4.9B). In addition, calpain activity was not changed by 24 h treatment with 
ouabain (Figure 4.9C). 
 
LTCC activity is decreased by aberrant ERK signaling in ADPKD 
ADPKD cells are known to have aberrantly active ERK signaling [133, 715-717]. 
Furthermore, the inhibition of MEK1/2 kinases, which activate ERK, have been shown to increase 
the membrane localization of 1-LTCC, and thus increase channel activity [718]. Therefore, we 
hypothesized that ADPKD cells may have less functional 1-LTCC due to a decreased presence 
of 1-LTCC in the membrane. We observed 1-LTCC localization by confocal microscopy and 
found that 30 minutes of pretreatment with the MEK1/2 inhibitor, U0126, increased the 
Figure 4.9 
 
Figure 4.9. Ouabain does not enhance the cleavage of LTCCs. A. Full length LTCC protein 
concentration is not decreased by 24 h treatment with ouabain. B. The proteolytic index of LTCC is 
not significantly increased by ouabain. C. Calpain activity is not significantly altered by ouabain. 
Dotted line represents CI1 value. *P<0.05. 
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localization of 1-LTCC to the plasma membrane in ADPKD cells (Fig. 4.10A). To further 
confirm this mechanism, we pretreated ADPKD cells with U0126, and assayed [Ca2+]i, with and 
without ouabain treatment. Ouabain was able to increase [Ca2+]i after pretreatment of the cells with 
U0126 (Fig. 4.10B). This suggests that decreased insertion of 1-LTCC into the plasma membrane 
as a result of MEK1/2 
overactivation in ADPKD cells 
is an additional mechanism that 
prevents the ouabain induced 




Figure 4.10. MEK activity affects the localization of LTCCs. 
(A) Representative images of LTCC Immunolocalization after 30 
min ± U0126. (B) Fura-2 trace showing U0126 pretreatment 
rescued the calcium response in ADPKD cells; composite of the 




 In this study, we found that ouabain is able to induce [Ca2+]i increase in NHK cells, but not 
in ADPKD cells. The [Ca2+]i rise in NHK cells was rapid, occurring in a short interval after ouabain 
addition (before one minute). This effect of ouabain is also sustained, since the changes in [Ca2+]i 
were found to persist even 24 h after ouabain incubation. Similar to our results, ouabain was shown 
to increase [Ca2+]i in different cell types, including normal renal proximal tubule cells. In this 
previous study, ouabain was shown to produce a Ca2+ wave, with an oscillatory pattern that had a 
periodicity of 1 Ca2+ spike every 4-5 minutes [403, 477, 558, 559]. We did not find a rhythmicity 
for the ouabain induced [Ca2+]i increase in NHK cells. However, this may reflect differences in 
the experimental design used in each study. We carried out our assays on cell populations, while 
other studies performed single cell recordings [403, 477, 558-560]. Assessment of the ouabain-
mediated [Ca2+]i response in aggregate cells may have masked the oscillations of individual cells, 
producing an asynchronous pattern derived from the combined firing of multiple cells. Some 
reports show that ouabain-induced Ca2+ oscillations have a lag-time of several minutes after 
ouabain addition [558, 560]. We have performed Ca2+ traces for up to 30 minutes after ouabain 
treatment (data not shown), which failed to show an oscillatory pattern. Alternatively, [Ca2+]i 
oscillations in response to ouabain may depend on differences in cell types in each study. This 
includes differences in species (mouse vs human) and the dissimilar renal origin of the cells 
(proximal tubule versus collecting duct). In this regard, it is interesting to postulate that the ouabain 
response uses different pathways in different cells types, pathways which can differentially affect 
[Ca2+]i or operate downstream of Ca2+. Despite the possible oscillatory differences, it is clear that 
normal renal epithelial cells respond to ouabain with an increase in [Ca2+]i that is not present in 
ADPKD cells.  
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Our experiments show that the [Ca2+]i rise caused by ouabain in NHK cells is prevented by 
eliminating Ca2+ from the medium. In addition, we find that depletion of ER Ca2+ with 
thapsigargin, or inhibition of IP3R with xestospongin-c or 2-APB did not inhibit the ouabain 
induced [Ca2+]i response in NHK cells. Moreover, ouabain did not modify ER or mitochondrial 
Ca2+ in NHK cells. Altogether, this shows that the [Ca2+]i rise that follows ouabain administration 
depends on an influx of Ca2+ from the medium bathing the cells and is not the result of Ca2+ 
translocation from intracellular stores to the cell cytosol. This observation is different from 
findings in renal proximal tubular cells. In those experiments, removal of extracellular Ca2+ did 
not inhibit the Ca2+ response of proximal tubule cells to ouabain [403, 560]. In addition, treatment 
with thapsigargin, or inhibition of IP3R completely abrogated the ouabain induced [Ca2+]i response 
in renal proximal tubular cells [558-560]. Furthermore, we did not observe the translocation of p65 
NFB into the nucleus, which had been observed in renal proximal cells. This reinforces the idea 
that epithelial cells from different nephron segments activate different mechanisms in response to 
ouabain.  
Yamaguchi et al. found NHK cells have constitutively higher [Ca2+]i than ADPKD cells 
[197], while Xu, et al. observed ADPKD cells to have lower ER Ca2+ than NHK cells [169]. In 
agreement with those studies, we observed that cytoplasmic and ER Ca2+ levels are intrinsically 
lower in ADPKD than in NHK cells. We extended these observations to mitochondria and found 
no differences in Ca2+ content of this organelle between NHK and ADPKD cells. At present the 
cause for the lower Ca2+ levels of ADPKD cells is not precisely known. PC2 is a non-specific Ca2+ 
channel and it appears to have a role in release of Ca2+ from the ER, either on its own [185] or in 
conjunction with IP3Rs [176, 212]. Overexpression of PC2 has been shown to decreases ER Ca2+ 
levels [211]. In contrast, expression of PC1 inhibits the Ca2+ leak from the ER, increases ER Ca2+ 
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refill [209, 210], and reduces ER Ca2+ release in response to stimulation [176, 212]. Thus, the 
mutations in polycystins leading to ADPKD may be responsible for the low ER and cytoplasmic 
Ca2+ observed in ADPKD cells.  
We found that the mechanisms that mediate the differences in the ouabain induced [Ca2+]i 
increase between NHK and ADPKD cells, depends on the action of LTCC. Therefore, the LTCC 
antagonist verapamil blocked the ouabain induced Ca2+ rise in NHK cells. In addition, the LTCC 
agonist Bay K8644 rescues the ouabain dependent Ca2+ response in ADPKD cells. A similar 
activation of LTCC by ouabain has been reported in non-renal cells [562-567]. Thus, we have 
established LTCCs as a new mechanism by which ouabain increases [Ca2+]i in kidney cells. In 
contrast to NHK cells, ouabain is not able to stimulate [Ca2+]i influx into ADPKD via LTCC.  
Alterations in LTCC, in particular the LTCC subclass CaV1.2, have been shown to play a role in 
cyst formation. In zebrafish, CaV1.2 localizes to primary cilia and its knock down results in the 
development of renal cysts [719]. Additionally, CaV1.2 is altered in PKD1 or PKD2 knockout 
mice [720]. Specifically, a band the size of the CaV1.2 cleavage product increases after knockout 
of either polycystin [720]. This suggests that the cleavage of 1-LTCC is directly linked to the 
proper function of PKD1 or PKD2. Furthermore, the complete knock-down of CaV1.2 in PKD1+/- 
zebrafish and in PKD1+/- mice greatly enhanced the cystic phenotype [720]. The importance of 
functional LTCCs in normal renal epithelial cells is further illustrated by studies in which treatment 
with verapamil, an LTCC antagonist, greatly enhanced cyst formation in the Cy/+ Han:SPRD rat 
model of ADPKD [683].  
A known regulator of LTCC cleavage is the calpain protease family. Our findings show 
that ADPKD cells have higher calpain activity than NHK cells. Another difference that we found 
in ADPKD cells, compared to NHK cells is the decrease in the calpain inhibitor calpastatin. The 
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lower levels of calpastatin explains the higher calpain activity that we measured in ADPKD cells. 
Dysregulation of calpain activity and alterations in calpastatin expression have not been reported 
before in ADPKD cells; therefore, we have encountered a new characteristic that distinguishes 
these cells from normal renal epithelial cells. We found that pharmacological inhibition of calpain 
reduces LTCC cleavage in ADPKD cells. The calpain inhibitor that we used (CI1) is known to 
target both calpain-1 and -2; however, it is possible that other members of the calpain family of 
proteins are also targeted. The calpain family includes 14 members [721]. While calpain-1 and 
calpain-2 have been detected in collecting duct cells [722, 723], the presence of other calpains in 
the kidney is unclear. In general, calpains 1, 2, 5, 7, and 10 are ubiquitously expressed (reviewed 
in [724]); and The Human Genome Atlas (www.proteinatlas.org) lists a number of calpain family 
members as expressed in the kidney. Therefore, it is possible that other members of the calpain 
family are involved in the exacerbated cleavage of LTCC in ADPKD cells. Calpains are 
hypothesized to function at sub-maximal capacity at normal physiological concentrations of 
[Ca2+]i as a safety mechanism to prevent unrestrained cleavage of substrates [725]. The binding of 
calpastatin to calpains limits the number of calpain molecules susceptible to activation [713]. 
Therefore, decreased expression of calpastatin expression would allow some calpain to become 
active even at low [Ca2+]i, as we have witnessed.   
ADPKD cells and several ADPKD experimental models are known to express abnormally 
high amounts of c-Myc [140, 356, 574, 622, 707, 709-711], and c-Myc overexpression alone is 
enough to cause renal cysts, as observed in SBM mice [356, 622, 708-711]. In this study we 
confirmed that ADPKD cells express higher levels of c-Myc than NHK cells. While we found c-
Myc significantly elevated in ADPKD cells, the increase we observed is not as robust as that 
reported by others. c-Myc is upregulated by serum growth factors [726-728], and therefore our use 
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of serum-free media in all experiments may have blunted c-Myc expression in the cells, preventing 
even higher expression levels of this transcription factor. Importantly, we showed that c-Myc 
overexpression is linked to downregulation of LTCC activity. Thus, inhibition of c-Myc 
transcriptional activities increased the expression of calpastatin, decreased calpain activity, and 
increased the amount of full-length LTCC as well as the [Ca2+]i in ADPKD cells. These results 
show that in NHK cells, normal levels of c-Myc and calpastatin maintain the activity of calpain at 
relatively low levels. This in turn favors the expression of higher levels of LTCC, through which 
ouabain acts to ultimately cause the increase in [Ca2+]i observed to occur in the NHK cells (Fig. 
4.11). Our results show that ouabain did not alter the expression of c-Myc, calpastatin, or calpain 
in NHK or ADPKD cells. Therefore, the difference in effect that ouabain has on [Ca2+]i in NHK 
and ADPKD cells is due to the dissimilar intrinsic activity of the c-Myc-calpastatin-calpain 
pathway that influences LTCC activity in the cells.  
An additional difference that we observed between the mechanisms that control [Ca2+]i in 
NHK and ADPKD cell is their response to NCX inhibition. We determined that NCX is expressed 
in both cell types. However, while our experiments cannot discard a role of NCX in the [Ca2+]i 
increase induced by ouabain in NHK cells, NCX appears not to be functional in ADPKD cells. 
This idea is based on the lack of effect that ORM10103 has in ADPKD cells. At present, the lack 
of activity of NCX in ADPKD cells is unclear. It is possible that the low [Ca2+]i levels in these 
cells and the continuous translocation of Ca2+ to replenish intracellular stores, prevent any possible 
increase in [Ca2+]i in the cytoplasm of the cells. Additional experiments will be needed to directly 




In conclusion, we have discovered molecular mechanisms by which ouabain increases 
[Ca2+]i in NHK cells and identified phenotypic changes which prevent ADPKD cells from 
responding to ouabain with a Ca2+ rise. The inability of ouabain to raise [Ca2+]i in ADPKD cells is 
relevant to the pathophysiology of ADPKD, since low [Ca2+]i is known to enhance ADPKD 
cystogenesis. This effect along with our previous results showing that ouabain stimulates cell 
proliferation and favors secretion of the cystic epithelium, highlights the importance of ouabain as 










OVERALL DISCUSSION and FUTURE DIRECTIONS 
The second hit [41] and third hit [72] theories of ADPKD progression suggest that 
unknown environmental factors play a large role in accelerating cyst growth. Indeed intrafamilial 
studies have shown that genetics alone cannot explain the variability observed in the progression 
of ADPKD to ESRD [44, 45].  One non-genetic factor shown to enhance the ADPKD phenotype 
is ouabain. This hormone acts directly on cystic epithelial cells collected from ADPKD patients to 
elicit both increased growth and increased fluid secretion though activation of the B-
RAF/MEK/ERK signaling cascade [322, 360, 491]. In contrast, ouabain did not elicit these effects 
in normal human collecting duct cells [322, 360, 491]. The results in this thesis have expanded our 
knowledge of the effects of ouabain on ADPKD cells, showing that ouabain is a factor that 
contributes to the abnormal phenotype of ADPKD cells. First, ouabain was found to increase 
apoptosis in the cells, which is a characteristic of ADPKD. Second, ouabain induced changes 
compatible with partial EMT of the cells, which corresponds to the dedifferentiated characteristics 
shown by ADPKD. Finally, ouabain failed to increase [Ca2+]i in ADPKD cells due to their 
constitutive low expression of LTCC; and possibly via the ERK-mediated maintenance of LTCC 
in intracellular compartments.  
 
Specific Aim 1: Define the action of ouabain-mediated apoptosis on ADPKD cells. 
ADPKD is paradoxically characterized by both increased proliferation and apoptosis. The 
working hypothesis for Chapter 2 was that ouabain would be able to stimulate ADPKD cell 
apoptosis through BCL-2 and BAX alterations, resulting in cytochrome c release from the 
mitochondria. This was found to be correct; ouabain was able to enhance the ADPKD phenotype 
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of increased apoptosis, as expected. The balance between proliferation and apoptosis was 
maintained, however, as ouabain also enhanced ADPKD-mediated proliferation, resulting in net 
increased proliferation, which would serve to aid cyst growth.  
Apoptosis is involved during kidney development, and is theorized to be important for 
lumenization or other morphogenetic processes [729].  In particular, cavitation, which involves 
lumen generation by apoptosis, is employed during tubulogenesis (reviewed by [730]). 
Additionally, apoptosis can also be instrumental in wound responses. Indeed, the enhanced 
caspase-3/7 activity caused by ouabain in ADPKD cells, may also have non-apoptotic roles. For 
instance, low levels of caspase activity can affect cytoskeletal rearrangements and cell fate 
decisions (reviewed in [731]).  In fact, after partial hepatectomy, liver regeneration is dependent 
on caspase-3 and -7 activation [732]. It has been hypothesized that some apoptotic cells die slowly, 
affording the time necessary to induce expression of mitogenic factors which prepares neighboring 
cells for the departure of the apoptotic cell [731]).  Signals that are transmitted from apoptotic cells 
include activators of the WNT, TGF and Hedgehog families, which are all active during cystic 
progression [254, 255, 584, 733]. As the data in Chapter 3 shows, ouabain increased TGF 
expression in ADPKD cells, while -catenin localization and expression was not found to change. 
The effect of ouabain on the hedgehog pathway in ADPKD has not yet been investigated, but may 
prove to be an interesting avenue for future study.  
ADPKD cells have constitutively altered concentrations of Ca2+, an element which can 
both inhibit or promote apoptosis, depending on cellular context. Ca2+ was first shown to induce 
apoptosis when in excess [734]. However, low [Ca2+]i is able to increase both proliferation and 
apoptosis in vascular smooth muscle cells, similar to what is observed in ADPKD [735]. While 
we observed ouabain-induced Ca2+ influx in NHK cells, we did not detect increased apoptosis in 
133 
 
NHK. Conversely, the lower [Ca2+]i levels in ADPKD cells were not further decreased by ouabain, 
yet apoptosis was enhanced. Thus, while [Ca2+]i may not be affecting ouabain-mediated apoptosis, 
organelle Ca2+ may still play a role. For example, both Ca2+ overload and depletion in the ER can 
result in protein misfolding and subsequent ER stress that might contribute to apoptosis [736]. 
While ER Ca2+ is decreased in ADPKD relative to NHK, we have not assessed whether ouabain 
affects ER stress proteins. We have, however, observed that ouabain-mediated apoptosis does rely 
on certain proteins which act on ER Ca2+. For instance, BAX protein expression is increased by 
ouabain in ADPKD cells. Overexpression of BAX promotes Ca2+ translocation from the ER to the 
mitochondria and subsequent cytochrome c release for apoptosome activation [737]. This 
movement of Ca2+ from the ER into the mitochondria can overload the mitochondria, resulting in 
apoptosis [738]. In a related pathway involving Ca2+ and apoptosis, the ouabain-mediated decrease 
in BCL-2 protein observed in ADPKD would promote apoptosis via several mechanisms. First, 
BCL-2 reduces the filling of the ER Ca2+ store and diminishes store-operated Ca2+ entry [739, 
740], thus preventing the overload of Ca2+ in the mitochondria. Alternatively, BCL-2 
overexpression also increases the ability of the mitochondria to uptake Ca2+ without overload, and 
BCL-2 also prevents the release of cytochrome c by inhibiting the opening of the mitochondrial 
permeability transition pore [741-743]. Although ouabain-mediated alterations to ER or 
mitochondrial Ca2+ were not observed, this apoptosis-inducing movement of Ca2+ ions from the 
ER to mitochondria may still have occurred in response to the ouabain-mediated alteration in BAX 
and BCL-2 expression in ADPKD cells. This hypothesis is based on two facts. 1) Ca2+ alterations 
were assayed at earlier time points than the time points used in the apoptosis study, so changes in 
organelle Ca2+ due to ouabain-mediated apoptosis may not yet have taken place. 2) Additionally, 
both organelles (ER and mitochondria) contain many Ca2+-binding proteins which may mask 
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actual increases in organelle Ca2+, as the fluorescent Ca2+ probes utilized in Chapter 4 assess only 
free-Ca2+ levels. Further studies will be needed to determine the link between Ca2+ and apoptosis 
in ADPKD cells, however it is clear that ouabain enhances the characteristic apoptotic phenotype 
of ADPKD. 
 
Specific Aim 2: Determine the role and mechanism of action of ouabain in inducing EMT changes 
in ADPKD. 
The working hypothesis for Chapter 3 was that ouabain, via the activation of the TGF 
pathway, would induces EMT-related changes that cause upregulation of mesenchymal markers, 
relaxation of cell adhesion properties, and increase motility and fibrosis in APDKD cells. Cellular 
aspects affected by EMT-like processes, such as adhesion, migration, polarity and ECM 
deposition, are extremely important in both development and response to injury [553, 650]. 
Ouabain did not fully stimulate EMT; however, enhancement of the mesenchymal state was 
achieved. Also, ouabain induced a decrease in cell-cell adhesion and increased cell mobility, but 
it did not affect cell invasiveness. Taken together, these results agree with the characteristics 
required for cyst formation. The ADPKD epithelium cannot be fully dedifferentiated, since it 
would then loose the polarity needed to carry on basal-to-apical secretion of fluid into the cyst 
lumen. In addition, complete dedifferentiation would also lower adhesion between cells and 
decrease the transepithelial resistance necessary to impede leakage of fluid from the cyst. Finally, 
the inability of ouabain to promote invasiveness agrees with ADPKD as being a proliferative but 
not metastatic disease [95]. 
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Ouabain was found to increase TGF expression as well as activate its downstream 
mediator, SMAD3. Elevated TGF signaling has been described in cystic cells [584], and my 
studies show ouabain further enhanced this ADPKD phenotype. Exposure of epithelial cells to 
TGF is a strong stimulus for EMT-signaling, causing upregulation of pro-mesenchymal E2A 
proteins (TCF3 and ITF1), and a concomitant downregulation of their inhibitors, the Id proteins 
[744]. Counterintuitively then, Id2 is upregulated in PKD1-null cells [745], probably via the 
transcriptional activities of c-Myc [746, 747]. Indeed, mutations in either polycystin lead to 
increased Id2 in the nucleus [748]. Thus, the upregulation of Id2 by c-Myc, despite increased TGF 
activity, may antagonize the classically observed EMT induced by TGF, causing the partial EMT 
in response to ouabain described in Chapter 3. The ouabain-mediated upregulation of TGF is 
expected to have a role in cystic progression rather than the induction of cysts, based on the 
literature [584, 749]. For example, in the Han:SPRD rat model of polycystic disease, expression 
of TGF and its target genes is low initially, but increases with the progression of the disorder 
[749]. Again, another study has found TGF signaling was not increased in initial stages of cyst 
formation but was increased during cyst expansion in models of polycystic kidney disease as well 
as in kidneys from ADPKD patients [584]. This role of ouabain in TGF cystic progression, 
therefore, favors ouabain as a factor responsible for the variability of cystic progression between 
individuals. 
A plethora of data suggest that polycystins are important in proper tissue repair and are 
instrumental in the morphogenesis programs indispensable in development [750]. Indeed, PC1 
expression increases after renal injury [71, 164], an event which has been suggested to provide the 
appropriate plasticity necessary during tissue repair [750]. Interestingly, SRC is also activated in 
response to renal injury and appears to participate in tubular regeneration [751], and PC1 has been 
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reported to interact with SRC and STAT3 in a complex that is speculated to facilitate tissue 
regeneration in response to normal renal insults [251, 752].  Interestingly, ouabain stimulates SRC 
activity in ADPKD cells [322, 491], and as NKA binds both PC1 CTT and SRC [582], it is 
tempting to speculate that ouabain may be contributing to the activity of the PC1-SRC-STAT3 
pathway, promoting the futile repair pathways purported to increase cell proliferation and 
cystogenesis in ADPKD [95].  
  
Specific Aim 3: Investigate the effect of ouabain on Ca2+ signaling in NHK and APDKD.  
ADPKD cells have constitutively lower intracellular Ca2+ than NHK cells, which alters 
their response to many different stimuli. The working hypothesis for Chapter 4 was that ouabain 
would affect the intracellular Ca2+ concentration in NHK cells, but not in ADPKD cells, due to 
dysfunctional Ca2+ signaling in ADPKD cells. Indeed, ouabain was able to increase [Ca2+]i in NHK 
cells, which was subsequently found to occur via LTCCs. Conversely, in ADPKD cells, LTCCs 
were inhibited by cleavage and by decreased localization into the membrane. While lower LTCC 
expression had been observed to cause renal cysts in animal models [719, 720], this had not been 
investigated in human samples prior to this thesis. Additionally, the observation of altered LTCC 
cleavage in ADPKD also led to the discovery of increased calpain activity in ADPKD cells, which 
also had not described prior to this thesis. 
The third hit theory of ADPKD progression is based on the observation that cystic growth 
is accelerated by wounding stress [72]. Interestingly, activity of LTCCs can be altered by 
extracellular matrix proteins, via an interaction with integrins, which could possibly play a role in 
tissue injury responses [753]. Serendipitously, Ca2+ influx via LTCCs occurs in response to 
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myocyte injury and coordinates the movement of vesicles filled with calpain-induced cleavage 
products to the plasma membrane for injury repair [573]. Additionally, the activation of calpains 
may be another aspect of the wound-like phenotype of ADPKD cells. For instance, the self-sealing 
repair of damaged plasma membranes requires the activity of calpains, which may act to remodel 
the cortical cytoskeleton [754]. Additionally, the expression of calpains is increased during skin 
wound healing [755]. Indeed, in renal injury by ischemia-reperfusion, expression of calpastatin is 
decreased [756] and is perhaps a common mechanism used in renal injury to activate calpains for 
repair processes. Conversely, forced expression of calpastatin during skin wounding, delays scar 
formation [757], again showing the importance of calpain activation in response to injury. 
Therefore, in Chapter 4, the involvement of LTCCs, calpains, and calpastatin can be tied to an 
injury response and thus suggest a role for ouabain as a promoter of the third hit leading to ADPKD 
progression. 
 
Physiologically important responses to ouabain between tubule cell types 
The work outlined in this thesis consistently found differences between the response to 
ouabain that had been described in proximal tubules cells, and the response observed in ADPKD 
cells. For instance, ouabain was observed to protect proximal tubule (PT) cells from apoptosis, via 
translocation of p65 NFB into the nucleus [403, 477, 558-560]. In collecting duct (CD) cells, this 
translocation was not observed to occur in either NHK or ADPKD. In fact, in ADPKD cells, 
induction of apoptosis was observed, not protection. Additionally, PT cells respond to ouabain 
with Ca2+ influx via IP3Rs [403, 477, 558-560], however, in CD cells the ouabain-mediated Ca2+ 
influx occurred through LTCCs. Others have also observed a difference in how these two cell types 
respond to ouabain. For instance a 12-hour exposure to ouabain (100 nM) causes the endocytosis 
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of NKA in LLCPK1 (proximal) cells but not in MDCK (collecting duct) cells [758]. Thus, PT cells 
respond to ouabain in a different manner than ADPKD cells.  
These two renal segments also respond to stress differently. For instance, following 
reductions of renal mass, mechanisms for sodium handling remain functional in the collecting 
duct, whereas in the proximal tubule, the handling of sodium is substantially altered and no longer 
respond [759]. This allows the “fine tuning” of sodium balance by the distal nephron to still 
proceed under stress [759]. As ouabain is involved in conditions of altered salt balance, as well as 
in renal stress, the differences between how proximal and collecting duct tubules respond to 
ouabain may have physiological importance. 
 Finally, PT and CD cells respond differently to polycystin mutations, as evidenced by the 
apparent collecting duct origin of the majority of cysts [131-133]. Interestingly, even during 
embryonic development, the two renal segments modify PC1 differently. For example, PC1 does 
not undergo GPS cleavage in the proximal tubule segments, while in the distal nephron segments 
(which includes the CD), cleaved PC1 products are important for normal tubulogenesis. An 
uncleavable PC1 mutant causes cyst formation only in the collecting duct [37, 127, 168]. Finally, 
the other polycystin, PC2, appears to be also differentially affected between the two cell types. In 
cultured PT cells, ouabain induces the translocation of PC2 from the ER to the plasma membrane 
[760]. Despite repeated attempts, (data not shown), ouabain has not been observed to cause a 
similar PC2 translocation in collecting duct cells, further emphasizing the physiologically 
important functional differences between how CD and PT cells respond to ouabain. 
 In conclusion this thesis provides new mechanistic evidence on the effects of the hormone 
ouabain in ADPKD. This work adds to other pro-cystogenic effects that ouabain has been shown 
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to trigger in ADPKD cells, and further supports the notion that ouabain is a circulating factor that 
can exacerbate the progression of the disease. 
 
Future Directions 
 Interesting differences in the effect of ouabain in NHK and ADPKD cells have been 
observed in this thesis, however the mechanisms underlying the cause of the dissimilar response 
to ouabain in each cell type is still unclear. Previous results showed that ADPKD cells contain a 
subpopulation of NKA with an abnormally high affinity for ouabain, allowing them to respond to 
ouabain in an exacerbated manner [322]. However, the reason for the difference in ouabain affinity 
in these cells is not clear. In this regard, the NKA accessory protein FYXD2 may be of particular 
interest as FXYD2 has increased expression in ADPKD cells relative to NHK [322], and enhances 
ouabain sensitivity [342]. Investigations into this increased affinity of ouabain to NKA of ADPKD 
cells will help in developing pharmacological approaches to block the cystogenic effects of 
ouabain. Alternatively, it is possible that ouabain levels could be elevated in patients with ADPKD, 
especially at times in which cystic growth is accelerated, such as in utero [410] or during 
compression of the renal parenchyma by the cysts [385, 388, 396, 397]. Therefore, determining 
plasma levels of ouabain in ADPKD patients versus healthy controls could be instrumental in 
understanding the disease. In addition, it has yet to be determined if ouabain has any effect on 
polycystin activities. As mentioned previously, ouabain, via SRC activation could promote the 
activity of a PC1/SRC/STAT3 complex [251, 752], and may provide further insights into the 
mechanism by which ADPKD cells have a unique response to ouabain. Further, as ADPKD is a 
ciliopathy, determining if ouabain has a role in ciliary-mediated processes could also provide 
insight into the effect of ouabain on ADPKD cells. Future work could also include ADPKD mouse 
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models in which the effects of ouabain or ouabain inhibitors could be observed in an in vivo system. 
Perhaps further work could also be directed towards learning more about the calpain isoforms 
present in ADPKD cells and if these isoforms differ from that in normal renal epithelial cells.  
The primary objective of this thesis was to better understand the mechanisms by which 
ouabain enhances several characteristics of ADPKD cells. A mechanistic understanding is a 
necessary first step for the development of pharmacological approaches to treat the disease. 
Eventually, methods to block ouabain, or downstream targets of ouabain, may be used clinically 
to limit cyst progression and prolong patient life. Additionally, this thesis has also revealed a new 
phenotype of ADPKD cystic cells, elevated calpain activity, which may prove to be especially 
pertinent to either the treatment or the understanding of this disease. Finally, this thesis has shed 
light on the differential ways ouabain affects proximal and collecting duct cells. Such findings are 
important due to the enigmatic systemic effects of ouabain. Any new knowledge pertaining to the 
action of ouabain may help explain the purpose of this incompletely understood hormone. Thus, 
the data presented in this thesis advances the knowledge of several fields and will hopefully be 
useful to subsequent researchers. 
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